▁patient ▁; ▁conditions
▁patient
▁medica re ▁patient ▁safety ▁monitoring ▁system ▁; ▁mp s ms ▁; ▁advers e ▁event ▁; ▁patients ▁; ▁hospital ized ▁; ▁a cute ▁my o card ial ▁in far ction ▁; ▁con ges tive ▁heart ▁failure ▁; ▁pneu monia ▁; ▁conditions ▁; ▁surgery
▁patients ▁; ▁hospital s
▁advers e ▁event ▁; ▁a cute ▁my o card ial ▁in far ction ▁; ▁con ges tive ▁heart ▁failure ▁; ▁advers e ▁events
▁patients ▁; ▁pneu monia ▁; ▁sur g ical ▁; ▁conditions
▁pressure ▁ul cer s ▁; ▁sur g ical ▁; ▁patients
▁patient
▁cross - talk ▁; ▁heart ▁; ▁adi pose ▁tissu e ▁; ▁cache ctic ▁heart ▁failure ▁; ▁patients ▁; ▁prospect ive ▁study
▁cardiac ▁cache xia
▁lipo lys is ▁; ▁ex pendi ture ▁; ▁b ▁na tri ure tic ▁pe pti des ▁; ▁np s
▁neuro hormon es ▁; ▁adi pok ines ▁; ▁fat ▁free ▁mass ▁; ▁ff m ▁; ▁fat ▁mass
▁ff m ▁; ▁dual ▁energy ▁x - ray ▁ab sor pti ometr y ▁; ▁d xa ▁; ▁patients ▁; ▁chronic ▁heart ▁failure ▁; ▁ch f ▁; ▁non - ca che ctic ▁ch f ▁; ▁my o card ial
▁bio mark ers ▁; ▁neuro hormon al ▁stimul ation ▁; ▁ inflammation ▁; ▁en dot heli al ▁dys function
▁n - termin al ▁prob np ▁; ▁ nt - prob np ▁; ▁mid region al ▁pro an p ▁; ▁mr - pro an p ▁; ▁adi pon ect in ▁; ▁eleva ted ▁; ▁ch f ▁; ▁cor related ▁; ▁b mi
▁in verse ▁corre lation ▁; ▁pro - ad re nom edu llin ▁; ▁mr - pro ad m ▁; ▁ff m
▁follow ▁up ▁; ▁ff m ▁; ▁patients
▁cor related ▁; ▁base line ▁; ▁ nt - prob np ▁; ▁mr - pro an p ▁; ▁mr - pro ad m
▁corre lation
▁plasma ▁np s ▁; ▁adi pon ect in ▁; ▁base line ▁; ▁ff m ▁; ▁corre late ▁; ▁np s ▁; ▁adi pon ect in ▁; ▁follow ▁up
▁prospect ive ly ▁; ▁ff m ▁; ▁stable
▁ diagnos is ▁; ▁heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction ▁; ▁clinic al ▁; ▁dop pler ▁e cho card i ography
▁patients ▁; ▁heart ▁failure ▁; ▁left ▁vent ri cular ▁; ▁e je ction ▁ fraction
▁prevale nce ▁; ▁heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction ▁; ▁h f pe f ▁; ▁prognos is
▁ lv ▁dia sto lic ▁dys function ▁; ▁combination ▁; ▁figure ▁; ▁h f pe f
▁clinic al ▁; ▁dia sto lic ▁dys function ▁; ▁mortal ity
▁ diagnos is ▁; ▁clinic al ▁; ▁prognos tic ▁; ▁dia sto lic ▁dys function ▁; ▁leading ▁; ▁h f pe f
▁european ▁society ▁of ▁card i ology ▁; ▁h f pe f ▁; ▁symptoms ▁; ▁heart ▁failure ▁; ▁pres er ved ▁ lv ▁e je ction ▁ fraction ▁; ▁non - dila ted ▁left ▁vent ric le ▁; ▁evidence ▁; ▁dia sto lic ▁dys function ▁; ▁ lv ▁relax ation ▁; ▁ lv ▁dia sto lic ▁sti ff ness ▁; ▁eleva ted ▁; ▁ lv ▁fill ing ▁pressure s
▁ lv ▁dia sto lic ▁dys function ▁; ▁fill ing ▁pressure s ▁; ▁non - in va sive ly ▁; ▁dop pler ▁e cho card i ography
▁an emia ▁; ▁patients ▁; ▁heart ▁disease ▁; ▁clinic al ▁practice ▁guide line ▁; ▁american ▁college ▁of ▁physician s
▁american ▁college ▁of ▁physician s ▁; ▁ac p ▁; ▁evidence ▁; ▁clinic al ▁; ▁an emia ▁; ▁patients ▁; ▁heart ▁disease
▁an emia ▁; ▁med line ▁; ▁co ch rane ▁libra ry

▁outcome s ▁; ▁mortal ity ▁; ▁hospital ization ▁; ▁exercise ▁ tolerance ▁; ▁quality ▁of ▁life ▁; ▁cardiovascular ▁events ▁; ▁my o card ial ▁in far ction ▁; ▁con ges tive ▁heart ▁failure ▁; ▁ar rhythm ia ▁; ▁cardiac ▁death ▁; ▁hyper tension ▁; ▁ve nous ▁ thro mbo e mbol ic ▁events ▁; ▁ ische mic ▁cerebro vas cular ▁events
▁clinic ians ▁; ▁patient ▁; ▁a ne mic ▁; ▁patients ▁; ▁heart ▁disease
▁evidence ▁; ▁ac p ▁; ▁clinic al ▁practice ▁guidelines
▁ac p ▁; ▁red ▁blood ▁cell ▁trans fusion ▁; ▁hem o glob in ▁; ▁hem o glob in ▁; ▁hospital ized ▁; ▁patients ▁; ▁corona ry ▁heart ▁disease
▁grade ▁; ▁evidence ▁; ▁ac p ▁; ▁er y thro po ies is - stimul ating ▁agents ▁; ▁patients ▁; ▁an emia ▁; ▁con ges tive ▁heart ▁failure ▁; ▁corona ry ▁heart ▁disease
▁grade ▁; ▁evidence ▁; ▁an emia ▁; ▁patients ▁; ▁heart ▁disease
▁an emia ▁; ▁patients ▁; ▁heart ▁disease
▁an emia ▁; ▁heart ▁disease
▁med line ▁; ▁em base ▁; ▁co ch rane ▁; ▁clinic al
▁blood ▁trans fusion s ▁; ▁er y thro po ies is - stimul ating ▁agents ▁; ▁an emia ▁; ▁con ges tive ▁heart ▁failure ▁; ▁corona ry ▁heart ▁disease ▁; ▁trans fusion
▁hem o glob in ▁; ▁health ▁; ▁outcome s

▁evidence ▁; ▁trans fusion ▁; ▁mortal ity ▁; ▁relative ▁risk ▁; ▁mortal ity ▁; ▁patients ▁; ▁a cute ▁corona ry ▁syndrome
▁evidence ▁; ▁intra ven ous ▁; ▁exercise ▁ tolerance ▁; ▁quality ▁of ▁life ▁; ▁patients ▁; ▁heart ▁failure
▁evidence ▁; ▁er y thro po ies is - stimul ating ▁agent ▁; ▁ therapy ▁; ▁ve nous ▁ thro mbo e mbol ism
▁trans fusion s ▁; ▁patients ▁; ▁heart ▁disease

▁trans fusion ▁; ▁mortal ity
▁intra ven ous ▁; ▁symptoms ▁; ▁patients ▁; ▁heart ▁failure
▁er y thro po ies is - stimul ating ▁agents ▁; ▁patients ▁; ▁an emia ▁; ▁heart ▁disease
▁remote ▁ ische mic ▁condition ing ▁; ▁patients ▁; ▁heart ▁failure
▁patients ▁; ▁heart ▁failure ▁; ▁h f ▁; ▁ ische mic ▁; ▁non ische mic ▁cardio my o pathi es ▁; ▁ pharma c ological ▁; ▁implant able ▁cardio ver ter ▁de fi br illa tors ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁cardiac ▁transplant ation ▁; ▁right ▁vent ri cular ▁assist ▁devices
▁patients ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁patients ▁; ▁h f ▁; ▁pres er ved ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁hospital ▁; ▁physician s ▁; ▁a cute ▁; ▁out patient ▁; ▁epidemi c ▁; ▁medical ▁; ▁financial ▁costs
▁emergency ▁department ▁; ▁a cute ▁heart ▁failure ▁; ▁clinic al ▁; ▁patient ▁; ▁colli ns
▁patient ▁; ▁emergency ▁department ▁; ▁a cute ▁heart ▁failure ▁; ▁ah f ▁; ▁clinic al
▁patients ▁; ▁ah f ▁; ▁risk ▁strat ification
▁mortal ity ▁; ▁patients ▁; ▁implant able ▁cardiac ▁de fi br illa tor ▁; ▁meta - analys is
▁mortal ity ▁; ▁heart ▁failure ▁; ▁h f ▁; ▁implant able ▁cardio ver ter ▁de fi br illa tors ▁; ▁i cd s
▁meta - analys is ▁; ▁mortal ity ▁; ▁patients
▁med line ▁; ▁em base ▁; ▁ cina hl
▁ambula tory ▁; ▁i cd ▁; ▁patients ▁; ▁mortal ity ▁; ▁multi vari able ▁re gression
▁meta - ana ly zed ▁; ▁mortal ity ▁; ▁random - effect s ▁models
▁i cd ▁; ▁patients
▁hazard ▁ratio ▁; ▁confidence ▁interval ▁; ▁base line ▁; ▁glo mer ular ▁filtr ation ▁rate ▁; ▁chronic ▁ob struct ive ▁pulmonar y ▁disease ▁; ▁diabetes ▁; ▁per i pher al ▁vas cular ▁disease ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁i cd ▁shock s ▁; ▁new ▁yor k ▁heart ▁association ▁class ▁; ▁at rial ▁fi bril lation ▁; ▁con ges tive ▁h f ▁; ▁mortal ity
▁ ische mic ▁cardio my o pathy ▁; ▁mortal ity
▁meta - analys is ▁; ▁mortal ity ▁; ▁patients
▁renal ▁dys function ▁; ▁chronic ▁ob struct ive ▁pulmonar y ▁disease ▁; ▁diabetes ▁; ▁per i pher al ▁vas cular ▁disease ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁i cd ▁shock s ▁; ▁follow - up ▁; ▁mortal ity ▁; ▁ ische mic ▁cardio my o pathy
▁bio mark ers
▁dop amine ▁; ▁nesi riti de ▁; ▁a cute ▁heart ▁failure ▁; ▁renal ▁dys function ▁; ▁rose ▁; ▁a cute ▁heart ▁failure ▁; ▁random ized
▁dop amine ▁; ▁nesi riti de ▁; ▁renal ▁function ▁; ▁patients ▁; ▁a cute ▁heart ▁failure ▁; ▁renal ▁dys function
▁place bo ▁; ▁dop amine ▁; ▁nesi riti de ▁; ▁bol us ▁; ▁di ure tic ▁; ▁ therapy ▁; ▁renal ▁function ▁; ▁patients ▁; ▁a cute ▁heart ▁failure ▁; ▁renal ▁dys function
▁double - blind ▁; ▁clinic al ▁; ▁renal ▁optimiza tion ▁strategie s ▁evaluation ▁; ▁rose ▁; ▁hospital ized ▁; ▁patients ▁; ▁a cute ▁heart ▁failure ▁; ▁renal ▁dys function ▁; ▁estima ted ▁glo mer ular ▁filtr ation ▁rate ▁; ▁random ized ▁; ▁ad mission
▁north ▁ america
▁random ized ▁; ▁dop amine ▁; ▁nesi riti de
▁random ized ▁; ▁double - blind ▁; ▁active ▁; ▁place bo
▁dop amine ▁; ▁nesi riti de ▁; ▁place bo
▁outcome s ▁; ▁co prima ry ▁end ▁points ▁; ▁end ▁point ▁; ▁change ▁; ▁se rum ▁cyst atin ▁c ▁; ▁renal ▁function ▁; ▁end ▁point
▁place bo ▁; ▁dop amine ▁; ▁dop amine ▁; ▁place bo ▁; ▁change ▁; ▁cyst atin ▁c ▁; ▁dop amine ▁; ▁place bo
▁nesi riti de ▁; ▁nesi riti de ▁; ▁place bo ▁; ▁change ▁; ▁cyst atin ▁c ▁; ▁nesi riti de ▁; ▁place bo
▁place bo ▁; ▁dop amine ▁; ▁nesi riti de ▁; ▁seconda ry ▁end ▁points ▁; ▁renal ▁function ▁; ▁clinic al ▁; ▁outcome s
▁a cute ▁heart ▁failure ▁; ▁renal ▁dys function ▁; ▁dop amine ▁; ▁nesi riti de ▁; ▁renal ▁function ▁; ▁di ure tic ▁; ▁ therapy
▁heart ▁failure ▁; ▁nurse
▁evidence - based ▁; ▁patient ▁; ▁outcome s

▁nurse s ▁; ▁magnet
▁systems ▁prote o mics ▁; ▁cardiac ▁chr omat in ▁; ▁nucleo lin ▁; ▁cel lular ▁plastic ity ▁; ▁cardio my o cy tes
▁my o cy te ▁hyper trop hy ▁; ▁heart ▁failure ▁; ▁global ▁gene ▁expression ▁; ▁d na ▁; ▁genom ic
▁chr omat in - as soci ated ▁protein s ▁; ▁chr omat in ▁structure ▁; ▁changing ▁; ▁d na ▁; ▁gene ▁expression ▁profile
▁chr omat in ▁sub prote om es ▁; ▁heart ▁failure ▁; ▁protein s ▁; ▁chr omat in ▁structure
▁tests ▁; ▁cardiac ▁growth ▁; ▁disease ▁; ▁chr omat in ▁; ▁remodel ing
▁prote o mics ▁; ▁chr omat in - as soci ated ▁protein s ▁; ▁disease
▁protein s ▁; ▁sub prote ome
▁protein s ▁; ▁expression ▁; ▁cardiac ▁hyper trop hy ▁; ▁protein s ▁; ▁nucleo lin
▁mor pho lino - based ▁; ▁nucleo lin ▁; ▁protein ▁expression
▁heart s ▁; ▁nucleo lin ▁; ▁cha mber ▁pattern ing ▁; ▁cardiac ▁loop ing ▁; ▁my o cy te ▁differenti ation
▁bone ▁mor pho gene tic ▁protein ▁4 ▁; ▁expression ▁; ▁r rna ▁tran scription ▁; ▁shift ▁; ▁hetero ch ro matic ▁chr omat in
▁chr omat in ▁sub prote ome ▁; ▁disease d ▁; ▁heart
▁nucleo lin ▁; ▁genom ic ▁re programm ing ▁; ▁disease
▁outcome s ▁; ▁my o card ial ▁ ische mic ▁events ▁; ▁patients ▁; ▁cardiac ▁re syn chron ization ▁ therapy
▁ ische mic ▁events ▁; ▁ies ▁; ▁patients ▁; ▁ ische mic ▁cardio my o pathy ▁; ▁ ic ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁de fi br illa tor ▁; ▁cr t - d
▁patients ▁; ▁ ic ▁; ▁multi center ▁automatic ▁de fi br illa tor ▁implant ation ▁trial - card iac ▁re syn chron ization ▁ therapy
▁multi varia te ▁co x ▁proportion al ▁hazard s ▁re gression ▁model ing ▁; ▁hospital ization ▁; ▁a cute ▁corona ry ▁syndrome s ▁; ▁corona ry ▁intervention s ▁; ▁patients
▁heart ▁failure ▁; ▁h f ▁; ▁death ▁; ▁cr t - d
▁patients ▁; ▁re vas cular ization ▁; ▁corona ry ▁arter y ▁by pass ▁surgery ▁; ▁hazard ▁ratio ▁; ▁per cuta ne ous ▁corona ry ▁intervention ▁; ▁sy sto lic ▁blood ▁pressure ▁; ▁left ▁bund le ▁bran ch ▁block ▁pattern ▁; ▁base line ▁; ▁electro card i ogram
▁cr t - d ▁; ▁ therapy
▁ies ▁; ▁cr t - d ▁; ▁heart ▁failure ▁; ▁death
▁cr t - d ▁; ▁patients ▁; ▁ ic ▁; ▁cr t - d ▁; ▁ies
▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁mortal ity ▁; ▁patients ▁; ▁heart ▁failure ▁; ▁heart ▁failure ▁survey ▁; ▁israel
▁heart ▁failure ▁; ▁h f ▁; ▁ therapie s ▁; ▁outcome s ▁; ▁patients ▁; ▁h f ▁; ▁pres er ved ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁l ve f
▁differenti al ▁effect ▁; ▁l ve f ▁; ▁mortal ity ▁; ▁hospital ization ▁; ▁a cute ▁; ▁de com pensa ted ▁h f
▁all - ca use ▁mortal ity ▁; ▁hospital ization ▁; ▁h f ▁; ▁l ve f ▁; ▁patients ▁; ▁heart ▁failure ▁survey ▁; ▁israel
▁patients ▁; ▁pres er ved ▁l ve f ▁; ▁l ve f
▁multi varia te ▁analysis ▁; ▁patients ▁; ▁pres er ved ▁l ve f ▁; ▁mortal ity ▁; ▁patients ▁; ▁l ve f ▁; ▁hazard ▁ratio ▁; ▁l ve f ▁; ▁pres er ved ▁l ve f
▁interaction ▁term ▁analysis ▁; ▁l ve f ▁; ▁patients ▁; ▁patients ▁; ▁mortal ity ▁; ▁l ve f ▁; ▁p ▁value
▁patients ▁; ▁hospital ized ▁; ▁h f ▁; ▁pres er ved ▁l ve f ▁; ▁mortal ity ▁; ▁patients ▁; ▁l ve f ▁; ▁l ve f ▁; ▁mortal ity
▁differenti al ▁effect ▁; ▁l ve f ▁; ▁mortal ity
▁circula ting ▁pro gen itor ▁cell s ▁; ▁outcome ▁; ▁heart ▁failure ▁; ▁patients ▁; ▁longitud in al
▁circula ting ▁pro gen itor ▁cell s ▁; ▁c pc s ▁; ▁en dot heli al ▁; ▁prognos tic ▁; ▁cardiovascular ▁disease s
▁c pc s ▁; ▁functional ▁capacity ▁; ▁outcome s ▁; ▁heart ▁failure ▁; ▁h f
▁ambula tory ▁; ▁h f ▁; ▁patients ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction
▁c pc s ▁; ▁functional ▁capacity ▁; ▁pe ak ▁vo 2
▁c pc s ▁; ▁early - out g row th ▁colon y - form ing ▁unit s ▁; ▁eo - cf us ▁; ▁cell s
▁mortal ity ▁; ▁h f ▁; ▁hospital ▁; ▁ad missions ▁; ▁transplant ▁; ▁vent ri cular ▁assist ▁device

▁cell s ▁; ▁functional ▁capacity ▁; ▁cell s ▁; ▁pe ak ▁vo 2
▁eo - cf us ▁; ▁diabetes ▁; ▁patients ▁; ▁diabetes ▁; ▁pe ak ▁vo 2 ▁; ▁patients ▁; ▁diabetes ▁; ▁eo - cf us ▁; ▁pe ak ▁vo 2
▁eo - cf us ▁; ▁mortal ity ▁; ▁hazard ▁ratio ▁; ▁confidence ▁interval
▁c pc s ▁; ▁outcome s ▁; ▁patients ▁; ▁diabetes
▁eo - cf us ▁; ▁cell s ▁; ▁functional ▁capacity ▁; ▁mortal ity ▁; ▁non dia be tic ▁; ▁patients
▁patients ▁; ▁diabetes ▁; ▁eo - cf us ▁; ▁functional ▁capacity

▁read mission
▁hospital ▁; ▁read mission ▁; ▁all - ca use ▁read mission ▁; ▁ac r ▁; ▁potential ▁prevent able ▁read mission ▁; ▁pp r ▁; ▁medica re ▁; ▁medica id ▁; ▁read mission ▁; ▁cm s
▁cali for nia ▁office ▁of ▁state wide ▁health ▁planning ▁and ▁development ▁patient ▁dis charge ▁data ▁non public ▁file
▁read mission ▁; ▁disease ▁; ▁heart ▁failure ▁; ▁h f ▁; ▁a cute ▁my o card ial ▁in far ction ▁; ▁ami ▁; ▁pneu monia
▁change ▁; ▁corre lation ▁; ▁hospital s ▁; ▁longitud in al
▁principal ▁; ▁hospital ▁; ▁h f ▁; ▁patients ▁; ▁cm s ▁; ▁conditions
▁corre lation s ▁; ▁ac r ▁; ▁cm s
▁pp r ▁; ▁ac r ▁; ▁cm s ▁; ▁cor related
▁hospital s
▁corre lation s ▁; ▁hospital ▁; ▁longitud in al ▁; ▁change
▁read missions ▁; ▁hospital
▁read mission
▁remote ▁monitoring ▁; ▁hospital ▁; ▁dis charge ▁; ▁patients ▁; ▁heart ▁failure ▁; ▁meta - analys is
▁read mission ▁; ▁hospital ▁; ▁heart ▁failure ▁; ▁dis charge
▁remote ▁monitoring ▁; ▁r m ▁; ▁heart ▁failure
▁r m ▁; ▁outcome s ▁; ▁dis charge d ▁; ▁ad mission ▁; ▁heart ▁failure
▁meta - analys is
▁med line ▁; ▁em base ▁; ▁psy c info
▁random ised - control led ▁trial s ▁; ▁ rc ts ▁; ▁observation al ▁co hor t ▁studies ▁; ▁contemporane ous ▁control ▁group
▁r m ▁; ▁tele monitor ing ▁; ▁implant ed ▁; ▁medical ▁; ▁structure d ▁telephone ▁support ▁; ▁st s ▁; ▁human - to - human ▁contact ▁; ▁ hh ▁; ▁human - to - machine ▁interface

▁ rc ts ▁; ▁patients ▁; ▁st s ▁; ▁ hh ▁; ▁st s
▁implant ed
▁significa nce ▁; ▁r m ▁; ▁all - ca use ▁mortal ity ▁; ▁st s ▁; ▁ hh ▁; ▁cri ▁; ▁cri ▁; ▁cri

▁mortal ity ▁; ▁st s
▁all - ca use ▁hospital isation s ▁; ▁st s
▁quality - of - life ▁; ▁patients
▁st s ▁; ▁ hh ▁; ▁medical ▁; ▁all - ca use ▁mortal ity ▁; ▁dis charge d ▁; ▁patients ▁; ▁heart ▁failure
▁r m
▁apo pto sis ▁; ▁chronic ▁heart ▁failure ▁; ▁ta chy car dia
▁apo pto sis ▁; ▁pa cing - indu ced ▁dil ated ▁cardio my o pathy
▁right ▁vent ri cular ▁pa cing ▁; ▁gene ▁expression s ▁; ▁bax ▁; ▁b cl -2 ▁; ▁cas pas e -3 ▁; ▁ rt q - pc r ▁; ▁interven tri cular ▁sept um ▁; ▁bio psi es ▁; ▁heart ▁failure
▁protein ▁; ▁gene s ▁; ▁western ▁blot ▁; ▁d na ▁fragment ation ▁; ▁tunel
▁gene ▁expression ▁; ▁bax ▁; ▁pa cing ▁; ▁b cl -2 ▁; ▁m rna ▁; ▁expression ▁; ▁heart ▁failure ▁; ▁b cl -2 ▁; ▁bax
▁cas pas e -3 ▁; ▁gene ▁expression ▁; ▁heart ▁failure
▁expression ▁; ▁bax ▁; ▁b cl -2 ▁; ▁protein s ▁; ▁pa cing
▁cas pas e ▁; ▁my o car dium
▁tunel ▁; ▁apo pto tic ▁cell s ▁; ▁tunel - posi tive ▁cell s
▁apo pto sis ▁; ▁path ogen es is ▁; ▁heart ▁failure
▁up tit ration ▁; ▁re nin - angi oten sin ▁system ▁block er ▁; ▁beta - block er ▁; ▁ therapy ▁; ▁patients ▁; ▁hospital ized ▁; ▁heart ▁failure ▁; ▁pres er ved ▁left ▁vent ri cular ▁e je ction ▁ fraction s
▁ambula tory ▁; ▁patients ▁; ▁heart ▁failure ▁; ▁h f ▁; ▁reduce d ▁e je ction ▁ fraction ▁; ▁re nin - angi oten sin ▁system ▁; ▁ras ▁; ▁β - block ers ▁; ▁all - ca use ▁mortal ity ▁; ▁read missions
▁h f ▁with ▁pres er ved ▁e je ction ▁ fraction ▁; ▁pe f ▁; ▁up tit ration ▁; ▁hospital ization
▁β - block er ▁; ▁up ti tra tions ▁; ▁patients ▁; ▁h fre f ▁; ▁h f pe f ▁; ▁hospital ▁; ▁ad mission
▁patients ▁; ▁h fre f ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁h f pe f ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁β - block er ▁; ▁h f ▁; ▁hospital ization
▁patients ▁; ▁β - block er ▁; ▁patients ▁; ▁up tit ration
▁patients ▁; ▁up tit ration ▁; ▁heart ▁rate ▁; ▁renal ▁function ▁; ▁spi rono lac tone
▁β - block er ▁; ▁up ti tra tions ▁; ▁com posit e ▁end - point ▁; ▁all - ca use ▁mortal ity ▁; ▁h f ▁; ▁read missions ▁; ▁h fre f ▁; ▁hazard ▁ratio ▁; ▁confidence ▁interval
▁heart ▁rate ▁; ▁blood ▁pressure ▁; ▁renal ▁function ▁; ▁spi rono lac tone ▁; ▁ras ▁block ers ▁; ▁β - block ers
▁β - block er ▁; ▁up tit ration ▁; ▁h f pe f
▁up tit ration ▁; ▁neuro hu moral ▁block ers ▁; ▁h f ▁; ▁hospital ization ▁; ▁patients ▁; ▁co - mor bid ity
▁ras - block er ▁; ▁up tit ration ▁; ▁clinic al ▁; ▁outcome ▁; ▁patients ▁; ▁h fre f ▁; ▁h f pe f
▁e je ction ▁ fraction ▁; ▁b - type ▁na tri ure tic ▁pe pti de ▁; ▁patients ▁; ▁hospital ized ▁; ▁heart ▁failure ▁; ▁in hospital ▁; ▁outcome s ▁; ▁get ▁with ▁the ▁guide line - heart ▁failure ▁registr y
▁heart ▁failure ▁; ▁h f ▁; ▁plasma ▁b - type ▁na tri ure tic ▁pe pti de ▁; ▁b np ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; ▁ef ▁; ▁h f
▁ef ▁; ▁b np ▁; ▁h f ▁; ▁patients ▁; ▁prognos tic ▁; ▁significa nce ▁; ▁b np ▁; ▁ef
▁hospital s ▁; ▁get ▁with ▁the ▁guidelines - heart ▁failure ▁; ▁h f ▁; ▁patients ▁; ▁ef ▁; ▁ef ▁; ▁ef ▁; ▁ef
▁primary ▁end ▁point ▁; ▁in hospital ▁; ▁mortal ity
▁multi varia te ▁models ▁; ▁odds ▁ratio s ▁; ▁account ing ▁; ▁hospital
▁patients ▁; ▁ef
▁ad mission ▁; ▁b np ▁; ▁reduce d ▁ef ▁; ▁pres er ved ▁ef ▁; ▁b np ▁; ▁ef
▁e je ction ▁ fraction ▁; ▁b np
▁in hospital ▁; ▁mortal ity ▁; ▁patients ▁; ▁b np ▁; ▁mortal ity
▁clinic al ▁; ▁b np ▁; ▁in hospital ▁; ▁mortal ity
▁ef ▁; ▁b np ▁; ▁b np ▁; ▁in hospital ▁; ▁mortal ity
▁ diagnos is ▁; ▁medical ▁; ▁heart ▁failure ▁; ▁can a dian ▁cardiovascular ▁society
▁heart ▁failure ▁; ▁h f ▁; ▁morbi d ity ▁; ▁mortal ity
▁ diagnos is ▁; ▁medical ▁; ▁h f
▁emergency ▁room ▁; ▁un diagnos ed ▁; ▁heart ▁disease ▁; ▁symptoms ▁; ▁h f ▁; ▁sur g ical ▁palli ation
▁grade ▁; ▁clinic al
▁vent ri cular ▁assist ▁devices ▁; ▁ therapie s
▁heart ▁failure ▁; ▁mortal ity
▁dod son
▁nurse ▁; ▁hospital ization ▁; ▁physician ▁; ▁dis charge ▁; ▁patients ▁; ▁hospital ized ▁; ▁heart ▁failure
▁mortal ity ▁; ▁read mission
▁in tuba tions ▁; ▁con ges tive ▁heart ▁failure
▁con ges tive ▁heart ▁failure ▁; ▁ch f
▁ch f ▁; ▁patients ▁; ▁emergency ▁department ▁; ▁in tuba ted
▁retro spec tive ▁co hor t
▁patients ▁; ▁physician s ▁; ▁hospital s ▁; ▁new ▁jersey ▁; ▁new ▁yor k
▁patients ▁; ▁ch f ▁; ▁international ▁classifica tion ▁of ▁disease s
▁ch f ▁; ▁ch f ▁; ▁patients ▁; ▁in tuba ted
▁student ▁t ▁test ▁; ▁confidence ▁interval s ▁; ▁ci s ▁; ▁re gression ▁analyse s
▁ch f
▁ch f ▁; ▁patients
▁con ges tive ▁heart ▁failure ▁; ▁corre lation ▁co e ffi cient
▁ch f ▁; ▁patients ▁; ▁in tuba ted
▁in tub ation
▁ch f ▁; ▁in tub ation
▁ch f
▁hem o dynamic ▁ph eno type ▁; ▁font an
▁font an ▁failure ▁; ▁sy sto lic ▁vent ri cular ▁function ▁; ▁ liver ▁disease
▁font an ▁failure ▁; ▁hem o dynamic ally ▁; ▁heart ▁failure ▁; ▁system ic ▁vas cular ▁resist ance ▁; ▁sv r ▁; ▁cardiac ▁index
▁symptom a tic ▁adult ▁font an ▁; ▁saf ▁; ▁patients ▁; ▁cat heter ization
▁as ym pto matic ▁; ▁pediatr ic ▁font an ▁; ▁patients ▁; ▁cat heter ization
▁clinic al
▁symptom a tic ▁; ▁new ▁yor k ▁heart ▁association ▁classes ▁; ▁saf
▁saf ▁; ▁cat heter ization ▁; ▁central ▁ve nous ▁pressure ▁; ▁sv r ▁; ▁cardiac ▁index
▁saf ▁; ▁incide nce ▁; ▁ liver ▁; ▁no du lar ity
▁patients ▁; ▁font an ▁circulation ▁; ▁sv r ▁; ▁cardiac ▁index
▁ liver ▁disease
▁font an ▁failure ▁; ▁circula tory ▁; ▁hem o dynamic ▁; ▁portal ▁hyper tension ▁; ▁cardiac ▁output
▁heart ▁; ▁hospital ization ▁; ▁death ▁; ▁patients ▁; ▁pres er ved ▁left ▁vent ri cular ▁e je ction ▁ fraction
▁heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction ▁; ▁h f pe f ▁; ▁cardiovascular ▁morbi d ity ▁; ▁mortal ity
▁patients ▁; ▁h f pe f ▁; ▁advers e ▁outcome s
▁patients ▁; ▁heart ▁failure ▁; ▁h f ▁; ▁heart ▁failure ▁ad her ence ▁and ▁re tention ▁trial ▁; ▁hart
▁hart ▁; ▁patients ▁; ▁new ▁yor k ▁heart ▁association ▁; ▁ny ha ▁; ▁hospital ized ▁; ▁h f ▁; ▁primary ▁outcome ▁; ▁death ▁; ▁h f ▁; ▁hospital ization
▁hart ▁; ▁patients ▁; ▁h f pe f ▁; ▁h f ▁with ▁reduce d ▁e je ction ▁ fraction ▁; ▁h fre f
▁multi varia te ▁models
▁patients ▁; ▁h f pe f ▁; ▁primary ▁outcome ▁; ▁odds ▁ratio ▁; ▁ny ha ▁class ▁i ii ▁; ▁6- minut e ▁walk ▁test ▁; ▁6- m w t ▁; ▁feet ▁; ▁pre scribe d ▁; ▁medication s
▁patients ▁; ▁h fre f ▁; ▁di ure tics ▁; ▁co - mor bid ities ▁; ▁6- m w t ▁; ▁feet ▁; ▁ny ha ▁class ▁i ii
▁functional ▁status ▁; ▁6- m w t ▁; ▁ny ha ▁class ▁; ▁patients ▁; ▁h f pe f ▁; ▁h fre f ▁; ▁pre scribe d ▁; ▁ therapy ▁; ▁patients ▁; ▁h f pe f ▁; ▁death ▁; ▁h f ▁; ▁hospital ization
▁exercise ▁; ▁training ▁; ▁patients ▁; ▁chronic ▁heart ▁failure ▁; ▁high - dens ity ▁lipo prote in
▁high - dens ity ▁lipo prote in ▁; ▁hd l ▁; ▁en dot heli al ▁cell ▁; ▁ni tric ▁oxid e
▁patients ▁; ▁cardiovascular ▁disease
▁exercise ▁; ▁training ▁; ▁en dot heli al ▁function
▁molecular ▁path ways ▁; ▁patients ▁; ▁chronic ▁heart ▁failure ▁; ▁ch f
▁hd l ▁; ▁healthy ▁; ▁hd l ▁; ▁healthy ▁; ▁patients ▁; ▁ch f - ny ha - i ii ▁; ▁hd l ▁; ▁ny ha - ii ib ▁; ▁patients ▁; ▁ch f - ny ha - ii ▁; ▁hd l ▁; ▁ny ha - ii
▁e cs ▁; ▁hd l ▁; ▁ phos phor y lation
▁malo ndi alde hy de
▁en dot heli al ▁function ▁; ▁flow - media ted ▁di la tation
▁prote ome ▁; ▁hd l
▁hd l ▁; ▁ny ha - ii ib ▁; ▁ phos phor y lation ▁; ▁ phos phor y lation ▁; ▁hd l ▁; ▁healthy

▁eleva ted ▁; ▁p 70 s 6 k ▁; ▁ pk c - β ii ▁; ▁hd l ▁; ▁ny ha - ii ib ▁; ▁malo ndi alde hy de ▁; ▁ bound ▁; ▁hd l ▁; ▁ny ha - ii ib ▁; ▁hd l ▁; ▁healthy
▁healthy ▁; ▁hd l ▁; ▁ch f - ny ha - ii ib ▁; ▁hd l
▁corre lation ▁; ▁flow - media ted ▁di la tation
▁hd l ▁; ▁ch f ▁; ▁vas cular
▁ch f
▁ nt - prob np ▁; ▁patients ▁; ▁a cute ▁heart ▁failure
▁plasma ▁n - termin al ▁pro - b - type ▁na tri ure tic ▁pe pti de ▁; ▁ nt - prob np ▁; ▁patients ▁; ▁a cute ▁heart ▁failure ▁; ▁h f ▁; ▁ad mission ▁; ▁emergency ▁department
▁ad mission ▁; ▁ nt - prob np ▁; ▁patients ▁; ▁a cute ▁h f ▁; ▁ diagnos is
▁ nt - prob np ▁; ▁plasma ▁; ▁patients ▁; ▁dys pne a ▁; ▁left ▁vent ri cular ▁dys function ▁; ▁ad mission
▁end ▁point
▁patients ▁; ▁patients
▁follow - up ▁; ▁patients
▁ nt - prob np ▁; ▁ad mission ▁; ▁ sensitiv ity ▁; ▁specific ity ▁; ▁confidence ▁interval ▁; ▁area ▁under ▁the ▁cur ve
▁eleva ted ▁; ▁ nt - prob np ▁; ▁ad mission ▁; ▁all - ca use ▁mortal ity ▁; ▁patients ▁; ▁a cute ▁h f ▁; ▁ad mission
▁ nt - prob np ▁; ▁ sensitiv ity
▁prospect ive
▁heart ▁failure ▁; ▁hyper tensi ve ▁heart ▁disease ▁; ▁ang io ten sin ▁i i ▁; ▁in fusion ▁; ▁nep hr ecto my ▁; ▁salt ▁load ing
▁heart ▁failure ▁; ▁h f ▁; ▁hyper tensi ve ▁heart ▁disease ▁; ▁h hd ▁; ▁pat ho phy si ology ▁; ▁ therapeut ic ▁; ▁h hd ▁; ▁stable ▁; ▁ph eno type s
▁h f ▁; ▁h hd ▁; ▁salt ▁load ing ▁; ▁un ine ph r ecto my ▁; ▁ang ▁i i ▁in fusion
▁ang ▁i i ▁in fusion ▁; ▁ang ▁i i ▁in fusion ▁; ▁un ine ph r ecto my ▁; ▁ang ▁i i ▁in fusion ▁; ▁salt ▁load ing ▁; ▁ang ▁i i ▁in fusion ▁; ▁un ine ph r ecto my ▁; ▁salt ▁load ing
▁sy sto lic ▁blood ▁pressure ▁; ▁eleva ted ▁; ▁left ▁vent ri cular ▁; ▁hyper trop hy
▁ lv ▁ fraction al ▁short en ing ▁; ▁lung ▁; ▁incide nce
▁ph eno type ▁; ▁per i operativ e ▁; ▁death s
▁ lv ▁fibro sis
▁oxid ative ▁stress ▁; ▁ gt pas e ▁; ▁rac 1 ▁; ▁activity ▁; ▁heart s
▁salt ▁load ing ▁; ▁un ine ph r ecto my ▁; ▁ang ▁i i ▁in fusion ▁; ▁cardiac ▁function ▁; ▁h f
▁h f ▁; ▁transition ▁; ▁compensa ted ▁ lv ▁hyper trop hy ▁; ▁h f ▁; ▁h hd
▁trop onin ▁t ▁; ▁n - termin al ▁pro - b - type ▁na tri ure tic ▁pe pti de ▁; ▁bio mark er ▁; ▁heart ▁failure ▁; ▁at hero sc ler osis ▁risk ▁in ▁communities
▁cardiovascular ▁disease s ▁; ▁heart ▁failure ▁; ▁h f ▁; ▁incide nce ▁; ▁h f
▁cardiac ▁trop onin ▁t ▁; ▁ct nt ▁; ▁n - termin al ▁pro - b - type ▁na tri ure tic ▁pe pti de ▁; ▁ nt - prob np ▁; ▁bio mark ers ▁; ▁h f ▁; ▁h f ▁; ▁at hero sc ler osis ▁risk ▁in ▁communities ▁; ▁a ric
▁ct nt ▁; ▁ nt - prob np ▁; ▁report ▁; ▁a ric ▁; ▁h f ▁; ▁sy sto lic ▁blood ▁pressure ▁; ▁anti hy per tensi ve ▁medication ▁; ▁diabetes ▁; ▁body ▁mass ▁index ▁; ▁corona ry ▁heart ▁disease ▁; ▁heart ▁rate ▁; ▁h f ▁; ▁area ▁under ▁the ▁receive r ▁operating ▁character istic ▁cur ve ▁; ▁au c ▁; ▁integrat ed ▁discrimina tion ▁improvement ▁; ▁net ▁re class ification ▁improvement ▁; ▁nr i
▁follow - up ▁; ▁h f
▁ct nt ▁; ▁ nt - prob np ▁; ▁a ric ▁; ▁h f ▁; ▁au cs ▁; ▁nr is
▁report ▁; ▁a ric ▁; ▁h f
▁ct nt ▁; ▁ nt - prob np ▁; ▁h f
▁ct nt ▁; ▁ nt - prob np ▁; ▁report ▁; ▁ct nt ▁; ▁ nt - prob np ▁; ▁clinic al ▁; ▁h f
▁left ▁vent ri cular ▁assist ▁device ▁; ▁right ▁vent ri cular ▁support
▁right ▁vent ri cular ▁; ▁ rv ▁; ▁left ▁vent ri cular ▁assist ▁device ▁; ▁l vad ▁; ▁outcome s
▁patients ▁; ▁ rv ▁support ▁; ▁l vad ▁; ▁patients ▁; ▁cardio ge nic ▁shock ▁; ▁my o card ial ▁in far ction ▁; ▁chronic ▁de com pensa ted ▁heart ▁failure
▁patients ▁; ▁bi ven tri cular ▁support ▁; ▁heart mate ▁i i ▁; ▁l vad ▁; ▁centri mag ▁; ▁right ▁vent ri cular ▁assist ▁device ▁; ▁r vad
▁patients ▁; ▁l vad ▁; ▁patients ▁; ▁bi ven tri cular ▁support
▁patients ▁; ▁heart mate ▁i i ▁; ▁l vad ▁; ▁centri mag ▁; ▁r vad
▁pre operativ e ▁; ▁operativ e ▁; ▁outcome s
▁patients ▁; ▁heart mate ▁i i ▁; ▁bi ven tri cular ▁support ▁; ▁heart mate ▁i i ▁; ▁implant ation
▁bi ven tri cular ▁support ▁; ▁r vad s ▁; ▁ex plant ed
▁hospital ▁; ▁dis charge
▁patients ▁; ▁heart mate ▁i i ▁; ▁l vad
▁bi ven tri cular ▁support ▁; ▁heart mate ▁i i ▁; ▁l vad ▁; ▁centri mag ▁; ▁r vad ▁; ▁mortal ity ▁; ▁hospital ▁; ▁dis charge
▁bi ven tri cular ▁dys function ▁; ▁outcome ▁; ▁patients ▁; ▁heart mate ▁i i
▁heart ▁transplant ation ▁; ▁left ▁vent ri cular ▁assist ▁device

▁left ▁vent ri cular ▁assist ▁devices ▁; ▁l vad s ▁; ▁chronic ▁end - s tage ▁heart ▁failure ▁; ▁ bridge ▁to ▁transplant ation ▁; ▁b tt ▁; ▁patients ▁; ▁destination ▁ therapy ▁; ▁d t
▁evidence ▁; ▁clinic al ▁; ▁continuo us - flow ▁l vad s ▁; ▁heart mate ▁i i ▁; ▁ hm ▁i i ▁; ▁heart ware ▁; ▁b tt ▁; ▁d t ▁; ▁patients
▁clinic al ▁; ▁ hm ▁i i ▁; ▁heart ware ▁; ▁patients ▁; ▁economic ▁; ▁ hm ▁i i
▁outcome
▁policy
▁complica tions ▁; ▁implant ation ▁; ▁l vad ▁ therapy ▁; ▁transplant ation ▁; ▁b tt ▁; ▁d t ▁; ▁medical ▁ therapy
▁b tt ▁; ▁d t ▁; ▁b tt ▁; ▁patients
▁b tt ▁; ▁d t ▁; ▁implant ation
▁evidence ▁; ▁l vad ▁; ▁transplant ation ▁; ▁patients ▁; ▁budget
▁evidence ▁; ▁economic ▁; ▁l vad ▁; ▁outcome s
▁bi ven tri cular ▁pa cing ▁; ▁left ▁heart ▁twist ▁; ▁strain ▁; ▁right ▁heart ▁failure
▁bi ven tri cular ▁pa cing ▁; ▁bi v p ▁; ▁cardiac ▁output ▁; ▁cardiac ▁; ▁surgery ▁; ▁patients
▁spec kle ▁track ing ▁e cho card i ography ▁; ▁ste ▁; ▁bi v p ▁; ▁a cute ▁; ▁right ▁vent ri cular ▁pressure ▁over load ▁; ▁ rv po
▁inferior ▁ve na ▁ca va ▁; ▁i vc
▁heart ▁block ▁; ▁pulmonar y ▁arter y ▁; ▁bi v p
▁e cho card i ogram s ▁; ▁left ▁vent ri cular ▁; ▁mid pap illa ry ▁; ▁at rio ven tri cular ▁de lay ▁; ▁av d ▁; ▁interven tri cular ▁de lay ▁; ▁v vd ▁; ▁ste ▁; ▁circum fer ential ▁strain ▁; ▁radi al ▁strain ▁; ▁rs
▁e cho card i ogram s ▁; ▁left ▁vent ri cular ▁base ▁; ▁mid pap illa ry ▁; ▁ap ex ▁; ▁base line ▁; ▁i vc ▁oc clusi on ▁; ▁bi v p ▁; ▁ste ▁; ▁rs
▁cor related ▁; ▁mix ed ▁linear ▁models
▁i vc ▁oc clusi on ▁; ▁cor related ▁; ▁rs ▁; ▁rs ▁synchron y
▁ rv po ▁; ▁bi v p ▁; ▁cor related ▁; ▁rs ▁synchron y
▁av d ▁; ▁v vd ▁; ▁free ▁wall ▁rs
▁cor related ▁; ▁sept al ▁; ▁wall ▁; ▁av d ▁; ▁free ▁wall ▁cs ▁; ▁v vd
▁che st ▁; ▁rs ▁; ▁rs ▁synchron y ▁; ▁ste ▁; ▁non in va sive ▁; ▁ rv po ▁; ▁rs ▁synchron y ▁; ▁strain ▁; ▁bi v p
▁corre lation ▁; ▁posts y sto lic ▁function
▁mit ral ▁sten osis ▁; ▁medical ▁treatment ▁; ▁heart ▁failure
▁reported ▁; ▁functional ▁mit ral ▁sten osis ▁; ▁ring ▁ann ulo plast y ▁; ▁ ische mic ▁mit ral ▁re gur gi tation
▁combination ▁; ▁surgery ▁; ▁dia sto lic ▁mit ral ▁val ve ▁te ther ing ▁; ▁anterior ▁le a flet ▁; ▁papil lar y ▁muscle s ▁; ▁left ▁vent ri cular ▁di la tation
▁report ▁; ▁mit ral ▁val ve ▁plast y ▁; ▁de genera tive ▁mit ral ▁re gur gi tation
▁heart ▁failure ▁; ▁hyper tension ▁; ▁mit ral ▁re gur gi tation ▁; ▁mit ral ▁sten osis ▁; ▁medical ▁treatment ▁; ▁heart ▁failure
▁functional ▁mit ral ▁sten osis ▁; ▁ring ▁ann ulo plast y ▁; ▁ ische mic ▁mit ral ▁re gur gi tation
▁combination ▁; ▁surgery ▁; ▁dia sto lic ▁mit ral ▁val ve ▁te ther ing ▁; ▁anterior ▁le a flet ▁; ▁papil lar y ▁muscle s ▁; ▁left ▁vent ri cular ▁; ▁di la tation
▁functional ▁ms ▁; ▁reported ▁; ▁patients ▁; ▁de genera tive ▁mr
▁functional ▁ms ▁; ▁patients ▁; ▁val ve ▁plast y ▁; ▁de genera tive ▁mr ▁; ▁dil ated ▁; ▁disease
▁functional ▁ms ▁; ▁ lv ▁di la tation ▁; ▁heart ▁failure ▁; ▁h f ▁; ▁functional ▁ms ▁; ▁h f ▁; ▁pro lapse ▁; ▁de genera tive ▁mit ral ▁val ve
▁grade ▁; ▁holo sy sto lic ▁mur mur ▁; ▁third ▁heart ▁sound ▁; ▁ap ex
▁blood ▁pressure ▁; ▁mit ral ▁val ve ▁plast y ▁; ▁de genera tive ▁mr ▁; ▁p 3 ▁pro lapse ▁; ▁chor dal ▁rup tures ▁; ▁tri ang ular ▁res ection ▁; ▁edge - to - ed ge ▁an asto mos is ▁; ▁ring ▁ann ulo plast y ▁; ▁physio ▁ring ▁30 ▁; ▁ed ward s ▁life science s ▁; ▁ir vine
▁surgery ▁; ▁h f ▁; ▁post operativ e ▁; ▁e cho card i ography ▁; ▁end - dia sto lic ▁volume ▁index ▁; ▁ lv ▁e je ction ▁ fraction ▁; ▁mit ral ▁val ve ▁opening ▁; ▁mit ral ▁val ve ▁area ▁; ▁m va
▁m va ▁; ▁continu ity ▁e qu ation ▁; ▁ lv ▁end - dia sto lic ▁volume ▁; ▁ lv ▁end - sy sto lic ▁volume ▁; ▁mit ral ▁fill ing ▁flow ▁; ▁m va ▁; ▁mit ral ▁fill ing ▁flow ▁; ▁continuo us ▁wa ve ▁dop pler ▁e cho card i ography ▁; ▁mit ral ▁val ve ▁plast y
▁h f
▁hyper tension ▁; ▁diabetes ▁mell itus ▁; ▁grade ▁; ▁sy sto lic ▁; ▁dia sto lic ▁mur mur s ▁; ▁ap ex
▁e cho card i ography ▁; ▁dil ated ▁ lv ▁; ▁end - dia sto lic ▁volume ▁index ▁; ▁ lv ▁e je ction ▁ fraction ▁; ▁mit ral ▁val ve ▁opening ▁; ▁m va
▁corona ry ▁ang i ography ▁; ▁les ions
▁patient ▁; ▁diagnose d ▁; ▁hyper tensi ve ▁ lv ▁dys function
▁sy sto lic ▁; ▁dia sto lic ▁mit ral ▁le a flet ▁motion s ▁; ▁organic ▁; ▁les ion
▁et i ology ▁; ▁diagnose d
▁h f ▁; ▁sur g ical
▁medical ▁treatment ▁; ▁h f ▁; ▁functional ▁ms ▁; ▁medical ▁treatment
▁surgery ▁; ▁medical ▁treatment ▁; ▁h f ▁; ▁hyper tension ▁; ▁vaso dila tors ▁; ▁di ure tics
▁h f ▁; ▁symptom ▁; ▁cardiac ▁mur mur s ▁; ▁blood ▁pressure
▁e cho card i ography ▁; ▁ lv ▁end - dia sto lic ▁volume ▁; ▁mit ral ▁val ve ▁opening ▁; ▁m va
▁patient ▁; ▁surgery ▁; ▁e cho card i ography
▁surgery ▁; ▁rhe u matic ▁; ▁surgery ▁; ▁m va
▁m va ▁; ▁sur g ical ▁; ▁implant ation ▁; ▁le a flet ▁; ▁le a flet ▁; ▁edge - to - ed ge ▁an asto mos is
▁surgery ▁; ▁m va
▁mit ral ▁re gur gi tation ▁; ▁h f ▁; ▁symptoms ▁; ▁surgery
▁surgery
▁patient ▁; ▁h f
▁hyper tension ▁; ▁ lv ▁di la tation ▁; ▁ lv ▁dys function ▁; ▁mit ral ▁val ve ▁; ▁organic ▁; ▁les ion ▁; ▁sy sto lic ▁; ▁dia sto lic ▁te ther ing ▁; ▁et i ology
▁functional ▁ms ▁; ▁ring ▁ann ulo plast y ▁; ▁ ische mic ▁mr ▁; ▁ lv ▁di la tation
▁patient ▁; ▁functional ▁ms ▁; ▁patient ▁; ▁val ve ▁plast y ▁; ▁de genera tive ▁mr ▁; ▁dil ated ▁; ▁disease
▁functional ▁ms ▁; ▁ lv ▁di la tation ▁; ▁functional ▁ms
▁h f ▁; ▁val ve ▁plast y ▁; ▁m va
▁surgery
▁medical ▁treatment ▁; ▁h f ▁; ▁h f ▁; ▁symptom ▁; ▁m va
▁surgery
▁sur g ical ▁; ▁patients ▁; ▁functional ▁ms
▁le a flet ▁; ▁patient ▁; ▁sub val vu lar ▁; ▁ann ular ▁ms
▁report ▁; ▁functional ▁ms ▁; ▁patient ▁; ▁val ve ▁plast y ▁; ▁de genera tive ▁mr ▁; ▁dil ated ▁; ▁disease
▁functional ▁ms ▁; ▁medical ▁treatment ▁; ▁sur g ical
▁risk ▁strat ification ▁; ▁death ▁; ▁all - ca use ▁hospital ization ▁; ▁heart ▁failure ▁; ▁clinic ▁; ▁out patient s
▁heart ▁failure ▁; ▁h f ▁; ▁risk ▁strat ification ▁; ▁in patient ▁; ▁out patient
▁collect ed ▁; ▁clinic al ▁; ▁death ▁; ▁medical ▁; ▁hospital ization ▁; ▁h f ▁; ▁clinic ▁; ▁out patient s
▁co x ▁model ing ▁; ▁heart ▁failure ▁patient ▁sever ity ▁index ▁; ▁h fps i ▁; ▁university ▁of ▁mich igan ▁; ▁h f ▁; ▁clinic ▁; ▁primary ▁outcome
▁h fps i ▁; ▁h f ▁; ▁clinic ▁; ▁outcome s ▁; ▁h fps i ▁; ▁outcome s ▁; ▁track ing ▁; ▁patients ▁; ▁h fps i
▁h fps i ▁; ▁blood ▁u rea ▁nit rogen ▁; ▁b - type ▁na tri ure tic ▁pe pti de ▁; ▁new ▁yor k ▁heart ▁association ▁class ▁; ▁diabetes ▁; ▁at rial ▁fi bril lation ▁; ▁all - ca use ▁hospital ization
▁c ▁statistic s
▁ka plan - me ier ▁cur ves ▁; ▁log - rank ▁testing ▁; ▁risk ▁strat ification ▁; ▁patients ▁; ▁patients
▁h fps i ▁; ▁death ▁; ▁medical ▁; ▁hospital ization ▁; ▁h f ▁; ▁clinic ▁; ▁out patient s ▁; ▁h f ▁; ▁health
▁incide nce ▁; ▁end - s tage ▁renal ▁disease ▁; ▁out patient s ▁; ▁sy sto lic ▁heart ▁failure
▁renal ▁dys function ▁; ▁prognos tic ▁; ▁heart ▁failure ▁; ▁h f ▁; ▁dys function ▁; ▁end - s tage ▁renal ▁disease ▁; ▁es rd
▁incide nce ▁; ▁es rd ▁; ▁out patient s ▁; ▁h f
▁patients ▁; ▁sy sto lic ▁h f ▁; ▁the ▁dan ish ▁heart ▁failure ▁database ▁; ▁es rd ▁; ▁dan ish ▁registr y ▁on ▁di al ysis
▁renal ▁function ▁; ▁the ▁chronic ▁ki dne y ▁disease ▁epidemi ology ▁collaboration ▁; ▁patients ▁; ▁estima ted ▁glo mer ular ▁filtr ation ▁rate ▁; ▁eg fr
▁co x ▁hazard ▁models ▁; ▁es rd ▁; ▁death ▁; ▁com posit e ▁end ▁point ▁; ▁es rd ▁; ▁death ▁; ▁es rd
▁patients
▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁eg fr
▁patients ▁; ▁es rd
▁base line ▁; ▁eg fr ▁; ▁eg fr ▁; ▁eg fr ▁; ▁hyper tension ▁; ▁di ure tics ▁; ▁es rd
▁es rd ▁; ▁out patient s ▁; ▁sy sto lic ▁h f ▁; ▁patients ▁; ▁eg fr
▁eg fr ▁; ▁di ure tics ▁; ▁hyper tension ▁; ▁patients ▁; ▁es rd
▁inter le u kin ▁receptor ▁; ▁st 2 ▁; ▁beta - block er ▁; ▁ therapy ▁; ▁chronic ▁heart ▁failure
▁st 2 ▁; ▁prognos is ▁; ▁heart ▁failure
▁changing ▁; ▁β - block er ▁; ▁s st 2
▁s st 2 ▁; ▁ therapy
▁heart ▁failure ▁; ▁left ▁vent ri cular ▁sy sto lic ▁dys function ▁; ▁post ▁hoc ▁analysis
▁medication ▁; ▁s st 2
▁cardiovascular ▁events ▁; ▁base line ▁; ▁s st 2 ▁; ▁met o pro lol ▁suc cina te
▁patients ▁; ▁s st 2 ▁; ▁ti tra ted ▁; ▁cardiovascular ▁event
▁s st 2 ▁; ▁s st 2 ▁; ▁outcome s
▁patients ▁; ▁s st 2 ▁; ▁cardiovascular ▁event
▁s st 2 ▁; ▁s st 2 ▁; ▁odds ▁ratio ▁; ▁cardiovascular ▁event
▁patients ▁; ▁s st 2 ▁; ▁s st 2 ▁; ▁odds ▁ratio s ▁; ▁cardiovascular ▁events
▁heart ▁failure ▁; ▁hospital ization ▁; ▁cardiovascular ▁death
▁ therapy ▁; ▁s st 2 ▁; ▁patients ▁; ▁chronic ▁heart ▁failure
▁ni tro x yl ▁; ▁h no ▁; ▁a cute ▁; ▁heart ▁failure
▁ni tro x yl ▁; ▁h no ▁; ▁in o tropi c ▁; ▁ lusi tropi c ▁; ▁vaso dila tor ▁; ▁in ▁vivo ▁; ▁camp
▁clinic al ▁; ▁nit rite ▁; ▁vas cular
▁report ▁; ▁stable ▁; ▁h no ▁donor ▁; ▁c xl -10 20 ▁; ▁my oc ty es ▁; ▁heart s ▁; ▁patients ▁; ▁heart ▁failure ▁; ▁h f
▁c xl -10 20 ▁; ▁h no ▁; ▁c xl -10 51 ▁; ▁t 1
▁vent ri cular ▁my o cy tes ▁; ▁sar com ere ▁; ▁short en ing
▁protein ▁kina se ▁a ▁; ▁gua ny late ▁cy cla se ▁; ▁contract ile ▁response
▁iso prot eren ol ▁; ▁c xl -10 20 ▁; ▁my o cy tes ▁; ▁heart s
▁an est het ized ▁; ▁corona ry ▁micro e mbol ization - indu ced ▁h f ▁; ▁c xl -10 20 ▁; ▁left ▁vent ri cular ▁end - dia sto lic ▁pressure ▁; ▁my o card ial ▁oxygen ▁consum p tion ▁; ▁e je ction ▁ fraction ▁; ▁maximal ▁vent ri cular ▁power ▁index
▁ta chy pac ing - indu ced ▁h f ▁; ▁c xl -10 20 ▁; ▁contract ility ▁; ▁end - sy sto lic ▁elastan ce ▁; ▁ve no arte rial ▁di lation
▁heart ▁rate
▁patients ▁; ▁sy sto lic ▁h f ▁; ▁c xl -10 20 ▁; ▁right ▁heart ▁fill ing ▁pressure s ▁; ▁system ic ▁vas cular ▁resist ance ▁; ▁cardiac ▁; ▁stroke ▁volume ▁index
▁heart ▁rate ▁; ▁arterial ▁pressure
▁h no ▁donor ▁; ▁my o card ial ▁function ▁; ▁evidence ▁; ▁h f
▁e cho car dio graphic ▁; ▁rever se ▁remodel ing ▁; ▁cardiac ▁re syn chron ization ▁ therapy
▁e cho car dio graphic ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁cr t
▁e cho car dio graphic ▁; ▁cr t
▁longitud in al ▁; ▁strain ▁; ▁left ▁vent ric le ▁; ▁e cho car dio graphic ▁; ▁patients ▁; ▁base line ▁; ▁e cho card i ography ▁; ▁cr t ▁; ▁follow - up ▁; ▁e cho card i ogram s
▁re gression ▁analysis ▁; ▁e cho car dio graphic ▁; ▁ lv ▁rever se ▁remodel ing ▁; ▁ lv ▁end - sy sto lic ▁volume
▁co x ▁proportion al ▁hazard s ▁models ▁; ▁death ▁; ▁transplant ation ▁; ▁ lv ▁assist ▁device ▁implant ation ▁; ▁heart ▁failure ▁; ▁hospital ization ▁; ▁follow - up
▁ lv ▁rever se ▁remodel ing ▁; ▁ lv ▁end - dia sto lic ▁ dimension ▁; ▁longitud in al ▁; ▁strain ▁; ▁left ▁vent ric le ▁; ▁left ▁at rial ▁area ▁; ▁right ▁vent ri cular ▁end - dia sto lic ▁area ▁index ▁; ▁right ▁at rial ▁; ▁right ▁vent ri cular ▁ fraction al ▁area ▁; ▁change
▁combination ▁; ▁e cho car dio graphic ▁; ▁ lv ▁rever se ▁remodel ing ▁; ▁ sensitiv ity ▁; ▁specific ity
▁follow - up ▁; ▁death s ▁; ▁heart ▁transplant ations ▁; ▁ lv ▁assist ▁device ▁implant ations ▁; ▁heart ▁failure ▁; ▁ad missions
▁heart ▁failure ▁; ▁ad mission ▁; ▁heart ▁transplant ation ▁; ▁ lv ▁assist ▁device ▁; ▁death ▁; ▁hazard ▁ratio ▁; ▁confidence ▁interval ▁; ▁death ▁; ▁hazard ▁ratio ▁; ▁confidence ▁interval ▁; ▁ ische mic ▁; ▁functional ▁class
▁e cho car dio graphic ▁; ▁patients ▁; ▁rever se ▁remodel ing ▁; ▁cr t ▁; ▁clinic al ▁; ▁outcome s
▁spi rono lac tone ▁; ▁sy sto lic ▁heart ▁failure
▁al do ster one ▁receptor ▁anta gon ists ▁; ▁random ized ▁; ▁morbi d ity ▁; ▁mortal ity ▁; ▁symptom a tic ▁sy sto lic ▁heart ▁failure
▁spi rono lac tone ▁; ▁diagnose d ▁; ▁sy sto lic ▁heart ▁failure ▁; ▁clinic al
▁diagnose d ▁; ▁heart ▁failure ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁spi rono lac tone ▁; ▁ka iser ▁permanente ▁; ▁north ern ▁cali for nia
▁patients ▁; ▁base line ▁; ▁se rum ▁creati nine ▁; ▁se rum ▁po tas s ium
▁co x ▁re gression ▁; ▁co varia tes ▁; ▁spi rono lac tone ▁; ▁death ▁; ▁hospital ization ▁; ▁hyper kal emia ▁; ▁a cute ▁ki dne y ▁injury
▁patients ▁; ▁follow - up ▁; ▁patients ▁; ▁spi rono lac tone ▁; ▁hospital ization ▁; ▁hazard ▁ratio ▁; ▁confidence ▁interval ▁; ▁death ▁; ▁hazard ▁ratio ▁; ▁confidence ▁interval
▁hyper kal emia ▁; ▁a cute ▁ki dne y ▁injury ▁; ▁spi rono lac tone ▁; ▁clinic al
▁spi rono lac tone ▁; ▁hyper kal emia ▁; ▁a cute ▁ki dne y ▁injury
▁sy sto lic ▁heart ▁failure ▁; ▁spi rono lac tone ▁; ▁hospital ization ▁; ▁death
▁spi rono lac tone ▁; ▁clinic al ▁; ▁medication s
▁vas cular ▁en dot heli al ▁growth ▁factor ▁block ade ▁; ▁beta - block er ▁; ▁ therapy ▁; ▁cardiac ▁function ▁; ▁ang io gene sis ▁; ▁remodel ing ▁; ▁heart ▁failure
▁ang io gene sis ▁; ▁post - my o card ial ▁in far ction ▁; ▁heart ▁; ▁heart ▁failure
▁vas cular ▁en dot heli al ▁growth ▁factor ▁; ▁veg f ▁; ▁transition ▁; ▁compensa tory ▁hyper trop hy ▁; ▁cardiac ▁failure
▁β - ad r energi c ▁receptor ▁block er ▁ therapy ▁; ▁my o card ial ▁per fusion ▁; ▁neo angi ogen es is ▁; ▁heart
▁sur g ically ▁; ▁my o card ial ▁in far ction ▁; ▁heart ▁failure ▁; ▁random ized ▁; ▁bis o pro lol
▁e cho card i ography ▁; ▁cardiac ▁; ▁cardiac ▁function
▁cardiac ▁ang io gene sis ▁; ▁in ▁vivo ▁corona ry ▁per fusion ▁; ▁cardiac ▁fibro sis
▁cardiac ▁veg f ▁expression ▁; ▁en dot heli al ▁no ▁synth ase ▁activa tion ▁; ▁heart s
▁pro angi ogen ic ▁; ▁veg f ▁path way ▁; ▁intra ven ously ▁; ▁inject ed ▁; ▁a den ovi ral ▁; ▁veg f ▁receptor ▁; ▁ade no virus
▁his t ological ▁; ▁cap illa ry ▁; ▁corona ry ▁per fusion
▁veg f ▁inhibi tion ▁; ▁cardiac ▁function ▁; ▁remodel ing
▁β - block ade ▁; ▁cardiac ▁ang io gene sis ▁; ▁heart ▁failure ▁; ▁veg f ▁signal ing ▁path way
▁cardiac ▁ang io gene sis ▁; ▁ therapy ▁; ▁cardiac ▁function ▁; ▁remodel ing
▁outcome s ▁; ▁patients ▁; ▁heart ▁failure ▁; ▁emergency ▁department
▁heart ▁failure ▁; ▁emergency ▁department ▁; ▁patient ▁; ▁outcome s
▁retro spec tive ▁co hor t ▁; ▁ed s ▁; ▁ diagnos is ▁; ▁heart ▁failure
▁ed s ▁; ▁como rbi di ties ▁; ▁hospital ized ▁; ▁adjust ed ▁odds ▁ratio ▁; ▁a or ▁; ▁confidence ▁interval ▁; ▁ed s ▁; ▁a or
▁patients ▁; ▁death ▁; ▁hospital ization ▁; ▁a or ▁; ▁a or ▁; ▁a or ▁; ▁a or
▁patients ▁; ▁hospital ized ▁; ▁death ▁; ▁all - ca use ▁read mission ▁; ▁a or ▁; ▁ed s ▁; ▁a or
▁ed s ▁; ▁dis charge ▁; ▁patients ▁; ▁heart ▁failure ▁; ▁outcome s ▁; ▁drive n ▁; ▁read missions
▁a cute ▁heart ▁failure
▁x ant hine ▁oxid ase ▁inhibi tion ▁; ▁left ▁vent ri cular ▁; ▁sy sto lic ▁; ▁dia sto lic ▁function ▁; ▁cardiac ▁volume ▁over load
▁x ant hine ▁oxid ase ▁; ▁xo ▁; ▁left ▁vent ri cular ▁; ▁my o cy tes ▁; ▁volume ▁over load ▁; ▁vo ▁; ▁mit ral ▁re gur gi tation ▁; ▁a orto ca val ▁fi stu la ▁; ▁ac f
▁at p ▁; ▁xo - media ted ▁ros ▁; ▁mito cho ndri al ▁respira tion ▁; ▁contract ile ▁function
▁xo ▁inhibi tion ▁; ▁cardio my o cy te ▁bio ener ge tics ▁; ▁ lv ▁function ▁; ▁chronic ▁ac f
▁spra gue - daw ley ▁; ▁random ized ▁; ▁ac f ▁; ▁allo puri nol
▁e cho card i ography ▁; ▁ lv ▁end - dia sto lic ▁ dimension ▁; ▁ lv ▁end - dia sto lic ▁pressure ▁; ▁wall ▁stress ▁; ▁lung ▁; ▁ac f
▁ lv ▁e je ction ▁ fraction ▁; ▁short en ing ▁; ▁sy sto lic ▁elastan ce ▁; ▁contract ile ▁efficiency ▁; ▁ac f ▁; ▁ac f ▁; ▁allo puri nol ▁; ▁cardio my o cy tes ▁; ▁extra cel lular ▁flux ▁anal y zer
▁contract ile ▁function ▁; ▁ lv ▁di la tation ▁; ▁ lv ▁end - dia sto lic ▁pressure ▁; ▁wall ▁stress ▁; ▁lung
▁allo puri nol ▁; ▁ lv ▁contract ile ▁function ▁; ▁xo - media ted ▁ros ▁; ▁my o fila ment ▁; ▁ sensitiv ity
▁ lv ▁remodel ing ▁; ▁dia sto lic ▁; ▁xo ▁inhibi tion ▁; ▁symptoms ▁; ▁hospital ization s ▁; ▁patients ▁; ▁severe ▁heart ▁failure
▁tissu e ▁dop pler ▁; ▁left ▁vent ri cular ▁fill ing ▁pressure ▁; ▁patients ▁; ▁stable ▁; ▁severe ▁sy sto lic ▁heart ▁failure
▁transmit ral ▁blood ▁flow ▁veloci ty ▁; ▁tissu e ▁dop pler ▁; ▁dia sto lic ▁mit ral ▁ann ulus ▁veloci ty ▁; ▁pulmonar y ▁cap illa ry ▁we dge ▁pressure ▁; ▁pc wp ▁; ▁patients ▁; ▁de com pensa ted ▁sy sto lic ▁heart ▁failure ▁; ▁h f
▁stable ▁h f
▁patients ▁; ▁left ▁vent ri cular ▁; ▁e je ction ▁ fraction ▁; ▁stable ▁h f ▁; ▁right - side d ▁cardiac ▁cat heter ization ▁; ▁trans t hora cic ▁e cho card i ography ▁; ▁transmit ral ▁flow ▁; ▁mit ral ▁ann ulus ▁veloci ties ▁; ▁sy stol e ▁; ▁dia stol e
▁ lv ▁e je ction ▁ fraction ▁; ▁pc wp
▁sept al ▁; ▁cor related ▁; ▁pc wp ▁; ▁p ▁values
▁area ▁under ▁the ▁receive r ▁operating ▁character istic ▁cur ve ▁; ▁au c ▁; ▁pc wp ▁; ▁confidence ▁interval ▁; ▁sept al ▁; ▁p ▁values
▁au cs ▁; ▁sept al ▁; ▁q rs ▁; ▁re syn chron ization
▁sept al ▁; ▁like li hood ▁ratio
▁diagnostic ▁; ▁patients ▁; ▁au c ▁; ▁au c
▁ lv ▁fill ing ▁pressure ▁; ▁stable ▁; ▁severe ▁sy sto lic ▁h f
▁sept al ▁; ▁diagnostic ▁; ▁fill ing ▁pressure s
▁tri cus pid ▁ann ular ▁plane ▁sy sto lic ▁ excursion ▁; ▁pulmonar y ▁arterial ▁sy sto lic ▁pressure ▁; ▁heart ▁failure ▁; ▁right ▁vent ri cular ▁contract ile ▁function ▁; ▁prognos is
▁e cho - der i ved ▁pulmonar y ▁arterial ▁sy sto lic ▁pressure ▁; ▁pas p ▁; ▁right ▁vent ri cular ▁; ▁ rv ▁; ▁tri cus pid ▁ann ular ▁plane ▁sy sto lic ▁ excursion ▁; ▁tap se ▁; ▁dia stol e ▁; ▁end - sy stol e ▁; ▁clinic al ▁; ▁follow - up ▁; ▁heart ▁failure ▁; ▁h f ▁; ▁patients ▁; ▁cardiac
▁tap se ▁; ▁longitud in al ▁ rv ▁fiber ▁short en ing ▁; ▁pas p ▁; ▁ rv ▁; ▁in ▁vivo ▁; ▁ rv ▁; ▁prognos is
▁h f ▁; ▁patients ▁; ▁h fre f ▁; ▁left ▁vent ri cular ▁; ▁e je ction ▁ fraction ▁; ▁h f pe f ▁; ▁e cho - dop pler ▁; ▁n - termin al ▁pro - bra in - type ▁na tri ure tic ▁pe pti de ▁; ▁advers e ▁events
▁follow - up ▁du ration
▁tap se ▁; ▁pas p ▁; ▁down ward ▁; ▁re gression ▁line ▁; ▁shift ▁; ▁pas p ▁; ▁tap se
▁h fre f ▁; ▁h f pe f ▁; ▁patients ▁; ▁re gression ▁line
▁tap se ▁; ▁pas p ▁; ▁tap se ▁; ▁pas p ▁; ▁co x ▁re gression ▁; ▁ka plan - me ier ▁analyse s ▁; ▁tap se ▁; ▁pas p
▁hazard ▁ratio s ▁; ▁multi varia te ▁re gression ▁; ▁tap se ▁; ▁pas p ▁; ▁hazard ▁ratio ▁; ▁tap se ▁; ▁new ▁yor k ▁heart ▁association ▁functional ▁class
▁tap se ▁; ▁pas p ▁; ▁down ward ▁; ▁h fre f ▁; ▁h f pe f ▁; ▁prognos tic ▁; ▁resolution
▁tap se ▁; ▁pas p ▁; ▁step ▁; ▁ rv ▁function ▁; ▁ lv ▁dys function
▁bottle ne ck ▁sten t ▁; ▁chronic ▁my o card ial ▁ ische mia ▁; ▁heart ▁failure
▁chronic ▁my o card ial ▁ ische mia ▁; ▁heart ▁failure ▁; ▁ therapeut ic
▁per cuta ne ous ▁; ▁chronic ▁my o card ial ▁ ische mia ▁; ▁sten t ▁; ▁poly te tra flu oro e thy lene
▁bottle ne ck ▁sten t ▁; ▁implant ed ▁; ▁la d ▁; ▁circum flex ▁arter y ▁; ▁l c x ▁; ▁l c x ▁; ▁la d
▁e je ction ▁ fraction ▁; ▁ef ▁; ▁in far ct ▁; ▁col lateral ▁growth ▁; ▁my o card ial ▁per fusion
▁anti ar rhythm ic ▁; ▁medication ▁; ▁death
▁bottle ne ck ▁sten t ▁; ▁my o card ial ▁in far ction ▁; ▁anti plate let ▁medication
▁ fraction al ▁flow ▁reserve ▁; ▁posi tron ▁e mission ▁tom ography ▁; ▁ ische mia ▁; ▁bottle ne ck ▁sten ting ▁; ▁left ▁vent ric le ▁; ▁la d
▁corona ry ▁oc clusi on ▁; ▁col lateral ▁growth ▁; ▁sten t
▁col lateral ▁growth
▁ef ▁; ▁l c x ▁; ▁la d ▁; ▁sten ting ▁; ▁in far cted ▁; ▁left ▁vent ric le ▁; ▁l c x ▁; ▁la d
▁mortal ity ▁; ▁l c x ▁; ▁la d ▁; ▁disease
▁implant ation ▁; ▁bottle ne ck ▁sten t ▁; ▁la d ▁; ▁l c x ▁; ▁my o card ial ▁ ische mia ▁; ▁sten t ▁; ▁ ische mic ▁heart ▁failure ▁; ▁sten t ▁; ▁ therapeut ic
▁heart ▁rate ▁re duction ▁; ▁i va bra dine ▁; ▁left ▁vent ric le ▁; ▁heart ▁failure ▁; ▁patients
▁heart ▁rate ▁; ▁i va bra dine ▁; ▁after load ▁; ▁patients ▁; ▁sy sto lic ▁heart ▁failure
▁arterial ▁elastan ce ▁; ▁ea ▁; ▁pulsa tile ▁after load ▁; ▁heart ▁; ▁pressure ▁volume ▁relation
▁ea ▁; ▁after load
▁patients ▁; ▁sy sto lic ▁heart ▁failure ▁; ▁e je ction ▁ fraction ▁; ▁random ized ▁; ▁place bo ▁; ▁i va bra dine ▁; ▁shift ▁; ▁sy sto lic ▁heart ▁failure ▁treatment ▁with ▁the ▁if ▁inhibi tor ▁i va bra dine ▁trial ▁; ▁patients ▁; ▁place bo ▁; ▁i va bra dine ▁; ▁e cho car dio graphic
▁ea ▁; ▁total ▁arterial ▁compliance ▁; ▁tac ▁; ▁end - sy sto lic ▁elastan ce ▁; ▁ees ▁; ▁base line
▁blood ▁pressure ▁; ▁arm ▁cu ff ▁; ▁stroke ▁volume ▁; ▁e je ction ▁ fraction ▁; ▁end - dia sto lic ▁volume ▁; ▁e cho card i ography
▁base line ▁; ▁ea ▁; ▁tac ▁; ▁ees ▁; ▁patients
▁i va bra dine ▁; ▁ea ▁; ▁tac ▁; ▁place bo
▁contract ility ▁; ▁vent ri cular - arte rial ▁coup ling ▁; ▁patients
▁hr ▁re duction ▁; ▁i va bra dine ▁; ▁tac ▁; ▁ea
▁ees ▁; ▁vent ri cular - arte rial ▁coup ling
▁heart ▁; ▁hr ▁re duction ▁; ▁patients ▁; ▁sy sto lic ▁heart ▁failure
▁pre operativ e ▁; ▁se rum ▁album in ▁; ▁patients ▁; ▁left ▁vent ri cular ▁assist ▁device ▁; ▁implant ation
▁hypo album in emia ▁; ▁prognos tic ▁; ▁patients ▁; ▁heart ▁failure
▁hypo album in emia ▁; ▁post operativ e ▁; ▁mortal ity ▁; ▁patients ▁; ▁left ▁vent ri cular ▁assist ▁device ▁; ▁l vad ▁; ▁implant ation
▁patients ▁; ▁l vad ▁; ▁implant ation
▁pre operativ e ▁; ▁clinic al ▁; ▁mortal ity
▁post operativ e ▁; ▁patients ▁; ▁pre operativ e ▁; ▁hypo album in emia ▁; ▁album in
▁l vad ▁; ▁surgery ▁; ▁patients ▁; ▁album in ▁; ▁hypo album in emia ▁; ▁surgery
▁multi varia te ▁analysis ▁; ▁pre operativ e ▁; ▁album in ▁; ▁mortal ity ▁; ▁l vad ▁; ▁implant ation ▁; ▁hazard ▁ratio ▁; ▁confidence ▁interval
▁album in ▁; ▁l vad ▁; ▁post operativ e
▁patients ▁; ▁pre operativ e ▁; ▁hypo album in emia ▁; ▁post operativ e ▁; ▁album in ▁; ▁hypo album in emia ▁; ▁album in ▁; ▁l vad
▁pre operativ e ▁; ▁hypo album in emia ▁; ▁prognos is ▁; ▁l vad ▁; ▁surgery
▁post operativ e ▁; ▁album in
▁album in ▁; ▁ inflammation ▁; ▁he pati c ▁; ▁prognos is ▁; ▁patients ▁; ▁l vad ▁; ▁implant ation
▁sur g ical ▁; ▁a or tic ▁val ve ▁insu ffi cie ncy ▁; ▁left ▁vent ri cular ▁assist ▁device ▁; ▁implant ation
▁a or tic ▁insu ffi cie ncy ▁; ▁mechanic al ▁circula tory ▁support ▁; ▁continuo us ▁flow ▁; ▁left ▁vent ri cular ▁assist ▁devices ▁; ▁l vad s ▁; ▁pulsa tile ▁devices
▁post - l vad ▁ai
▁report ▁; ▁patients ▁; ▁a or tic ▁val ve ▁; ▁surgery ▁; ▁post - l vad ▁ai
▁patients ▁; ▁l vad ▁; ▁implant ation
▁l vad s ▁; ▁heart mate ▁i i ▁; ▁tho ra tec ▁corp ▁; ▁pleasant on ▁; ▁ca lif ▁; ▁hvad ▁; ▁heart ware ▁; ▁fram ing ham
▁patients ▁; ▁sur g ical
▁follow - up ▁; ▁l vad ▁; ▁patients ▁; ▁heart ▁failure
▁medical ▁ therapy ▁; ▁patients ▁; ▁redo ▁ster no to my ▁; ▁a or tic ▁val ve ▁; ▁bio pro sthetic ▁val ve ▁replace ment ▁; ▁da cro n ▁patch ▁ closure ▁; ▁a or tic ▁val ve ▁; ▁patients ▁; ▁trans cat heter ▁a or tic ▁val ve ▁procedure ▁; ▁surgery ▁; ▁a or tic ▁val ve
▁patients ▁; ▁functional ▁capacity ▁; ▁symptoms
▁patient ▁; ▁post operativ ely ▁; ▁multi organ ▁failure ▁; ▁se psis
▁sur g ical ▁; ▁post - l vad ▁ai ▁; ▁a or tic ▁val ve ▁; ▁le a flet ▁; ▁bio pro sthetic ▁a or tic ▁val ve ▁replace ment ▁; ▁functional ▁capacity ▁; ▁l vad ▁; ▁patients ▁; ▁symptom a tic
▁trans cat heter ▁; ▁invasi ve ▁; ▁surgery
▁clinic al ▁; ▁outcome s ▁; ▁heart ▁failure ▁; ▁charm ▁; ▁cand es ar tan ▁in ▁heart ▁failure ▁assessment ▁of ▁re duction ▁in ▁mortal ity ▁and ▁morbi d ity
▁outcome s ▁; ▁heart ▁failure ▁; ▁h f
▁h f
▁patients
▁patients ▁; ▁h f ▁; ▁obes e ▁; ▁body ▁mass ▁index ▁; ▁ idio pathi c - dila ted ▁cardio my o pathy
▁medication
▁patients ▁; ▁clinic al ▁; ▁radi ological ▁; ▁h f ▁; ▁hospital ization
▁quality ▁of ▁life ▁; ▁all - ca use ▁mortal ity ▁; ▁mortal ity
▁cardiovascular ▁mortal ity ▁; ▁multi vari able ▁adjust ment ▁; ▁hazard ▁ratio ▁; ▁confidence ▁interval ▁; ▁hazard ▁ratio ▁; ▁confidence ▁interval
▁h f ▁; ▁hospital ization
▁et i ology ▁; ▁como rbi di ties ▁; ▁patients ▁; ▁outcome s
▁clinic al ▁; ▁radi ological ▁; ▁h f ▁; ▁quality ▁of ▁life
▁outcome s ▁; ▁hospital ization
▁random ized ▁; ▁walking ▁; ▁patients ▁; ▁severe ▁heart ▁failure
▁patients ▁; ▁heart ▁failure ▁; ▁cardiac ▁rehabilita tion
▁random ized ▁; ▁walking ▁; ▁cardiac ▁rehabilita tion ▁; ▁functional ▁capacity ▁; ▁outcome s ▁; ▁patients ▁; ▁severe ▁heart ▁failure
▁patients ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction ▁; ▁cardiac ▁rehabilita tion ▁; ▁walking ▁; ▁exercise
▁primary ▁outcome ▁; ▁functional ▁capacity ▁; ▁6- minut e ▁walk ▁test ▁; ▁6 m w t
▁walking ▁; ▁functional ▁capacity ▁; ▁6 m w t ▁; ▁physical ▁; ▁activity ▁; ▁symptoms ▁; ▁hospital ▁anxiety ▁and ▁depression ▁scale
▁symptoms
▁walking ▁; ▁cardiac ▁rehabilita tion ▁; ▁functional ▁capacity ▁; ▁outcome s ▁; ▁patients ▁; ▁heart ▁failure
▁exercise
▁left ▁vent ri cular ▁e je ction ▁time ▁; ▁a cute ▁heart ▁failure ▁; ▁pre cap illa ry ▁pulmonar y ▁hyper tension
▁non in va sive ▁; ▁patients ▁; ▁pulmonar y ▁hyper tension ▁; ▁heart ▁failure
▁right ▁vent ric le ▁; ▁lead s ▁; ▁stroke ▁volume ▁; ▁short ens ▁; ▁left ▁vent ri cular ▁e je ction ▁time ▁; ▁l vet
▁arterial ▁ton ometr y ▁; ▁l vet ▁; ▁prognos tic ▁; ▁patients ▁; ▁pre cap illa ry ▁ph ▁; ▁heart ▁failure
▁clinic al ▁; ▁arter y ▁ton ometr y ▁; ▁prospect ive ly ▁; ▁ad mission ▁; ▁patients ▁; ▁i cu ▁; ▁clinic al
▁l vet ▁; ▁a or tic ▁pressure
▁i cu ▁; ▁mortal ity
▁ad mission ▁; ▁l vet ▁; ▁patients ▁; ▁outcome ▁; ▁to no metric
▁l vet ▁; ▁ sensitiv ity ▁; ▁specific ity ▁; ▁death ▁; ▁i cu
▁prognos tic ▁; ▁ad mission ▁; ▁brain ▁na tri ure tic ▁pe pti de ▁; ▁b np ▁; ▁creati nine ▁; ▁na trem ia
▁dobu tamine ▁; ▁fur os em ide ▁; ▁outcome
▁creati nine ▁; ▁b np ▁; ▁fur os em ide ▁; ▁dobu tamine ▁; ▁no re pine ph rine ▁; ▁outcome
▁change ▁; ▁l vet ▁; ▁ad mission ▁; ▁follow - up ▁; ▁outcome
▁mortal ity
▁short en ed ▁; ▁l vet ▁; ▁i cu ▁; ▁ad mission ▁; ▁prognos tic ▁; ▁patients ▁; ▁pre cap illa ry ▁ph ▁; ▁heart ▁failure
▁prognos tic
▁right ▁at rial ▁my xo ma ▁; ▁pulmonar y ▁e mbol ism ▁; ▁right ▁heart ▁failure
▁my xo mas ▁; ▁cardiac ▁; ▁benign ▁tumor s ▁; ▁left ▁at rium ▁; ▁right ▁at rium
▁my xo mas ▁; ▁right ▁at rium ▁; ▁embo lize ▁; ▁pulmonar y ▁arterial ▁vas cula ture
▁report ▁; ▁patient ▁; ▁right ▁at rial ▁my xo ma ▁; ▁massive ▁e mbol ism ▁; ▁pulmonar y ▁arteri es ▁; ▁sur g ically ▁; ▁right ▁at rial ▁; ▁pulmonar y ▁e mbol ecto my
▁right ▁at rium ▁; ▁pro lapse ▁; ▁tri cus pid ▁val ve ▁; ▁ste no tic ▁physio log y
▁left ▁pulmonar y ▁arter y ▁; ▁right ▁pulmonar y ▁arter y
▁sur g ical ▁; ▁hypothe r mic ▁circula tory ▁arrest
▁patient ▁; ▁as ym pto matic ▁; ▁follow - up
▁heart ▁failure ▁; ▁patients ▁; ▁rhe um ato id ▁ar thri tis ▁; ▁t n f ▁anta gon ist
▁heart ▁failure ▁; ▁h f ▁; ▁tumor ▁nec rosi s ▁factor ▁; ▁t n f ▁; ▁t n f ▁anta gon ists ▁; ▁disease ▁; ▁severe ▁h f
▁h f ▁; ▁patients ▁; ▁rhe um ato id ▁ar thri tis ▁; ▁ra
▁health care
▁ra ▁; ▁met ho tre xa te ▁; ▁t n f ▁anta gon ist ▁; ▁non - bi ological ▁disease ▁mod ifying ▁anti r heu matic ▁drug ▁; ▁n bd mar d
▁co x ▁re gression ▁models ▁; ▁pro pens ity ▁score ▁; ▁oral ▁; ▁gluco cor tico id ▁; ▁h f ▁; ▁hospital isation s ▁; ▁loop ▁di ure tics
▁n bd mar d ▁; ▁t n f ▁anta gon ist ▁; ▁base line ▁; ▁co varia tes
▁t n f ▁anta gon ists ▁; ▁n bd mar d
▁eleva ted ▁; ▁h f
▁eleva ted
▁oral ▁; ▁gluco cor tico ids ▁; ▁h f
▁t n f ▁anta gon ists ▁; ▁h f ▁; ▁hospital ▁; ▁ad missions ▁; ▁n bd m ards ▁; ▁ra
▁exercise ▁; ▁quality ▁of ▁life ▁; ▁heart ▁failure
▁economic ▁; ▁nh s ▁; ▁chronic ▁; ▁disease ▁; ▁exercise ▁; ▁a cute ▁; ▁hospital
▁health
▁mix ed - met hod s ▁study ▁; ▁exercise ▁; ▁patients ▁; ▁heart ▁failure
▁primary ▁outcome s ▁; ▁functional ▁capacity ▁; ▁quality ▁of ▁life
▁seconda ry ▁outcome ▁; ▁patient ▁; ▁post
▁quality ▁of ▁life ▁; ▁functional ▁capacity
▁evidence
▁seconda ry ▁outcome s
▁fra il ty ▁; ▁heart ▁failure ▁; ▁health
▁fra il ty ▁; ▁heart ▁failure ▁; ▁h f
▁fra il ty ▁; ▁health ▁; ▁outcome s
▁fra il ty ▁; ▁h f
▁fra il ty ▁; ▁health ▁ab c ▁short ▁physical ▁performance ▁battery ▁; ▁hab c ▁battery ▁; ▁gi ll ▁index ▁; ▁h f

▁follow ▁up ▁; ▁h f
▁fra il ty ▁; ▁gi ll ▁index ▁; ▁h f
▁hab c ▁battery ▁; ▁h f ▁; ▁health ▁ab c ▁h f ▁model ▁; ▁death
▁diabetes ▁mell itus ▁; ▁cardiovascular ▁disease ▁; ▁base line
▁hab c ▁battery ▁; ▁health ▁ab c ▁h f ▁risk ▁model ▁; ▁change ▁; ▁c - index ▁; ▁net - re class ification - improv ement ▁; ▁h f
▁fra il ty ▁; ▁h f
▁vaso press in ▁; ▁con ges tive ▁heart ▁failure
▁neuro hormon al ▁; ▁pat ho phy si ology ▁; ▁con ges tive ▁heart ▁failure ▁; ▁ch f
▁prognos is ▁; ▁patients ▁; ▁ch f ▁; ▁ therapeut ic ▁; ▁neuro hormon al ▁systems
▁anta gon ists ▁; ▁re nin - angi oten sin - al do ster one ▁; ▁sympa the tic ▁ner vous ▁systems ▁; ▁clinic al ▁; ▁outcome s ▁; ▁ch f
▁argi nine ▁vaso press in ▁; ▁av p ▁; ▁physio logic ▁; ▁ch f ▁; ▁av p ▁; ▁vaso press in ▁receptor ▁anta gon ist ▁; ▁ therapy ▁; ▁ therapeut ic ▁; ▁ch f
▁n fat ▁; ▁mir -25 ▁; ▁tran scription ▁factor ▁; ▁hand 2 ▁; ▁heart ▁failure
▁gene ▁; ▁path ological ▁; ▁heart ▁disease ▁; ▁tran scription ▁factors ▁; ▁driving ▁; ▁gene
▁report ▁; ▁calci ne uri n ▁; ▁n fat ▁; ▁mir -25 ▁; ▁expression ▁; ▁basic ▁heli x - loop - heli x ▁; ▁bh lh ▁; ▁tran scription ▁factor ▁; ▁d hand ▁; ▁hand 2 ▁; ▁disease d ▁; ▁my o car dium
▁hand 2 ▁; ▁healthy ▁; ▁heart ▁muscle ▁; ▁cell s ▁; ▁ph eno type ▁; ▁path ological ▁; ▁hyper trop hy
▁hand 2 ▁; ▁hyper trop hy ▁; ▁fibro sis ▁; ▁vent ri cular ▁dys function ▁; ▁gene
▁in ▁vivo ▁; ▁mir -25 ▁; ▁anta go mir ▁; ▁cardiac ▁dys function ▁; ▁mur ine ▁; ▁my o car dium ▁; ▁heart ▁failure
▁micro rna s ▁; ▁expression ▁; ▁bh lh ▁; ▁tran scription ▁factor ▁; ▁hand 2 ▁; ▁my o car dium ▁; ▁gene ▁; ▁heart ▁failure
▁epidemi ology ▁; ▁chronic ▁heart ▁failure ▁; ▁bis o pro lol
▁prevale nce ▁; ▁chronic ▁heart ▁failure ▁; ▁hung ary
▁heart ▁failure ▁; ▁neuro - hormon al ▁system ▁; ▁ang io ten sin ▁convert ing ▁enzym e ▁inhibi tors ▁; ▁ang io ten sin ▁receptor ▁block ers ▁; ▁ang io ten sin ▁convert ing ▁enzym e ▁inhibi tors ▁; ▁beta ▁receptor ▁block ers ▁; ▁mineral o cor tico id ▁receptor ▁anta gon ists
▁in o tropi c ▁effect ▁; ▁beta ▁block ers ▁; ▁heart ▁failure
▁beta ▁block ers ▁; ▁mortal ity ▁; ▁patients ▁; ▁heart ▁failure
▁bis o pro lol ▁; ▁mortal ity
▁my o card ial ▁; ▁ir s 1 ▁; ▁ir s 2 ▁; ▁heart ▁failure ▁; ▁p 38 al pha ▁; ▁map k ▁; ▁insulin ▁resist ance
▁cardiac ▁failure ▁; ▁death ▁; ▁patients ▁; ▁type ▁2 ▁diabetes ▁; ▁diabetes ▁; ▁heart ▁failure
▁insulin ▁resist ance ▁; ▁type ▁2 ▁diabetes ▁; ▁insulin ▁receptor ▁substrat es ▁1 ▁; ▁ir s 1 ▁; ▁ir s 2 ▁; ▁cel lular ▁metabolism
▁ir s 1 ▁; ▁ir s 2 ▁; ▁heart ▁; ▁hyper insu line mia ▁; ▁my o card ial ▁insulin ▁resist ance ▁; ▁cel lular ▁dys function ▁; ▁ir s 1 ▁; ▁ir s 2 ▁; ▁heart - specific ▁ir s 1 ▁and ▁ir s 2 ▁gene ▁double - k no ckou t ▁; ▁h - d ko ▁; ▁ liver - specific ▁ir s 1 ▁and ▁ir s 2 ▁double - k no ckou t ▁; ▁l - d ko
▁h - d ko ▁; ▁vent ri cular ▁mass ▁; ▁cardiac ▁apo pto sis ▁; ▁fibro sis ▁; ▁cardiac ▁metabol ic ▁gene ▁expression ▁; ▁at p
▁l - d ko ▁; ▁cardiac ▁; ▁ir s 1 ▁; ▁ir s 2 ▁; ▁protein s ▁; ▁heart ▁failure ▁; ▁cardiac ▁energy ▁metabolism ▁gene ▁expression ▁; ▁p 38 α ▁; ▁mit ogen - activa ted ▁protein ▁kina se ▁; ▁p 38
▁vent ri cular ▁cardio my o cy tes ▁; ▁chronic ▁; ▁insulin ▁; ▁ir s 1 ▁; ▁ir s 2 ▁; ▁protein s ▁; ▁insulin ▁; ▁p 38 ▁; ▁cardiac ▁dys function ▁; ▁insulin ▁resist ance ▁; ▁type ▁2 ▁diabetes
▁medication s ▁; ▁out patient s ▁; ▁heart ▁failure ▁; ▁ nc dr ▁pinna cle
▁out patient s ▁; ▁heart ▁failure ▁and ▁reduce d ▁e je ction ▁ fraction ▁; ▁patient
▁card i ology ▁; ▁national ▁cardiovascular ▁disease ▁registr y ▁practice ▁innovation ▁and ▁clinic al ▁ excellence ▁registr y
▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tors ▁; ▁ang io ten sin ▁receptor ▁block ers ▁; ▁β - block ers ▁; ▁patients ▁; ▁heart ▁failure ▁and ▁reduce d ▁e je ction ▁ fraction
▁re gression ▁models ▁; ▁como rbi di ties
▁rate ▁ratio ▁; ▁ therapy ▁; ▁patient ▁; ▁como rbi di ties
▁patients
▁pre scription ▁; ▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tors ▁; ▁ang io ten sin ▁receptor ▁block ers ▁; ▁inter quart ile ▁range ▁; ▁β - block ers ▁; ▁inter quart ile ▁range ▁; ▁inter quart ile ▁range
▁rate ▁ratio ▁; ▁confidence ▁interval ▁; ▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tors ▁; ▁ang io ten sin ▁receptor ▁block ers ▁; ▁ therapy ▁; ▁confidence ▁interval ▁; ▁β - block ers ▁; ▁ therapy
▁medication s ▁; ▁patients ▁; ▁heart ▁failure ▁and ▁reduce d ▁e je ction ▁ fraction ▁; ▁out patient
▁patients ▁; ▁heart ▁failure ▁and ▁reduce d ▁e je ction ▁ fraction
▁cardio toxic ity ▁; ▁patients ▁; ▁breast ▁cancer
▁tras tuz um ab ▁; ▁ad ju vant ▁; ▁outcome s ▁; ▁cardio toxic ity ▁; ▁con ges tive ▁heart ▁failure ▁; ▁ch f
▁ch f ▁; ▁patients
▁breast ▁cancer ▁; ▁patients ▁; ▁medica re ▁; ▁diagnose d ▁; ▁breast ▁cancer ▁; ▁che mo therapy ▁; ▁se er - medi care ▁; ▁te xas ▁; ▁medica re
▁ch f
▁che mo therapy ▁; ▁tras tuz um ab ▁; ▁como rbi di ties ▁; ▁ch f ▁; ▁international ▁classifica tion ▁of ▁disease s ▁; ▁health care ▁common ▁procedure ▁co ding ▁system ▁code s
▁de script ive ▁statistic s ▁; ▁co x ▁proportion al ▁hazard s ▁models
▁patients ▁; ▁tras tuz um ab

▁tras tuz um ab ▁; ▁ch f ▁; ▁non tras tuz um ab ▁users
▁tras tuz um ab ▁; ▁ch f ▁; ▁non tras tuz um ab ▁users ▁; ▁hazard ▁ratio
▁patients ▁; ▁corona ry ▁arter y ▁disease ▁; ▁hyper tension ▁; ▁tras tuz um ab ▁; ▁administration ▁; ▁ch f
▁breast ▁cancer ▁; ▁patients ▁; ▁ch f ▁; ▁reported ▁; ▁clinic al
▁patients ▁; ▁tras tuz um ab ▁; ▁cardiac ▁; ▁como rbi di ties
▁administration ▁; ▁ch f
▁das h ▁; ▁mortal ity ▁; ▁heart ▁failure ▁; ▁health
▁patients ▁; ▁heart ▁failure ▁; ▁h f ▁; ▁evidence ▁; ▁outcome s ▁; ▁h f
▁dieta ry ▁approach es ▁to ▁stop ▁hyper tension ▁; ▁das h ▁; ▁mortal ity ▁; ▁post meno paus al ▁; ▁h f
▁health ▁; ▁followed ▁up ▁; ▁h f ▁; ▁hospital ization ▁; ▁death ▁; ▁contact
▁das h
▁co x ▁proportion al ▁hazard s ▁models ▁; ▁health ▁; ▁health ▁; ▁hazard ▁ratio s ▁; ▁confidence ▁interval s
▁follow - up ▁; ▁h f ▁; ▁hospital ization
▁multi vari able - ad just ed ▁hazard ▁ratio s ▁; ▁das h
▁mortal ity
▁das h ▁; ▁mortal ity ▁; ▁h f ▁; ▁non signif i cant
▁cardiovascular ▁; ▁conditions ▁; ▁patients ▁; ▁h f
▁st 2 ▁; ▁ambula tory ▁; ▁patients ▁; ▁heart ▁failure ▁; ▁functional ▁capacity ▁; ▁outcome s
▁st 2 ▁; ▁cardio protec tive ▁signal ing ▁; ▁my o car dium ▁; ▁bio mark er ▁; ▁heart ▁failure ▁; ▁h f
▁st 2 ▁; ▁functional ▁capacity ▁; ▁clinic al ▁; ▁outcome s ▁; ▁ambula tory ▁; ▁patients ▁; ▁h f ▁; ▁heart ▁failure ▁; ▁outcome s ▁; ▁exercise ▁; ▁training ▁; ▁h f - action ▁; ▁random ized ▁; ▁exercise ▁; ▁training ▁; ▁h f
▁h f - action ▁; ▁random ized ▁; ▁patients ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁new ▁yor k ▁heart ▁association ▁class ▁i i ▁; ▁h f ▁; ▁exercise ▁; ▁training
▁st 2 ▁; ▁patients ▁; ▁plasma
▁corre lation s ▁; ▁co x ▁models ▁; ▁st 2 ▁; ▁functional ▁capacity ▁; ▁outcome s
▁base line ▁; ▁st 2 ▁; ▁inter quart ile ▁range
▁st 2 ▁; ▁functional ▁capacity
▁uni vari able ▁analysis ▁; ▁st 2 ▁; ▁death ▁; ▁hospital ization ▁; ▁hazard ▁ratio ▁; ▁cardiovascular ▁death ▁; ▁h f ▁; ▁hospital ization ▁; ▁hazard ▁ratio ▁; ▁all - ca use ▁mortal ity ▁; ▁hazard ▁ratio ▁; ▁hazard ▁ratio s
▁multi vari able ▁models ▁; ▁st 2 ▁; ▁outcome s ▁; ▁clinic al ▁; ▁amino - termin al ▁pro - b - type ▁na tri ure tic ▁pe pti de
▁st 2 ▁; ▁c ▁statistic ▁; ▁net ▁re class ification ▁improvement ▁; ▁integrat ed ▁discrimina tion ▁improvement
▁st 2 ▁; ▁functional ▁capacity ▁; ▁outcome s ▁; ▁ambula tory ▁; ▁patients ▁; ▁h f
▁extend ed ▁criteri a ▁cardiac ▁transplant ation
▁extend ed ▁criteri a ▁cardiac ▁transplant ▁; ▁ecc t ▁; ▁transplant ▁; ▁donor s ▁; ▁transplant ▁; ▁como r bid ity
▁pau city ▁; ▁outcome s
▁patients ▁; ▁heart ▁transplant ▁; ▁prospect ive ly ▁; ▁ecc t
▁base line ▁; ▁outcome s ▁; ▁ecc t ▁; ▁cardiac ▁transplant
▁co x ▁proportion al ▁hazard s ▁models
▁clinic al ▁; ▁ecc t
▁patients ▁; ▁heart ▁transplant ▁; ▁ecc t
▁patients ▁; ▁cardiac ▁transplant ▁; ▁ecc t ▁; ▁patients ▁; ▁diabetes ▁mell itus ▁; ▁chronic ▁ki dne y ▁disease ▁; ▁estima ted ▁glo mer ular ▁filtr ation ▁rate
▁base line ▁; ▁cardiac ▁transplant ▁; ▁ecc t
▁multi varia te ▁model ▁; ▁creati nine ▁; ▁hazard ▁ratio ▁; ▁confidence ▁interval ▁; ▁mortal ity
▁ecc t ▁; ▁heart ▁failure ▁; ▁ therapy ▁; ▁patients
▁renal ▁dys function ▁; ▁morbi d ity
▁change ▁; ▁read missions ▁; ▁follow - up ▁; ▁heart ▁failure ▁; ▁read mission
▁change ▁; ▁follow - up ▁; ▁read missions ▁; ▁hospital ▁; ▁follow - up
▁out patient ▁; ▁patients ▁; ▁heart ▁failure ▁; ▁hospital ▁; ▁dis charge ▁; ▁read missions ▁; ▁patient ▁; ▁follow - up
▁heart ▁failure ▁; ▁dis charge s ▁; ▁university ▁of ▁connect i cut ▁health ▁center ▁; ▁patients ▁; ▁follow - up
▁change ▁; ▁read mission ▁; ▁follow - up ▁; ▁follow - up
▁patients ▁; ▁heart ▁failure ▁; ▁sy sto lic ▁heart ▁failure
▁all - ca use ▁read missions
▁follow - up
▁university ▁of ▁connect i cut ▁heart ▁failure ▁center ▁; ▁heart ▁failure ▁; ▁nurse ▁prac ti tioner
▁patients ▁; ▁blood ▁; ▁medication
▁patients ▁; ▁dis charge ▁; ▁follow - up ▁; ▁medication
▁hospital ▁; ▁read mission ▁; ▁patients ▁; ▁heart ▁failure ▁; ▁follow - up
▁patients ▁; ▁heart ▁failure ▁; ▁diagnostic ▁; ▁medication ▁; ▁follow - up
▁cardiac ▁magnetic ▁res on ance ▁post contra st ▁t 1 ▁time ▁; ▁outcome ▁; ▁patients ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction
▁pat ho phy si ology ▁; ▁heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction ▁; ▁h f pe f ▁; ▁my o card ial ▁extra cel lular ▁matri x
▁my o card ial ▁extra cel lular ▁matri x ▁; ▁cardiac ▁magnetic ▁res on ance ▁; ▁t 1 ▁ma pping ▁; ▁path obi ology ▁; ▁pat ho phy si ology ▁; ▁prognos is
▁patients ▁; ▁h f pe f ▁; ▁prospect ive
▁diagnostic ▁; ▁tests ▁; ▁cardiac ▁magnetic ▁res on ance ▁imagin g ▁; ▁t 1 ▁ma pping ▁; ▁invasi ve ▁hem o dynamic ▁assessment s ▁; ▁base line
▁patients ▁; ▁h f pe f ▁; ▁longitud in al ▁; ▁cardiac ▁event
▁cardiac ▁magnetic ▁res on ance ▁; ▁t 1 ▁time ▁; ▁hazard ▁ratio ▁; ▁confidence ▁interval ▁; ▁left ▁at rial ▁area ▁; ▁hazard ▁ratio ▁; ▁confidence ▁interval ▁; ▁pulmonar y ▁vas cular ▁resist ance ▁; ▁hazard ▁ratio ▁; ▁confidence ▁interval ▁; ▁cardiac ▁events
▁patients ▁; ▁t 1 ▁times ▁; ▁cardiac ▁events
▁extra cel lular ▁matri x ▁; ▁left ▁vent ri cular ▁; ▁bio psi es ▁; ▁tissu e fax s ▁; ▁cor related ▁; ▁t 1 ▁time
▁t 1 ▁time ▁; ▁cor related ▁; ▁right ▁vent ri cular - pul mon ary ▁arterial ▁coup ling ▁; ▁pulmonar y ▁vas cular ▁resist ance ▁; ▁right ▁vent ri cular ▁e je ction ▁ fraction
▁cardiac ▁magnetic ▁res on ance ▁post contra st ▁t 1 ▁time ▁; ▁prognos is ▁; ▁h f pe f ▁; ▁post contra st ▁t 1 ▁; ▁bio mark er ▁; ▁h f pe f
▁heart ▁magnetic ▁res on ance ▁imagin g ▁; ▁che lation ▁; ▁compliance ▁; ▁heart ▁disease ▁; ▁patients ▁; ▁tha lassa emia ▁major
▁heart ▁magnetic ▁res on ance ▁imagin g ▁; ▁che lation ▁; ▁patient ▁; ▁compliance ▁; ▁heart ▁failure ▁; ▁ar rhythm ias
▁cardiac
▁heart ▁; ▁heart ▁failure ▁; ▁ar rhythm ias
▁che lation ▁; ▁heart ▁ir on
▁compliance
▁e je ction ▁ fraction ▁; ▁clinic al ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁mild ▁heart ▁failure
▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁cr t ▁; ▁mild ▁heart ▁failure ▁; ▁h f ▁; ▁patients ▁; ▁q rs ▁prolong ation ▁; ▁e je ction ▁ fraction ▁; ▁ef
▁cr t ▁; ▁sy sto lic ▁dys function ▁; ▁outcome s ▁; ▁re syn chron ization ▁rever ses ▁remodel ing ▁in ▁sy sto lic ▁left ▁vent ri cular ▁dys function ▁; ▁rever se ▁; ▁patients ▁; ▁left ▁vent ri cular ▁; ▁e je ction ▁ fraction ▁; ▁l ve f
▁patients ▁; ▁base line ▁; ▁ef ▁; ▁ef ▁; ▁core
▁l ve f ▁; ▁clinic al ▁; ▁cr t ▁; ▁cr t ▁; ▁sy sto lic ▁volume ▁index ▁; ▁ lv ▁mass
▁death ▁; ▁h f ▁; ▁hospital ization ▁; ▁cr t ▁; ▁hazard ▁ratio
▁l ve f ▁; ▁clinic al ▁; ▁rever se ▁remodel ing ▁; ▁death ▁; ▁h f ▁; ▁hospital ization ▁; ▁hazard ▁ratio
▁co varia tes ▁; ▁cr t ▁; ▁death ▁; ▁h f ▁; ▁hospital ization ▁; ▁hazard ▁ratio ▁; ▁l ve f
▁mild ▁h f ▁; ▁q rs ▁prolong ation ▁; ▁l ve f ▁; ▁cr t ▁; ▁rever se ▁remodel ing ▁; ▁clinic al ▁; ▁sy sto lic ▁dys function
▁my o card ial ▁; ▁titi n ▁hypo phos phor y lation ▁; ▁heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction ▁; ▁metabol ic
▁obes ity ▁; ▁diabetes ▁mell itus ▁; ▁metabol ic ▁; ▁como rbi di ties ▁; ▁heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction
▁my o card ial ▁dia sto lic ▁dys function ▁; ▁ dd ▁; ▁collage n ▁de position ▁; ▁titi n
▁my o card ial ▁ dd ▁; ▁collage n ▁de position ▁; ▁titi n ▁; ▁obes e ▁; ▁diabet ic ▁; ▁z s f 1 ▁; ▁heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction
▁wis tar - ky oto ▁; ▁z s f 1 ▁; ▁obes e ▁; ▁z s f 1 ▁; ▁obes e ▁; ▁z s f 1 ▁; ▁followed ▁up ▁; ▁metabol ic ▁; ▁renal ▁; ▁e cho car dio graphic ▁; ▁hem o dynamic ally ▁; ▁eu than ization
▁my o card ial ▁collage n ▁; ▁collage n ▁cross - link ing ▁; ▁titi n ▁; ▁iso form s ▁; ▁ phos phor y lation
▁rest ing ▁tension ▁; ▁f pass ive ▁; ▁muscle ▁; ▁k cl - ki ▁; ▁titi n ▁; ▁titi n ▁; ▁extra cel lular ▁matri x ▁; ▁f pass ive
▁z s f 1 ▁; ▁hyper tensi ve ▁; ▁obes e ▁; ▁z s f 1 ▁; ▁hyper tensi ve ▁; ▁diabet ic
▁obes e ▁; ▁z s f 1 ▁; ▁heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction ▁; ▁lung ▁; ▁pres er ved ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁left ▁vent ri cular ▁ dd
▁my o card ial ▁ dd ▁; ▁muscle ▁; ▁titi n ▁hypo phos phor y lation
▁s 39 91 ▁; ▁n 2 bus ▁; ▁s 12 884 ▁; ▁pe v k
▁obes e ▁; ▁z s f 1 ▁; ▁heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction
▁titi n ▁hypo phos phor y lation ▁; ▁my o card ial ▁ dd
▁ster nal ▁; ▁heart mate ▁i i
▁left ▁vent ri cular ▁assist ▁devices ▁; ▁l vad s ▁; ▁patients ▁; ▁heart ▁failure ▁; ▁incide nce ▁; ▁pump ▁dys function ▁; ▁pump
▁dys function ▁; ▁pump ▁; ▁drive line ▁; ▁pump ▁; ▁cura tive
▁redo ▁ster no to my ▁; ▁cardio pul mon ary ▁by pass
▁heart mate ▁i i ▁; ▁l vad s ▁; ▁patients
▁patients ▁; ▁ex tuba ted ▁; ▁blood ▁; ▁trans fusion
▁death s ▁; ▁stroke s
▁kansa s ▁city ▁cardio my o pathy ▁question naire ▁; ▁patients ▁; ▁heart ▁failure ▁; ▁reduce d ▁e je ction ▁ fraction
▁epidemi c ▁; ▁heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction ▁; ▁h f pe f ▁; ▁patients ▁; ▁health ▁; ▁symptoms ▁; ▁quality ▁of ▁life
▁kansa s ▁city ▁cardio my o pathy ▁question naire ▁; ▁k cc q ▁; ▁h f ▁with ▁reduce d ▁ef ▁; ▁patients ▁; ▁h f pe f
▁prospect ive ▁; ▁h f ▁; ▁patients ▁; ▁h f ▁with ▁reduce d ▁ef ▁; ▁ef ▁; ▁h f pe f ▁; ▁ef
▁new ▁yor k ▁heart ▁association ▁class ▁; ▁k cc q ▁; ▁symptom ▁; ▁spe ar man ▁corre lation s ▁; ▁2- way ▁a nova ▁; ▁patients ▁; ▁h f ▁with ▁reduce d ▁ef ▁; ▁h f pe f
▁k cc q ▁; ▁ka plan - me ier ▁cur ves ▁; ▁death ▁; ▁all - ca use ▁hospital ization
▁co varia te ▁adjust ment ▁; ▁co x ▁proportion al ▁hazard s ▁models

▁patients ▁; ▁h f pe f
▁k cc q ▁; ▁new ▁yor k ▁heart ▁association ▁class ▁; ▁patients ▁; ▁h f pe f ▁; ▁h f ▁with ▁reduce d ▁ef
▁k cc q ▁; ▁patients ▁; ▁h f pe f ▁; ▁log ▁rank ▁; ▁ef
▁k cc q ▁; ▁patients ▁; ▁h f pe f
▁patients ▁; ▁h f pe f ▁; ▁k cc q ▁; ▁health ▁; ▁prognos tic
▁clinic al ▁; ▁change
▁patients ▁; ▁chronic ▁organ ▁failure
▁tug ▁; ▁patients ▁; ▁chronic ▁ob struct ive ▁pulmonar y ▁disease ▁; ▁cop d ▁; ▁chronic ▁heart ▁failure ▁; ▁ch f ▁; ▁chronic ▁renal ▁failure ▁; ▁cr f

▁patients
▁inter quart ile ▁range ▁; ▁body ▁mass ▁index ▁; ▁inter quart ile ▁range ▁; ▁cop d ▁; ▁ch f ▁; ▁cr f

▁outcome ▁; ▁tug ▁test

▁intra class ▁corre lation ▁co e ffi cient ▁; ▁i cc ▁; ▁ka ppa ▁co e ffi cient ▁; ▁standard ▁error ▁of ▁measure ment ▁; ▁minimal ▁detect able ▁change ▁; ▁m d c
▁cop d ▁; ▁ch f ▁; ▁cr f ▁; ▁i cc ▁; ▁ka ppa ▁co ef fici ents
▁confidence ▁interval

▁standard ▁error ▁of ▁measure ment ▁; ▁m d c ▁; ▁m d c
▁tug ▁test ▁; ▁patients ▁; ▁cop d ▁; ▁ch f ▁; ▁cr f
▁standard ▁error ▁of ▁measure ment ▁; ▁m d c ▁; ▁clinic al ▁; ▁change
▁global ▁left ▁vent ri cular ▁longitud in al ▁sy sto lic ▁strain ▁; ▁cardiovascular ▁events ▁; ▁patients ▁; ▁at rial ▁fi bril lation
▁global ▁left ▁vent ri cular ▁longitud in al ▁sy sto lic ▁strain ▁; ▁gl s ▁; ▁left ▁vent ri cular ▁; ▁cardiovascular ▁; ▁at rial ▁fi bril lation
▁gl s
▁observation al ▁co hor t ▁study
▁card i ology ▁; ▁hospital
▁patients ▁; ▁patients ▁; ▁e cho car dio graphic
▁outcome ▁; ▁gl s ▁; ▁beat ▁; ▁co x ▁proportion al ▁hazard s ▁analyse s
▁death ▁; ▁stroke ▁; ▁hospital isation ▁; ▁heart ▁failure
▁death s ▁; ▁stroke ▁; ▁hospital isation s ▁; ▁heart ▁failure ▁; ▁follow - up
▁multi varia te ▁analysis ▁; ▁gl s
▁gl s ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁l ve f ▁; ▁sy sto lic ▁mit ral ▁ann ulus ▁veloci ty ▁; ▁multi varia te ▁models
▁gl s ▁; ▁co x ▁model ▁; ▁chronic ▁heart ▁failure ▁; ▁hyper tension ▁; ▁diabetes ▁; ▁stroke ▁; ▁estima ted ▁glo mer ular ▁filtr ation ▁rate ▁; ▁l ve f
▁gl s ▁; ▁l ve f ▁; ▁prognos tic ▁; ▁clinic al ▁; ▁e cho car dio graphic ▁; ▁sy sto lic
▁prognos tic ▁; ▁right ▁vent ri cular ▁contract ile ▁reserve ▁; ▁patients ▁; ▁pulmonar y ▁hyper tension
▁exercise - indu ced ▁pulmonar y ▁arter y ▁sy sto lic ▁pressure ▁; ▁pas p ▁; ▁stress ▁dop pler ▁e cho card i ography ▁; ▁right ▁vent ri cular ▁contract ile ▁reserve ▁; ▁patients ▁; ▁pulmonar y ▁hyper tension ▁; ▁right ▁heart ▁failure
▁prospect ive ▁study ▁; ▁patients ▁; ▁invasi ve ly ▁; ▁diagnose d ▁; ▁pulmonar y ▁arterial ▁hyper tension ▁; ▁in opera ble ▁; ▁chronic ▁ thro mbo e mbol ic ▁pulmonar y ▁hyper tension ▁; ▁right ▁vent ri cular ▁; ▁pump ▁; ▁stable ▁; ▁pulmonar y ▁arterial ▁hyper tension ▁; ▁medication ▁; ▁non in va sive ▁; ▁stress ▁e cho card i ography ▁; ▁cardio pul mon ary ▁exercise ▁testing
▁exercise - indu ced ▁pas p ▁; ▁right ▁vent ri cular ▁contract ile ▁reserve ▁; ▁patients ▁; ▁exercise - indu ced ▁pas p
▁patients ▁; ▁followed ▁up
▁multi varia te ▁analyse s
▁patients ▁; ▁exercise - indu ced ▁pas p ▁; ▁pas p ▁; ▁patients ▁; ▁pas p
▁medication ▁; ▁rest ing ▁hem o dynamic s
▁pas p ▁; ▁6- minut e ▁walking ▁distance ▁; ▁pe ak ▁o 2
▁multi varia te ▁co x ▁model ▁; ▁pas p ▁; ▁exercise ▁; ▁pe ak ▁o 2 ▁; ▁prognos tic ▁; ▁hazard ▁ratio ▁; ▁pe ak ▁o 2 ▁; ▁pas p
▁exercise - indu ced ▁pas p ▁; ▁clinic al ▁; ▁prognos tic ▁; ▁pulmonar y ▁hyper tension ▁; ▁patients ▁; ▁right ▁vent ri cular ▁contract ile ▁reserve
▁stress ▁dop pler ▁e cho card i ography ▁; ▁prognos tic ▁; ▁pulmonar y ▁hyper tension ▁; ▁patients
▁hem o glob in ▁; ▁exercise ▁; ▁training ▁; ▁health ▁; ▁patients ▁; ▁chronic ▁heart ▁failure ▁; ▁h f - action ▁; ▁random ized
▁an emia ▁; ▁patients ▁; ▁chronic ▁heart ▁failure ▁; ▁h f ▁; ▁prevale nce ▁; ▁outcome s
▁an emia ▁; ▁h f ▁; ▁health - related ▁quality ▁of ▁life ▁; ▁hr qol ▁; ▁h f
▁hem o glob in ▁; ▁h gb ▁; ▁hr qol ▁; ▁hr qol ▁; ▁patients ▁; ▁heart ▁failure ▁; ▁outcome s ▁; ▁exercise ▁; ▁training ▁; ▁h f - action
▁h f - action ▁; ▁random ized ▁; ▁exercise ▁; ▁training ▁; ▁patients ▁; ▁h f ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction s ▁; ▁hr qol ▁; ▁kansa s ▁city ▁cardio my o pathy ▁question naire ▁; ▁k cc q ▁; ▁base line
▁hr qol ▁; ▁linear ▁mix ed ▁models ▁; ▁intention - to - tre at
▁base line ▁; ▁h gb ▁; ▁cor related ▁; ▁base line ▁; ▁k cc q ▁; ▁h gb ▁; ▁exercise ▁; ▁training ▁; ▁hr qol
▁h gb ▁; ▁cor related ▁; ▁base line ▁; ▁hr qol
▁base line ▁; ▁h gb ▁; ▁exercise ▁; ▁training ▁; ▁k cc q
▁h f - action ▁; ▁corre lation ▁; ▁base line ▁; ▁h gb ▁; ▁base line ▁; ▁hr qol ▁; ▁k cc q
▁hr qol ▁; ▁exercise ▁; ▁training ▁; ▁base line ▁; ▁h gb
▁cardiac - re syn chron ization ▁ therapy ▁; ▁heart ▁failure ▁; ▁n arrow ▁q rs ▁complex
▁cardiac - re syn chron ization ▁ therapy ▁; ▁cr t ▁; ▁morbi d ity ▁; ▁mortal ity ▁; ▁chronic ▁sy sto lic ▁heart ▁failure ▁; ▁wide ▁q rs ▁complex
▁patients ▁; ▁n arrow ▁q rs ▁complex ▁; ▁cr t ▁; ▁patients
▁random ized ▁; ▁cr t ▁; ▁patients ▁; ▁new ▁yor k ▁heart ▁association ▁class ▁i ii ▁; ▁heart ▁failure ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁q rs ▁du ration ▁; ▁e cho car dio graphic ▁; ▁evidence ▁; ▁left ▁vent ri cular ▁dys syn chron y
▁patients ▁; ▁implant ation ▁; ▁cr t
▁outcome ▁; ▁death ▁; ▁hospital ization ▁; ▁heart ▁failure

▁patients ▁; ▁random ization
▁primary ▁outcome ▁; ▁patients ▁; ▁cr t ▁; ▁hazard ▁ratio ▁; ▁confidence ▁interval
▁death s ▁; ▁cr t ▁; ▁hazard ▁ratio
▁patients ▁; ▁sy sto lic ▁heart ▁failure ▁; ▁q rs ▁du ration ▁; ▁cr t ▁; ▁death ▁; ▁hospital ization ▁; ▁heart ▁failure ▁; ▁mortal ity
▁car vedi lol ▁; ▁met o pro lol ▁; ▁implant able ▁cardio ver ter - de fi br illa tor ▁; ▁ therapy ▁; ▁ma dit - cr t ▁; ▁multi center ▁automatic ▁de fi br illa tor ▁implant ation ▁with ▁cardiac ▁re syn chron ization ▁ therapy
▁car vedi lol ▁; ▁met o pro lol ▁; ▁end point ▁; ▁implant able ▁cardio ver ter - de fi br illa tor ▁; ▁ therapy ▁; ▁ma dit - cr t ▁; ▁multi center ▁automatic ▁de fi br illa tor ▁implant ation ▁with ▁cardiac ▁re syn chron ization ▁ therapy
▁car vedi lol ▁; ▁met o pro lol ▁; ▁ therapy ▁; ▁heart ▁failure ▁; ▁patients
▁patients ▁; ▁ma dit - cr t
▁co x ▁re gression ▁analysis ▁; ▁patients ▁; ▁beta - block ers ▁; ▁beta - block ers ▁; ▁primary ▁end point ▁; ▁ therapy ▁; ▁anti ta chy car dia ▁pa cing ▁; ▁at p ▁; ▁shock ▁ therapy
▁seconda ry ▁end point s ▁; ▁ therapy ▁; ▁at rial ▁fi bril lation ▁; ▁at rial ▁ta chy ar rhythm ias ▁; ▁at p ▁; ▁shock ▁ therapy
▁ therapy ▁; ▁patients ▁; ▁follow - up
▁car vedi lol ▁; ▁ therapy ▁; ▁met o pro lol ▁; ▁hazard ▁ratio ▁; ▁confidence ▁interval
▁at p ▁; ▁shock ▁ therapy
▁ therapy ▁; ▁at rial ▁fi bril lation ▁; ▁patients ▁; ▁car vedi lol ▁; ▁met o pro lol
▁beta - block ers
▁heart ▁failure ▁; ▁patients ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁de fi br illa tor ▁; ▁implant able ▁cardio ver ter - de fi br illa tor ▁; ▁car vedi lol ▁; ▁at p ▁; ▁shock ▁ therapy ▁; ▁met o pro lol
▁ therapy ▁; ▁at rial ▁fi bril lation ▁; ▁patients ▁; ▁car vedi lol ▁; ▁met o pro lol
▁ma dit - cr t ▁; ▁multi center ▁automatic ▁de fi br illa tor ▁implant ation ▁with ▁cardiac ▁re syn chron ization ▁ therapy
▁prote o mics ▁; ▁pressure - over load - indu ced ▁heart ▁failure ▁; ▁mito cho ndri al - tar get ed ▁pe pti des
▁pe pti des ▁; ▁sz eto - sch iller ▁; ▁s s ▁; ▁s s 20 ▁; ▁cardiac ▁function ▁; ▁prote om ic ▁remodel ing ▁; ▁signal ing ▁path ways
▁prote o mics ▁; ▁prote o mics ▁; ▁trans verse ▁a or tic ▁con stri ction ▁; ▁tac ▁; ▁heart ▁failure ▁; ▁signal ing ▁path way ▁; ▁ingen u ity ▁path way ▁analysis
▁protein s ▁; ▁tac
▁act in ▁cy tos kelet on ▁; ▁mito cho ndri al ▁function ▁; ▁metabolism ▁; ▁gly col ysis ▁; ▁gluco ne ogen es is ▁; ▁cit rate ▁cycle
▁s s 31 ▁; ▁con ges tive ▁heart ▁failure ▁; ▁ph eno type s ▁; ▁mito cho ndri al ▁; ▁tac ▁; ▁mito cho ndri al ▁prote ome ▁; ▁mito cho ndri al ▁; ▁non mi to cho ndri al ▁protein
▁ingen u ity ▁path way ▁analysis
▁s s 20 ▁; ▁heart ▁failure ▁; ▁prote o mics ▁; ▁act in ▁cy tos kelet on ▁; ▁s s 20 ▁; ▁mito cho ndri al ▁; ▁metabol ic ▁path ways
▁signal ing ▁path ways ▁; ▁pressure - over load - indu ced ▁heart ▁failure
▁prote om ic ▁; ▁mito cho ndri al - tar get ed ▁pe pti de ▁; ▁s s 31 ▁; ▁mito cho ndri al ▁function ▁; ▁tac ▁; ▁clinic al ▁; ▁mito cho ndri al - tar get ed ▁pe pti de ▁; ▁drugs ▁; ▁heart ▁failure
▁q rs ▁ morph ology ▁; ▁outcome s ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁re syn chron ization - de fi bril lation ▁for ▁ambula tory ▁heart ▁failure ▁trial ▁; ▁raf t
▁q rs ▁ morph ology ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁cr t
▁ec g ▁; ▁cr t ▁; ▁clinic al
▁re syn chron ization - de fi bril lation ▁for ▁ambula tory ▁heart ▁failure ▁trial ▁; ▁implant able ▁; ▁primary ▁end ▁point ▁; ▁all - ca use ▁mortal ity ▁; ▁heart ▁failure ▁; ▁hospital ization
▁patients ▁; ▁at rial ▁fi bril lation ▁; ▁pace maker
▁base line ▁; ▁ec gs ▁; ▁electro car dio graph ers
▁patients
▁left ▁bund le - bran ch ▁block ▁; ▁l bb b
▁patients ▁; ▁l bb b ▁; ▁implant able ▁; ▁primary ▁outcome ▁; ▁primary ▁outcome
▁q rs ▁du ration
▁patients ▁; ▁q rs ▁; ▁hazard ▁ratio ▁; ▁primary ▁outcome ▁; ▁patients ▁; ▁q rs ▁; ▁hazard ▁ratio
▁patients ▁; ▁l bb b ▁; ▁q rs ▁; ▁implant able
▁implant able ▁; ▁patients ▁; ▁q rs ▁du ration
▁q rs
▁hospital ization s ▁; ▁re frac tory ▁con ges tive ▁heart ▁failure ▁; ▁per ito ne al ▁di al ysis
▁per ito ne al ▁di al ysis ▁; ▁p d ▁; ▁di ure tic ▁; ▁volume ▁over load ▁; ▁heart ▁failure ▁; ▁h f
▁p d ▁; ▁clinic al ▁; ▁hospital ization s ▁; ▁complica tions ▁; ▁ therapy ▁; ▁end - s tage ▁h f
▁transplant ▁; ▁patients ▁; ▁p d ▁; ▁h f ▁; ▁clinic al
▁e je ction ▁ fraction ▁; ▁ef ▁; ▁patients ▁; ▁ny ha ▁class ▁i i ib ▁; ▁symptoms ▁; ▁right ▁vent ri cular ▁dys function
▁patients ▁; ▁chronic ▁ki dne y ▁disease ▁; ▁ ck d
▁p d ▁; ▁di ure tic ▁; ▁per i pher al ▁ed ema ▁; ▁functional ▁class
▁re - hospital ization ▁; ▁ad missions ▁; ▁patient
▁p d ▁; ▁di ure tic ▁; ▁h f ▁; ▁outcome s ▁; ▁clinic al ▁; ▁hospital ization s ▁; ▁p d related ▁; ▁complica tions
▁p d ▁; ▁con ges tive ▁heart ▁failure ▁; ▁ch f
▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁patients ▁; ▁heart ▁failure
▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁cr t ▁; ▁patients ▁; ▁heart ▁failure ▁; ▁h f ▁; ▁outcome s ▁; ▁cr t ▁; ▁di al ysis ▁; ▁reported
▁cr t ▁; ▁patients
▁patients ▁; ▁bund le ▁bran ch ▁ morph ology ▁; ▁diabetes ▁mell itus ▁; ▁cardio my o pathy ▁; ▁β - block er ▁; ▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tor ▁; ▁ang io ten sin ▁i i ▁receptor ▁block er
▁base line ▁; ▁e cho card i ogram s ▁; ▁evidence ▁; ▁rever se ▁remodel ing
▁complica tions ▁; ▁di al ysis ▁; ▁patients
▁e je ction ▁ fraction ▁; ▁patients
▁di al ysis ▁; ▁patients ▁; ▁h f ▁; ▁hospital ization ▁; ▁all - ca use ▁hospital ization ▁; ▁mortal ity ▁; ▁h f ▁; ▁hospital ization ▁; ▁death
▁rever se ▁remodel ing ▁; ▁e je ction ▁ fraction ▁; ▁mortal ity ▁; ▁all - ca use ▁hospital ization s ▁; ▁h f ▁; ▁hospital ization s ▁; ▁di al ysis ▁; ▁patients
▁patients ▁; ▁h f ▁; ▁cr t ▁; ▁implant ation ▁; ▁complica tions
▁di al ysis ▁; ▁patients ▁; ▁implant ation
▁di al ysis ▁; ▁patients ▁; ▁advers e ▁events ▁; ▁e cho car dio graphic ▁; ▁outcome s
▁das h ▁; ▁dia sto lic ▁function ▁; ▁vent ri cular - arte rial ▁coup ling ▁; ▁hyper tensi ve ▁heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction
▁heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction ▁; ▁h f pe f ▁; ▁cardiovascular ▁reserve
▁h f pe f ▁; ▁so dium ▁; ▁vent ri cular ▁; ▁vas cular ▁sti ff ness
▁dieta ry ▁approach es ▁to ▁stop ▁hyper tension ▁; ▁das h ▁; ▁left ▁vent ri cular ▁dia sto lic ▁function ▁; ▁arterial ▁elastan ce ▁; ▁vent ri cular - arte rial ▁coup ling ▁; ▁hyper tensi ve ▁h f pe f
▁patients ▁; ▁hyper tension ▁; ▁compensa ted ▁h f pe f ▁; ▁das h ▁; ▁so dium
▁base line ▁; ▁central ▁blood ▁pressure ▁; ▁radi al ▁arterial ▁ton ometr y ▁; ▁cardiovascular ▁function ▁; ▁e cho car dio graphic ▁; ▁invasi ve ly
▁dia sto lic ▁function ▁; ▁dia sto lic ▁fill ing ▁formal ism ▁; ▁relax ation ▁; ▁dop pler ▁mit ral ▁in flow ▁veloci ty ▁; ▁e - wa ve
▁arterial ▁elastan ce ▁; ▁ea ▁; ▁end - sy sto lic ▁elastan ce ▁; ▁ees ▁; ▁vent ri cular - arte rial ▁coup ling ▁; ▁ees ▁; ▁ea
▁wil co xon ▁match ed - pair s ▁signed - rank ▁tests
▁das h ▁; ▁clinic ▁; ▁bra chi al ▁sy sto lic ▁pressure ▁; ▁central ▁end - sy sto lic ▁pressure
▁dia sto lic ▁function ▁; ▁ea ▁; ▁vent ri cular - arte rial ▁coup ling ▁; ▁ees ▁; ▁ea
▁patients ▁; ▁hyper tensi ve ▁h f pe f ▁; ▁das h ▁; ▁vent ri cular ▁dia sto lic ▁function ▁; ▁arterial ▁elastan ce ▁; ▁vent ri cular - arte rial ▁coup ling
▁resist in ▁; ▁heart ▁failure ▁; ▁breast ▁cancer
▁resist in ▁; ▁insulin ▁resist ance ▁; ▁mono cy tes ▁; ▁infla mma tory
▁clinic al ▁; ▁connected ▁; ▁eleva ted ▁; ▁resist in ▁; ▁heart ▁failure
▁resist in ▁; ▁heart ▁failure ▁; ▁mur ine ▁; ▁resist in ▁; ▁trans ge nic ▁; ▁ret n ▁; ▁gene ▁; ▁resist in
▁resist in ▁; ▁a cute ▁; ▁an thra cycli ne - indu ced ▁cardio toxic ity
▁do xor ubi cin ▁; ▁resist in
▁do xor ubi cin - indu ced ▁cardio toxic ity ▁; ▁resist in ▁; ▁ret n
▁cardiac ▁m rna ▁; ▁infla mma tory ▁; ▁cell ▁a dhe sion ▁gene s ▁; ▁ret n
▁macro pha ges ▁; ▁cardio my o cy tes ▁; ▁do xor ubi cin ▁; ▁in ▁vi tro ▁; ▁resist in ▁; ▁m rna ▁; ▁protein ▁expression
▁resist in ▁; ▁breast ▁cancer ▁; ▁patients ▁; ▁cardio toxic ity
▁resist in ▁; ▁che mo therapy ▁; ▁eleva ted ▁; ▁cardio toxic ity
▁eleva tion ▁; ▁resist in ▁; ▁cor related ▁; ▁e je ction ▁ fraction
▁eleva ted ▁; ▁resist in ▁; ▁bio mark er ▁; ▁an thra cycli ne - indu ced ▁cardio toxic ity ▁; ▁heart ▁failure ▁; ▁macro pha ges
▁resist in ▁; ▁ inflammation ▁; ▁metabolism ▁; ▁heart ▁disease
▁outcome s ▁; ▁cat heter ▁ab lation ▁; ▁at rial ▁fi bril lation ▁; ▁patients ▁; ▁heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction
▁cat heter ▁ab lation ▁; ▁at rial ▁fi bril lation ▁; ▁patients ▁; ▁heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction ▁; ▁h f pe f
▁clinic al ▁; ▁h f pe f
▁cat heter ▁ab lation ▁; ▁patients ▁; ▁compensa ted ▁h f pe f ▁; ▁left ▁vent ri cular ▁; ▁e je ction ▁ fraction
▁cat heter ▁ab lation ▁; ▁sinus ▁ rhythm
▁ lv ▁strain ▁; ▁strain ▁; ▁e cho card i ography ▁; ▁base line ▁; ▁ab lation
▁follow - up
▁ pharma ce ut ically
▁complica tions ▁; ▁follow - up
▁multi varia te ▁co x ▁re gression ▁analyse s ▁; ▁hyper tension ▁; ▁sinus ▁ rhythm ▁; ▁hazard ▁ratio ▁; ▁confidence ▁interval
▁sy sto lic ▁; ▁ lv ▁e je ction ▁ fraction ▁; ▁ lv ▁strain ▁; ▁strain ▁; ▁sy stol e ▁; ▁dia sto lic ▁; ▁ lv ▁strain ▁rate ▁; ▁dia stol e ▁; ▁transmit ral ▁flow ▁; ▁patients ▁; ▁sinus ▁ rhythm ▁; ▁follow - up
▁ pharma ce u tical s ▁; ▁patients ▁; ▁h f pe f
▁random ized ▁; ▁af ▁ab lation
▁nic oran dil ▁; ▁mito cho ndri al ▁dys function ▁; ▁heart ▁failure ▁; ▁cardio protec tion
▁cardio toxic ity ▁; ▁do xor ubi cin ▁; ▁anti - neo plast ic ▁agent
▁cardio protec tive ▁; ▁nic oran dil ▁; ▁hem o dynamic ▁; ▁mito cho ndri al ▁dys function ▁; ▁administration ▁; ▁do xor ubi cin
▁do xor ubi cin ▁; ▁inject ed

▁nic oran dil ▁; ▁oral ly ▁; ▁do xor ubi cin
▁heart ▁rate ▁; ▁a or tic ▁; ▁blood ▁flow ▁; ▁do xor ubi cin
▁heart s ▁; ▁cas pas e -3 ▁; ▁activity ▁; ▁ phos pho creati ne ▁; ▁a den ine ▁nucleo ti des ▁; ▁cy to ch rom e ▁c ▁; ▁b cl 2 ▁; ▁bax ▁; ▁cas pas e ▁3 ▁; ▁expression
▁mito cho ndri al ▁oxid ative ▁ phos phor y lation ▁capacity ▁; ▁creati ne ▁; ▁kina se ▁; ▁activity ▁; ▁oxid ative ▁stress ▁; ▁d na ▁fragment ation
▁nic oran dil ▁; ▁heart ▁rate ▁; ▁a or tic ▁; ▁blood ▁flow ▁; ▁mito cho ndri al ▁; ▁oxid ative ▁stress ▁; ▁do xor ubi cin ▁; ▁cardio toxic ity
▁nic oran dil ▁; ▁ phos pho creati ne ▁; ▁a den ine ▁nucleo ti des ▁; ▁mito cho ndri al ▁oxid ative ▁ phos phor y lation ▁capacity ▁; ▁creati ne ▁; ▁kina se ▁; ▁activity
▁nic oran dil ▁; ▁cardio protec tion ▁; ▁apo pto tic ▁signal ing ▁path way ▁; ▁d na ▁fragment ation ▁; ▁mito cho ndri al
▁nic oran dil ▁; ▁cy to toxic ▁; ▁do xor ubi cin ▁; ▁ehrlich ▁car cino ma
▁nic oran dil ▁; ▁heart ▁failure ▁; ▁hem o dynamic ▁; ▁mito cho ndri al ▁dys function ▁; ▁anti tum or ▁; ▁activity
▁pre operativ e ▁; ▁renal ▁dys function ▁; ▁cardiovascular ▁events ▁; ▁stroke ▁; ▁my o card ial ▁in far ction ▁; ▁heart ▁failure ▁; ▁death ▁; ▁isola ted ▁corona ry ▁arter y ▁by pass ▁graf ting
▁renal ▁dys function ▁; ▁mortal ity ▁; ▁my o card ial ▁in far ction ▁; ▁corona ry ▁arter y ▁by pass ▁graf ting ▁; ▁ca bg
▁pre operativ e ▁; ▁renal ▁dys function ▁; ▁stroke ▁; ▁my o card ial ▁in far ction ▁; ▁heart ▁failure ▁; ▁ca bg
▁evidence - based ▁; ▁heart ▁disease ▁; ▁ therapie s ▁; ▁patients ▁; ▁ca bg ▁; ▁swe den
▁in patient ▁; ▁primary ▁end ▁point ▁; ▁re hospital ization ▁; ▁stroke ▁; ▁my o card ial ▁in far ction ▁; ▁heart ▁failure ▁; ▁ca bg
▁logistic ▁re gression ▁; ▁primary ▁outcome ▁; ▁seconda ry ▁outcome ▁; ▁death
▁follow - up ▁; ▁cardiovascular ▁events ▁; ▁death s
▁patients ▁; ▁a cute ▁ki dne y ▁injury ▁; ▁post operativ ely
▁odds ▁ratio s ▁; ▁confidence ▁interval s ▁; ▁cardiovascular ▁events ▁; ▁at rial ▁fi bril lation ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁diabetes ▁mell itus ▁; ▁per i pher al ▁vas cular ▁disease ▁; ▁my o card ial ▁in far ction ▁; ▁heart ▁failure ▁; ▁stroke ▁; ▁patients ▁; ▁estima ted ▁glo mer ular ▁filtr ation ▁rate ▁; ▁non signif i cant ▁; ▁a cute ▁ki dne y ▁injury
▁death ▁; ▁patients ▁; ▁estima ted ▁glo mer ular ▁filtr ation ▁rate ▁; ▁odds ▁ratio ▁; ▁confidence ▁interval
▁renal ▁dys function ▁; ▁all - ca use ▁mortal ity ▁; ▁cardiovascular ▁events ▁; ▁post operativ e ▁; ▁ca bg
▁heart ▁failure
▁heart ▁failure ▁; ▁clinic al ▁; ▁medicine ▁; ▁prevale nce ▁; ▁corona ry ▁disease
▁corona ry ▁disease ▁; ▁leading ▁; ▁heart ▁failure
▁disease ▁; ▁account ing ▁; ▁cardiac ▁transplant s
▁cardiac ▁; ▁symptoms ▁; ▁con geni tal ▁; ▁les ions
▁les ions ▁; ▁sept al ▁; ▁sur g ical
▁con geni tal ▁; ▁heart ▁; ▁les ions
▁dia sto lic ▁failure ▁; ▁cardio my o pathi c
▁patients ▁; ▁heart ▁failure ▁; ▁my o card ial ▁function ▁; ▁dil ated ▁; ▁contract ing ▁; ▁vent ric les ▁; ▁a eti ologie s
▁heart ▁failure ▁; ▁ diagnos is ▁; ▁my o card itis ▁; ▁dil ated ▁cardio my o pathy ▁; ▁heart ▁failure ▁; ▁heart ▁failure ▁; ▁an thra cycli ne ▁; ▁disease
▁molecular ▁sc af fold s ▁; ▁heart ▁; ▁path ology
▁cardio my o cy tes ▁; ▁my o car dium ▁; ▁conditions
▁conditions ▁; ▁remodel ling ▁; ▁leading ▁; ▁heart ▁failure
▁signal ling ▁path ways ▁; ▁cardiac ▁remodel ling
▁trans duction ▁path ways ▁; ▁engage ▁; ▁signal ling ▁protein s
▁signal ling ▁path way ▁; ▁remodel ling
▁signal o some ▁complex ▁; ▁sc af fold ▁protein ▁; ▁drive s ▁; ▁kina ses ▁; ▁ phos phor y lation ▁; ▁effect or ▁mole cules
▁sc af fold ▁protein s ▁; ▁cardiac ▁remodel ling ▁; ▁field ▁; ▁ therapeut ic
▁cardiac ▁a my lo idos is
▁report ▁; ▁patient ▁; ▁ diagnos is ▁; ▁ ische mic - hy per tensi ve ▁cardio my io pathy ▁; ▁ang ina ▁; ▁my o card ial ▁ ische mia ▁; ▁corona ry ▁arteri es
▁cardiac ▁magnetic ▁res on ance ▁; ▁a my lo ido tic ▁; ▁ diagnos is ▁; ▁multiple ▁mye loma ▁; ▁osteo me dulla ry ▁bio psy
▁fra il ty ▁; ▁heart ▁failure
▁fra il ty ▁; ▁prognos tic ▁; ▁heart ▁failure ▁; ▁h f ▁; ▁bi ological ▁ph eno type
▁h f
▁minne s ota ▁; ▁h f
▁fra il ty ▁; ▁bi ological ▁ph eno type ▁; ▁physical ▁; ▁activity
▁fra il ty
▁deficit ▁index
▁patients ▁; ▁fra il ▁; ▁fra il ▁; ▁bi ological ▁ph eno type
▁deficit ▁index
▁follow - up ▁; ▁patients
▁e je ction ▁ fraction ▁; ▁patients ▁; ▁fra il ▁; ▁bi ological ▁ph eno type ▁; ▁death ▁; ▁fra il ty ▁; ▁deficit ▁index ▁; ▁death
▁death ▁; ▁c - stat istic s ▁; ▁bi ological ▁ph eno type ▁; ▁deficit ▁index
▁deficit ▁index ▁; ▁bi ological ▁ph eno type ▁; ▁mortal ity
▁bi ological ▁ph eno type ▁; ▁clinic ally ▁; ▁deficit ▁index ▁; ▁medical ▁; ▁fra il ty
▁a cute ▁heart ▁failure
▁a cute ▁heart ▁failure ▁; ▁h f ▁; ▁ pharma c ologic ▁; ▁ therapeut ics ▁; ▁calci um - sensi t izing ▁agents ▁; ▁anta gon ists ▁; ▁en do the lin ▁; ▁vaso press in ▁; ▁ad enos ine
▁ pharma c ologic ▁; ▁a cute ▁h f ▁; ▁advers e ▁event ▁; ▁chronic ▁h f
▁a cute ▁h f ▁; ▁relax - ah f ▁; ▁astronaut ▁; ▁pronto ▁; ▁patient ▁; ▁patients ▁; ▁end ▁points
▁a cute ▁h f
▁na tri ure tic ▁pe pti des ▁; ▁point ▁of ▁care ▁; ▁ambula tory
▁na tri ure tic ▁pe pti des ▁; ▁np s ▁; ▁b - type ▁np ▁; ▁n - termin al ▁pro - b - type ▁np ▁; ▁ diagnos is ▁; ▁a cute ▁heart ▁failure ▁; ▁patients ▁; ▁emergency ▁department ▁; ▁a cute ▁dys pne a
▁meta - analyse s ▁; ▁patients
▁np s ▁; ▁advers e ▁outcome s ▁; ▁patients ▁; ▁heart ▁failure ▁; ▁pulmonar y ▁e mbol ism ▁; ▁diabetes ▁; ▁che mo therapy
▁na tri ure tic ▁pe pti de ▁; ▁bio mark ers ▁; ▁point ▁of ▁care ▁; ▁poc
▁poc ▁; ▁np s ▁; ▁clinic al
▁poc ▁; ▁diagnostic
▁point - of - care ▁; ▁out patient ▁; ▁a cute ▁heart ▁failure
▁poc ▁; ▁frame ▁; ▁patient ▁; ▁consultation ▁; ▁patients
▁clinic al
▁advantage ▁; ▁poc
▁heart ▁failure ▁; ▁read mission ▁; ▁outcome
▁center s ▁for ▁medica re ▁and ▁medica id ▁services ▁; ▁cm s ▁; ▁hospital ▁; ▁outcome s ▁; ▁reported ▁; ▁mortal ity ▁; ▁read mission ▁; ▁penal ties
▁hospital s ▁; ▁patients ▁; ▁hospital ized ▁; ▁heart ▁failure ▁; ▁h f ▁; ▁conditions ▁; ▁a cute ▁my o card ial ▁in far ction ▁; ▁pneu monia ▁; ▁conditions
▁card i ology ▁; ▁bro modo main ▁; ▁halt s ▁; ▁heart ▁failure
▁heart ▁failure ▁; ▁h f ▁; ▁leading ▁; ▁mortal ity ▁; ▁society
▁path ological ▁; ▁remodel ling ▁; ▁heart ▁; ▁cardiac ▁hyper trop hy ▁; ▁h f ▁; ▁death ▁; ▁fibro sis ▁; ▁ inflammation
▁h f ▁; ▁chr omat in ▁hyper ace ty lation
▁report ing ▁; ▁cell ▁; ▁an and
▁bet ▁; ▁bro modo main ▁protein s ▁; ▁bet s ▁; ▁a ce tyl - ly sine ▁reader ▁protein s ▁; ▁h f ▁; ▁path ogen es is ▁; ▁h f
▁remodel ling ▁; ▁h f ▁; ▁ha emo dynamic ▁; ▁neuron al ▁stress ors
▁activa te ▁; ▁signal ▁trans duction ▁; ▁tran scription ▁factors ▁; ▁path ological ▁; ▁cardio my o cy tes ▁; ▁tran scription ▁factors ▁; ▁epi gene tic ▁; ▁chr omat in ▁structure
▁epi gene tic ▁; ▁protein s ▁; ▁hi stone ▁a ce tyl transfer as es ▁; ▁epi gene tic ▁; ▁hi stone ▁de ace ty las es ▁; ▁cardiac ▁; ▁disease
▁bro modo main ▁protein s
▁j q 1 ▁; ▁bet s ▁; ▁chr omat in ▁; ▁down stream ▁signal ling ▁; ▁ rna ▁; ▁poly mera se ▁i i ▁; ▁pol ▁i i
▁bet s ▁; ▁in ▁vi tro ▁; ▁neuro hormon ally ▁; ▁heart ▁disease ▁; ▁na nomo lar ▁; ▁j q 1 ▁; ▁ phen yle ph rine - media ted ▁hyper trop hy ▁; ▁cardio my o cy tes ▁; ▁path ological ▁; ▁gene ▁in duction
▁bet ▁; ▁bro modo main - conta ining ▁protein ▁4 ▁; ▁br d 4 ▁; ▁cardiac
▁gene ▁expression ▁; ▁cardio my o cy tes ▁; ▁j q 1 ▁; ▁drug ▁; ▁gene s
▁in ▁vivo ▁; ▁h f ▁; ▁ phen yle ph rine ▁; ▁ha emo dynamic ▁; ▁sur g ical ▁; ▁trans verse ▁a or tic ▁con stri ction ▁; ▁tac ▁; ▁j q 1 ▁; ▁path ological ▁; ▁cardiac ▁hyper trop hy
▁system ic ▁blood ▁pressure
▁cardiac ▁; ▁j q 1 ▁; ▁bet ▁; ▁path ological ▁; ▁cardiac ▁; ▁gene ▁expression
▁bet s ▁; ▁tac ▁; ▁h f
▁bet s ▁; ▁signal ▁trans duction ▁; ▁pol ▁i i ▁; ▁tran scription ▁factor ▁; ▁h f ▁; ▁path ogen es is ▁; ▁nuclear ▁factor ▁of ▁activa ted ▁t ▁cell s ▁; ▁n fat ▁; ▁nuclear ▁factor - κ b ▁; ▁n f - κ b ▁; ▁tran scription ▁factor ▁; ▁gata 4
▁bet s ▁; ▁tran scription al ▁pause ▁release ▁; ▁path ological
▁epi gene tic ▁; ▁cardiac ▁; ▁cardiac ▁; ▁gene ▁; ▁signal ▁trans duction ▁; ▁path ological ▁; ▁gene ▁expression ▁; ▁h f
▁t 1- ma pping ▁; ▁m ri ▁; ▁tid al ▁respira tion ▁; ▁my o card ial ▁t 1 ▁; ▁heart ▁failure
▁puls e ▁; ▁my o card ial ▁t 1 ▁; ▁heart ▁failure
▁yor k shire ▁; ▁implant ed ▁; ▁pace makers ▁; ▁vent ri cular ly ▁; ▁beat s ▁; ▁heart ▁failure
▁m ri ▁scanner ▁; ▁base line ▁; ▁heart ▁failure
▁t 1- ma pping ▁; ▁tid al ▁respira tion ▁; ▁administration ▁; ▁ gado lini um - che late ▁contrast ▁agent
▁t 1- ma pping ▁; ▁base line ▁; ▁heart ▁failure
▁fibro sis ▁; ▁heart ▁failure ▁; ▁my o card ial ▁tissu e ▁; ▁left ▁vent ri cular ▁; ▁tri ch rom e ▁blue ▁his t ologic ▁analysis
▁base line ▁; ▁heart ▁failure ▁; ▁t 1- ma pping ▁; ▁administration ▁; ▁administration
▁heart ▁failure ▁; ▁his t ological ly ▁; ▁my o card ial ▁collage n ▁; ▁healthy ▁; ▁heart ▁failure
▁t 1- ma pping ▁; ▁my o card ial ▁; ▁heart ▁failure
▁t 1 ▁; ▁my o card ial ▁collage n ▁; ▁my o card ial
▁t 1 ▁ma pping ▁; ▁clinic ally ▁; ▁my o card ial ▁fibro sis
▁heart ▁failure
▁heart ▁failure ▁; ▁h f ▁; ▁ therapy
▁implant able ▁cardio ver ter - de fi br illa tors ▁; ▁i cd s ▁; ▁mortal ity ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁cr t ▁; ▁symptoms ▁; ▁mortal ity
▁collect ed ▁; ▁patients ▁; ▁sy sto lic ▁dys function
▁patients ▁; ▁sy sto lic ▁function ▁; ▁ therapeut ic
▁ therapeut ic ▁; ▁diagnostic ▁; ▁fluid ▁over load
▁diagnostic ▁; ▁h f
▁heart ▁failure ▁; ▁disease ▁; ▁ therapeut ics
▁heart ▁failure ▁; ▁h f ▁; ▁cardiovascular ▁; ▁hospital ization
▁mortal ity ▁; ▁morbi d ity ▁; ▁health - care ▁; ▁budget
▁h f ▁with ▁pres er ved ▁e je ction ▁ fraction ▁; ▁h f pe f ▁; ▁hyper tension
▁drugs ▁; ▁h f ▁with ▁reduce d ▁e je ction ▁ fraction ▁; ▁h fre f
▁h f pe f
▁un fold ed ▁protein ▁response ▁; ▁cardiac ▁so dium ▁; ▁sy sto lic ▁; ▁heart ▁failure
▁heart ▁failure ▁; ▁h f ▁; ▁m rna ▁s plic ing ▁; ▁cardiac ▁; ▁sc n 5 a ▁; ▁en do plas mic ▁reti culum
▁activa te ▁; ▁un fold ed ▁protein ▁response ▁; ▁up r ▁; ▁sc n 5 a ▁; ▁remodel ing ▁; ▁h f
▁up r ▁; ▁sc n 5 a ▁; ▁vent ri cular ▁sy sto lic ▁h f ▁; ▁human ▁induc ed ▁pluri potent ▁stem ▁cell - der i ved ▁cardio my o cy tes ▁; ▁hip sc - cm s
▁cell s ▁; ▁ang io ten sin ▁i i ▁; ▁ang ii ▁; ▁hypo xia ▁; ▁sc n 5 a ▁; ▁m rna ▁s plic ing ▁; ▁sc n 5 a
▁up r ▁; ▁protein ▁kina se ▁r - like ▁er ▁kina se ▁; ▁per k ▁; ▁cal ret icul in ▁; ▁ chop ▁; ▁h f
▁sc n 5 a ▁; ▁ang ii ▁; ▁hypo xia ▁; ▁expression ▁; ▁up r ▁; ▁down regul ation
▁per k ▁; ▁sc n 5 a ▁; ▁kv 4.3 ▁; ▁mr nas ▁; ▁trans ient ▁receptor ▁potential ▁ cation ▁channel ▁m 7 ▁; ▁tr pm 7 ▁; ▁m rna
▁per k ▁; ▁sc n 5 a ▁; ▁kv 4.3 ▁; ▁m rna ▁; ▁m rna ▁sp lice
▁up r ▁; ▁m rna ▁sp lice ▁; ▁cardiac ▁; ▁h f
▁sc n 5 a ▁; ▁up r ▁; ▁down regul ation ▁; ▁cardiac ▁; ▁gene s ▁; ▁h f
▁a cute ▁right ▁heart ▁failure ▁; ▁pulmonar y ▁hyper tension
▁right ▁vent ric le ▁; ▁ rv ▁; ▁cardiac ▁function ▁; ▁medical
▁et i ologic ▁; ▁a cute ▁ rv ▁failure ▁; ▁left ▁vent ri cular ▁dys function
▁ rv ▁failure ▁; ▁diagnostic ▁; ▁left ▁vent ri cular ▁dys function
▁ rv ▁; ▁pat ho phy si ologic ▁; ▁ rv ▁dys function
▁patients ▁; ▁a cute ▁ rv ▁failure ▁; ▁chronic ▁pulmonar y ▁arterial ▁hyper tension ▁; ▁pah ▁; ▁a cute ▁; ▁pulmonar y ▁e mbol ism
▁chronic ▁pah ▁; ▁clinic al ▁; ▁hospital ized ▁; ▁patients ▁; ▁a cute ▁; ▁ rv ▁de com pensa tion ▁; ▁ pharma c ologic ▁; ▁ therapie s ▁; ▁ rv ▁failure ▁; ▁pah
▁a cute ▁ rv ▁failure ▁; ▁pulmonar y ▁e mbol ism ▁; ▁mortal ity ▁; ▁diagnostic
▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; ▁my o card ial ▁in far ction
▁epidemi ology ▁; ▁my o card ial ▁in far ction ▁; ▁mi ▁; ▁outcome s ▁; ▁heart ▁failure ▁; ▁h f
▁h f ▁; ▁mi ▁; ▁reduce d ▁e je ction ▁ fraction ▁; ▁ef
▁h f ▁; ▁mi
▁ol m sted ▁count y ▁; ▁minne s ota ▁; ▁mi ▁; ▁diagnose d ▁; ▁h f ▁; ▁followed - up
▁fram ing ham ▁heart ▁study ▁; ▁h f ▁; ▁ef
▁mi ▁; ▁mi ▁; ▁h f
▁patient ▁; ▁st - seg ment - elevat ion ▁mis ▁; ▁kill ip ▁class ▁; ▁como r bid ▁; ▁conditions
▁follow - up ▁; ▁patients ▁; ▁h f
▁hazard ▁ratio s ▁; ▁confidence ▁interval ▁; ▁h f ▁; ▁h f
▁patient ▁; ▁mi ▁; ▁hazard ▁ratio s ▁; ▁h f
▁h f ▁; ▁h f ▁with ▁reduce d ▁ef ▁; ▁h f ▁with ▁pres er ved ▁ef ▁; ▁change ▁; ▁h f ▁; ▁mi
▁select ive ▁beta - block ers ▁; ▁cardiac ▁sympa the tic ▁activity ▁; ▁hemos tas is ▁; ▁patients ▁; ▁heart ▁failure
▁car vedi lol ▁; ▁non sel ective ▁β - block er ▁; ▁select ive ▁β - block er ▁; ▁met o pro lol ▁; ▁ thro mbo e mbol ic ▁events ▁; ▁heart ▁failure
▁cardiac ▁sympa the tic ▁activity ▁; ▁β - block er
▁corre late s ▁; ▁coa gul ability
▁prospect ive ▁; ▁random ized ▁; ▁cross over ▁study ▁; ▁outcome ▁; ▁stable ▁heart ▁failure ▁; ▁patients ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁homo zy go us ▁; ▁ha plo type ▁; ▁β 2- recept or ▁; ▁random ized ▁; ▁car vedi lol ▁; ▁met o pro lol
▁primary ▁outcome ▁; ▁sympa the tic ▁activity ▁; ▁my o card ial ▁was hout
▁seconda ry ▁outcome s ▁; ▁hemos tas is
▁cardiac ▁was hout ▁; ▁car vedi lol ▁; ▁met o pro lol ▁; ▁β 2- ad r energi c ▁receptor ▁ha plo type
▁car vedi lol ▁; ▁von ▁will e brand ▁factor ▁; ▁met o pro lol ▁; ▁β 2- ad r energi c ▁receptor ▁ha plo type
▁met o pro lol ▁; ▁car vedi lol ▁; ▁sympa the tic ▁activity ▁; ▁von ▁will e brand ▁factor
▁car vedi lol ▁; ▁ thro mbo e mbol ic ▁events ▁; ▁patients ▁; ▁heart ▁failure ▁; ▁β 2- recept or ▁ha plo type
▁pre scribi ng ▁; ▁medication s ▁; ▁heart ▁failure
▁patient ▁; ▁pre scribi ng ▁; ▁medication s ▁; ▁medical
▁mix ed - met hod s ▁study ▁; ▁health ▁care ▁; ▁sy sto lic ▁heart ▁failure ▁; ▁pre scribe d ▁; ▁β - block er ▁; ▁ang io ten sin ▁convert ing ▁enzym e ▁inhibi tor ▁; ▁ang io ten sin - recept or ▁block er
▁clinic ▁; ▁clinic ians ▁; ▁patients

▁patients ▁; ▁drugs ▁; ▁heart ▁failure ▁; ▁bio medic al ▁; ▁non pre scribi ng ▁; ▁patients
▁clinic ian ▁; ▁non pre scribi ng ▁; ▁patient
▁bio medic al ▁; ▁non pre scribi ng ▁; ▁patients
▁clinic ians ▁; ▁patients ▁; ▁patient ▁; ▁clinic ian ▁; ▁medication ▁; ▁patient
▁pre scribi ng ▁; ▁ang io ten sin ▁convert ing ▁enzym e ▁inhibi tor ▁; ▁ang io ten sin - recept or ▁block ers ▁; ▁β - block ers ▁; ▁patients ▁; ▁heart ▁failure ▁; ▁medication s ▁; ▁medical
▁medical
▁para sy mpa the tic ▁tone ▁; ▁py rido stig mine ▁; ▁vent ri cular ▁dys function ▁; ▁heart ▁failure
▁heart ▁failure ▁; ▁h f ▁; ▁eleva ted ▁; ▁sympa the tic ▁activity ▁; ▁para sy mpa the tic ▁control ▁; ▁heart
▁evidence ▁; ▁para sy mpa the tic ▁; ▁ therapeut ic ▁; ▁h f
▁para sy mpa the tic ▁neuro trans mission ▁; ▁a ce tyl cho line ster ase ▁inhibi tion
▁a ce tyl cho line ster ase ▁inhibi tor ▁; ▁py rido stig mine ▁; ▁sympa t hova gal ▁balance ▁; ▁cardiac ▁remodel ing ▁; ▁cardiac ▁function ▁; ▁h f ▁; ▁my o card ial ▁in far ction
▁my o card ial ▁in far ction
▁py rido stig mine ▁; ▁administration ▁; ▁met hy la tropi ne ▁; ▁propra no lol ▁; ▁cardiac ▁; ▁sympa t hova gal ▁balance
▁ta chy car dic ▁; ▁met hy la tropi ne ▁; ▁va gal ▁tone ▁; ▁bra dy car dic ▁; ▁propra no lol ▁; ▁sympa the tic ▁tone
▁h f ▁; ▁py rido stig mine ▁; ▁bas al ▁heart ▁rate ▁; ▁sympa the tic ▁control ▁of ▁heart ▁rate
▁py rido stig mine ▁; ▁my o cy te ▁; ▁collage n ▁; ▁left ▁vent ric le
▁py rido stig mine ▁; ▁vas cular ▁en dot heli al ▁growth ▁factor ▁; ▁protein ▁; ▁left ▁vent ric le ▁; ▁my o card ial ▁ang io gene sis
▁cardiac ▁function ▁; ▁cat heter
▁h f ▁; ▁py rido stig mine ▁; ▁stroke ▁volume ▁; ▁e je ction ▁ fraction ▁; ▁cardiac ▁output ▁; ▁contract ility ▁; ▁left ▁vent ric le
▁administration ▁; ▁py rido stig mine ▁; ▁corona ry ▁arter y ▁liga tion ▁; ▁cardiac ▁; ▁sympa the tic ▁tone ▁; ▁cardiac ▁remodel ing ▁; ▁left ▁vent ri cular ▁dys function ▁; ▁h f
▁electro me chan ical ▁de lay ▁; ▁dys syn chron ous ▁heart ▁failure
▁left ▁bund le ▁bran ch ▁block ▁; ▁remodel ing ▁; ▁dys syn chron ous ▁heart ▁failure ▁; ▁h f ▁; ▁heart
▁vent ri cular ▁; ▁wall ▁sti ff ness
▁dys syn chron ous ▁h f ▁; ▁electro me chan ical ▁de lay ▁; ▁em d ▁; ▁my o cy te ▁de po lar ization ▁; ▁my o fi ber ▁short en ing
▁h f ▁; ▁remodel ing ▁; ▁em d ▁; ▁dys syn chron ous ▁fail ing ▁heart
▁remodel ing ▁; ▁em d
▁dys syn chron ous ▁non fail ing ▁; ▁h f ▁; ▁combination s ▁; ▁remodel ing
▁left ▁bund le ▁bran ch ▁block
▁em d ▁; ▁dys syn chron ous ▁h f ▁; ▁remodel ing ▁; ▁insigni fica nt ly
▁dys syn chron ous ▁h f ▁; ▁my o fi ber ▁short en ing ▁; ▁sept um ▁; ▁my o fi ber ▁short en ing ▁; ▁stretch ▁; ▁wall
▁my o fi ber ▁dynamic s ▁; ▁my o fi ber ▁short en ing ▁; ▁em d ▁; ▁dys syn chron ous ▁h f
▁right ▁vent ri cular ▁function ▁; ▁prognos is ▁; ▁heart ▁failure
▁right ▁vent ri cular ▁; ▁ rv ▁; ▁prognos is ▁; ▁patients ▁; ▁heart ▁failure ▁; ▁h f
▁cache xia ▁; ▁ rv ▁function
▁ rv ▁dys function ▁; ▁prognos is ▁; ▁h f
▁h f ▁; ▁prospect ive ▁; ▁dual - ener gy ▁x - ray ▁ab sor pti ometr y ▁; ▁e cho card i ography ▁; ▁blood
▁followed ▁up ▁; ▁advers e ▁events ▁; ▁death ▁; ▁transplant ation ▁; ▁circula tory ▁assist ▁device
▁ rv ▁dys function ▁; ▁body ▁mass ▁index ▁; ▁fat ▁mass ▁; ▁cache xia
▁ rv ▁dys function ▁; ▁cor related ▁; ▁lean ▁body ▁mass
▁follow - up
▁ rv ▁dys function ▁; ▁hazard ▁ratio ▁; ▁confidence ▁interval ▁; ▁cache xia ▁; ▁hazard ▁ratio ▁; ▁multi varia te ▁analyse s
▁body ▁mass ▁index ▁; ▁fat ▁mass ▁; ▁fat - free ▁mass
▁ rv ▁dys function ▁; ▁cardiac ▁cache xia
▁lean ▁mass ▁; ▁advers e ▁outcome ▁; ▁adi pose ▁tissu e ▁; ▁cardio protec tive ▁; ▁h f
▁if - chan nel ▁inhibi tion ▁; ▁hem o dynamic ▁; ▁exercise ▁ tolerance ▁; ▁heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction ▁; ▁random ized
▁i va bra dine ▁; ▁exercise ▁capacity ▁; ▁left ▁vent ri cular ▁fill ing ▁; ▁patients ▁; ▁heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction ▁; ▁h f pe f
▁symptoms ▁; ▁h f pe f ▁; ▁dia sto lic ▁fill ing ▁time ▁; ▁heart ▁rate ▁; ▁symptoms
▁patients ▁; ▁h f pe f ▁; ▁i va bra dine ▁; ▁place bo ▁; ▁double - blind
▁cardio pul mon ary ▁exercise ▁testing ▁; ▁e cho car dio graphic ▁; ▁my o card ial ▁function ▁; ▁left ▁vent ri cular ▁fill ing ▁; ▁exercise
▁i va bra dine ▁; ▁base line ▁; ▁follow - up ▁; ▁exercise ▁capacity ▁; ▁met s ▁; ▁met s ▁; ▁pe ak ▁oxygen ▁up take ▁; ▁pe ak ▁early ▁dia sto lic ▁mit ral ▁flow ▁veloci ty ▁; ▁pe ak ▁early ▁dia sto lic ▁mit ral ▁ann ular ▁veloci ty
▁chr ono tropi c ▁response ▁; ▁heart ▁rate ▁; ▁exercise ▁; ▁base line ▁; ▁follow - up ▁; ▁tests ▁; ▁heart ▁rate ▁; ▁exercise
▁ therapy ▁; ▁i va bra dine ▁; ▁change ▁; ▁pe ak ▁early ▁dia sto lic ▁mit ral ▁flow ▁veloci ty ▁; ▁pe ak ▁early ▁dia sto lic ▁mit ral ▁ann ular ▁veloci ty ▁; ▁corre late s ▁; ▁exercise ▁capacity ▁; ▁ therapy ▁; ▁i va bra dine ▁; ▁cor related ▁; ▁pe ak ▁oxygen ▁up take
▁patients ▁; ▁h f pe f ▁; ▁i va bra dine ▁; ▁exercise ▁capacity ▁; ▁left ▁vent ri cular ▁fill ing ▁pressure ▁; ▁exercise ▁; ▁pe ak ▁early ▁dia sto lic ▁mit ral ▁flow ▁veloci ty ▁; ▁pe ak ▁early ▁dia sto lic ▁mit ral ▁ann ular ▁veloci ty
▁patient ▁; ▁symptom a tic ▁; ▁ therapeut ic ▁; ▁exercise ▁; ▁hem o dynamic
▁use ▁of ▁exercise ▁and ▁medical ▁ therapie s ▁to ▁improve ▁cardiac ▁function ▁among ▁patients ▁with ▁ex er tional ▁short ness ▁of ▁breath ▁due ▁to ▁lung ▁con gestion
▁clinic al ▁; ▁corona ry ▁arter y ▁disease ▁; ▁patients ▁; ▁sy sto lic ▁heart ▁failure ▁; ▁et i ology
▁corona ry ▁arter y ▁disease ▁; ▁cad ▁; ▁sy sto lic ▁heart ▁failure ▁; ▁h f
▁cad ▁; ▁sy sto lic ▁h f ▁; ▁prognos tic
▁patients ▁; ▁sy sto lic ▁h f ▁; ▁et i ology ▁; ▁corona ry ▁ang i ography
▁clinic al ▁; ▁rule ▁; ▁cad ▁; ▁sy sto lic ▁h f
▁patients ▁; ▁corona ry ▁ang i ography ▁; ▁ diagnos is ▁; ▁sy sto lic ▁h f ▁; ▁et i ology ▁; ▁e je ction ▁ fraction
▁multi varia te ▁logistic ▁re gression ▁analysis ▁; ▁rule ▁; ▁cad ▁; ▁sten osis ▁; ▁3- ves sel ▁cad ▁; ▁2- ves sel ▁cad ▁; ▁left ▁anterior ▁descend ing ▁arter y
▁diagnostic ▁; ▁rule ▁; ▁prospect ive ly
▁patients ▁; ▁cad ▁; ▁cad
▁cad ▁; ▁diabetes ▁; ▁odds ▁ratio ▁; ▁electro car dio graphic ▁q ▁wa ves ▁; ▁left ▁bund le ▁bran ch ▁block ▁; ▁odds ▁ratio ▁; ▁non dia bete s ▁; ▁dys li pide mia ▁; ▁hyper tension ▁; ▁odds ▁ratio
▁rule ▁; ▁patients ▁; ▁cad ▁; ▁patients ▁; ▁cad
▁prospect ive ▁; ▁patients ▁; ▁rule ▁; ▁ sensitiv ity ▁; ▁specific ity ▁; ▁cad ▁; ▁ sensitiv ity ▁; ▁cad
▁clinic al ▁; ▁rule ▁; ▁patients ▁; ▁cad ▁; ▁ang i ography ▁; ▁patients ▁; ▁sy sto lic ▁h f ▁; ▁cost
▁vaso press in ▁receptor ▁anta gon ist ▁; ▁to lv ap tan ▁; ▁heart ▁failure ▁; ▁patients
▁to lv ap tan ▁; ▁vaso press in ▁type ▁2 ▁receptor ▁anta gon ist
▁to lv ap tan ▁; ▁hypo na trem ia ▁; ▁unit ed ▁states ▁; ▁japan ▁; ▁con ges tive ▁heart ▁failure ▁; ▁patients ▁; ▁di ure tic ▁; ▁ therapy ▁; ▁se rum ▁so dium ▁; ▁sy sto lic ▁function
▁drug ▁; ▁japan
▁di ure tic ▁; ▁heart ▁failure ▁; ▁outcome s
▁di ure tics ▁; ▁symptoms ▁; ▁patients ▁; ▁heart ▁failure ▁; ▁h f
▁prospect ive ▁; ▁di ure tics ▁; ▁morbi d ity ▁; ▁mortal ity
▁di ure tic ▁; ▁neuro hormon al ▁; ▁symptoms ▁; ▁fluid ▁over load
▁di ure tic ▁; ▁outcome s ▁; ▁h f
▁patient ▁; ▁heart ▁failure ▁with ▁reduce d ▁e je ction ▁ fraction
▁heart ▁failure
▁ therapie s ▁; ▁medication ▁; ▁physical ▁ therapy ▁; ▁implant able ▁de fi br illa tors ▁; ▁circula tory ▁support ▁; ▁transplant ation ▁; ▁risk ▁strat ification ▁; ▁patient ▁; ▁heart ▁failure ▁; ▁ therapie s ▁; ▁disease

▁ phos pho dies tera se -2 ▁; ▁heart s ▁; ▁beta - ad r energi c ▁response s ▁; ▁cardio my o cy tes
▁my o card ial ▁; ▁ phos pho dies tera se -2 ▁; ▁p de 2 ▁; ▁heart ▁failure ▁; ▁h f ▁; ▁beta - ad r energi c ▁receptor ▁; ▁β - ar ▁; ▁healthy ▁; ▁disease d ▁; ▁cardio my o cy tes
▁ cycli c ▁ad enos ine ▁mono phos pha te ▁; ▁camp ▁; ▁ cycli c ▁gua no sine ▁mono phos pha te ▁; ▁c g mp ▁; ▁heart s
▁p de ▁; ▁p de 2 ▁; ▁c g mp ▁; ▁leading ▁; ▁camp ▁hydro lys is ▁; ▁cross ▁talk ▁; ▁c g mp ▁; ▁camp ▁signal ing
▁p de 2 ▁; ▁h f
▁immun o blo tting ▁; ▁video ▁edge ▁det ection ▁; ▁epi flu o resc ence ▁micro s copy ▁; ▁my o card ial ▁tissu es ▁; ▁cardio my o cy tes ▁; ▁h f
▁my o card ial ▁; ▁p de 2 ▁; ▁expression ▁; ▁activity ▁; ▁h f
▁chronic ▁; ▁β - ar ▁; ▁cate chol amine ▁; ▁in fusion s ▁; ▁p de 2 ▁; ▁expression ▁; ▁camp ▁; ▁activity ▁; ▁cor related ▁; ▁cardiac ▁; ▁β - ar ▁responsive ness
▁disease d ▁; ▁cardio my o cy tes ▁; ▁p de 2 ▁; ▁activity ▁; ▁c g mp ▁synth es is ▁; ▁ni tric ▁oxid e ▁; ▁donor s ▁; ▁p de 2 ▁inhibi tion ▁; ▁β - ar ▁responsive ness
▁p de 2 ▁; ▁healthy ▁; ▁cardio my o cy tes ▁; ▁camp ▁; ▁in o tropi c ▁effect ▁; ▁a cute ▁; ▁β - ar ▁; ▁contract ility
▁cardio my o cy tes ▁; ▁hyper trop hic
▁p de 2 ▁; ▁heart s ▁; ▁a cute ▁; ▁β - ar
▁cardiac ▁stress ▁; ▁β - ar ▁; ▁drive
▁my o card ial ▁; ▁p de 2 ▁; ▁intra cel lular ▁; ▁anti ad r energi c ▁; ▁ therapeut ic ▁; ▁h f
▁e pler en one ▁; ▁patients ▁; ▁hyper kal emia ▁; ▁renal ▁function ▁; ▁emphasis - h f ▁; ▁e pler en one ▁; ▁patients ▁; ▁hospital ization ▁; ▁heart ▁failure
▁e pler en one ▁; ▁patients ▁; ▁hyper kal emia ▁; ▁renal ▁function ▁; ▁emphasis - h f ▁; ▁patients ▁; ▁heart ▁failure ▁and ▁reduce d ▁e je ction ▁ fraction ▁; ▁h f - ref ▁; ▁new ▁yor k ▁heart ▁association ▁; ▁ny ha ▁; ▁functional ▁class ▁; ▁estima ted ▁glo mer ular ▁filtr ation ▁rate ▁; ▁eg fr ▁; ▁se rum ▁po tas s ium
▁patients ▁; ▁ therapy ▁; ▁hospital ized ▁; ▁cardiovascular
▁e pler en one ▁; ▁patients ▁; ▁h f - ref ▁; ▁hyper kal emia ▁; ▁patients
▁patients ▁; ▁hyper kal emia ▁; ▁patients ▁; ▁diabetes ▁; ▁eg fr ▁; ▁sy sto lic ▁blood ▁pressure ▁; ▁po tas s ium ▁; ▁hyper kal emia ▁; ▁leading ▁; ▁hospital ization ▁; ▁hospital ization ▁; ▁primary ▁outcome ▁; ▁hospital ization ▁; ▁h f ▁; ▁cardiovascular ▁mortal ity
▁patients ▁; ▁e pler en one ▁; ▁po tas s ium ▁; ▁po tas s ium ▁; ▁hospital ization ▁; ▁hyper kal emia ▁; ▁medication ▁; ▁advers e ▁events
▁e pler en one ▁; ▁primary ▁com posit e ▁end point
▁patients ▁; ▁chronic ▁; ▁h f - ref ▁; ▁ny ha ▁functional ▁class ▁i i ▁; ▁eg fr ▁; ▁po tas s ium ▁; ▁e pler en one ▁; ▁hyper kal emia
▁outcome s ▁; ▁patients ▁; ▁new ▁yor k ▁heart ▁association ▁; ▁ny ha ▁; ▁heart ▁failure ▁; ▁e pler en one ▁; ▁place bo ▁; ▁heart ▁failure ▁; ▁medicine s ▁; ▁emphasis - h f
▁at rial ▁fi bril lation ▁; ▁con ges tive ▁heart ▁failure ▁; ▁cost ▁; ▁ rhythm - control ▁; ▁rate - control
▁at rial ▁fi bril lation ▁; ▁patients ▁; ▁heart ▁failure
▁rate - control ▁; ▁outcome s
▁economic ▁; ▁patients ▁; ▁heart ▁failure ▁; ▁qué bec ▁; ▁can ada
▁at rial ▁fi bril lation ▁; ▁con ges tive ▁heart ▁failure ▁; ▁health ▁care ▁; ▁ex pendi tures ▁; ▁patients ▁; ▁qué bec ▁; ▁random ized ▁; ▁ rhythm ▁; ▁rate - control
▁costs ▁; ▁qué bec ▁health ▁insurance ▁board ▁; ▁costs ▁; ▁on tario ▁case ▁cost ing ▁initiative
▁patients ▁; ▁e je ction ▁ fraction
▁base line ▁; ▁ rhythm - control ▁; ▁rate - control
▁costs ▁; ▁ex pendi tures
▁rate - control ▁; ▁patients ▁; ▁cardiac ▁; ▁drive n ▁; ▁cardio version s ▁; ▁costs ▁; ▁anti ar rhythm ic ▁drugs ▁; ▁cad ▁; ▁patient ▁; ▁confidence ▁interval ▁; ▁patient
▁ex pendi tures ▁; ▁hospital ization s ▁; ▁non car dio vas cular ▁; ▁diagnose s ▁; ▁implant able ▁cardiac ▁ar rhythm ia ▁devices ▁; ▁non car dio vas cular ▁; ▁drugs ▁; ▁rate - control
▁cost ▁; ▁patient ▁; ▁ rhythm - control ▁; ▁rate - control
▁ therapeut ic ▁; ▁patients ▁; ▁severe ▁heart ▁failure ▁; ▁financial
▁skelet al ▁muscle ▁; ▁sar com ere ▁; ▁patients ▁; ▁heart ▁failure ▁; ▁type ▁2 ▁diabetes
▁h f ▁; ▁heart ▁failure ▁; ▁t 2 d ▁; ▁type ▁2 ▁diabetes ▁; ▁sk m ▁; ▁skelet al ▁muscle
▁epi cate chin - rich ▁coco a ▁; ▁sk m ▁; ▁mito cho ndri al ▁structure ▁; ▁tau b ▁; ▁rami rez - s anche z ▁; ▁ci ar aldi ▁; ▁per kin s ▁; ▁mur phy ▁; ▁na vi aux ▁; ▁ho gan ▁; ▁ce ball os ▁; ▁mais el ▁; ▁hen ry




▁mito cho ndri al ▁structure ▁; ▁sar come ric ▁micro structure
▁patients ▁; ▁h f ▁; ▁t 2 d ▁; ▁er c ▁; ▁vo 2 max ▁; ▁maximum ▁oxygen ▁consum p tion ▁; ▁sk m ▁; ▁bio psi es
▁western ▁blot ▁; ▁immun oh isto che mist ry ▁; ▁electro n ▁micro s copy
▁report ▁; ▁da pc ▁; ▁dys trop hin - as soci ated ▁protein ▁complex ▁; ▁sar come ric ▁micro structure ▁; ▁base line
▁er c ▁; ▁da pc ▁protein ▁; ▁sar come ric ▁micro structure ▁; ▁sk m ▁; ▁my o fi bre ▁regenera tion
▁vo 2 max ▁; ▁significa nce
▁warrant ▁; ▁er c ▁; ▁epi cate chin ▁; ▁muscle
▁medicine ▁; ▁dil ated ▁cardio my o pathy ▁; ▁patients ▁; ▁heart ▁failure
▁medicine ▁; ▁patients ▁; ▁dil ated ▁cardio my o pathy ▁; ▁d cm ▁; ▁heart ▁failure
▁bio medic al ▁; ▁bio medic al ▁; ▁patients ▁; ▁d cm ▁; ▁heart ▁failure ▁; ▁pub med
▁meta - analys is ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁left ▁vent ri cular ▁dia sto lic ▁end ▁diameter ▁; ▁outcome
▁patients
▁bio medic al ▁; ▁bio medic al ▁; ▁relative ▁risk ▁; ▁confidence ▁interval ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁left ▁vent ri cular ▁dia sto lic ▁end ▁diameter ▁; ▁outcome
▁advers e ▁events
▁meta - analys is ▁; ▁bio medic al ▁; ▁bio medic al ▁; ▁patients ▁; ▁d cm ▁; ▁heart ▁failure
▁follow - up ▁; ▁system ic ▁; ▁advers e ▁events ▁; ▁patients ▁; ▁d cm ▁; ▁heart ▁failure
▁base line ▁; ▁follow - up ▁; ▁pa f ▁; ▁activity ▁; ▁metabol ic ▁; ▁enzym es ▁; ▁patients ▁; ▁heart ▁failure ▁; ▁healthy
▁plate let - activa ting ▁factor ▁; ▁pa f ▁; ▁metabol ic ▁; ▁enzym es ▁; ▁follow - up ▁; ▁patients ▁; ▁diagnose d ▁; ▁heart ▁failure ▁; ▁h f ▁; ▁healthy
▁pa f ▁; ▁bio syn the tic ▁enzym es ▁; ▁lys o - pa f ▁a ce tyl transfer ase ▁; ▁lys o - pa f - at ▁; ▁1- al kyl -2 - ace tyl - s n - gly cer ol ▁cho line phos pho transfer ase ▁; ▁pa f - c pt ▁; ▁cata bo lic ▁iso en zy mes ▁; ▁pa f - ace tyl hydro lase ▁; ▁pa f - ah ▁; ▁lipo prote in - as soci ated ▁ phos pho lipa se ▁a 2 ▁; ▁l p - pla 2 ▁; ▁leuk o cy tes
▁base line ▁; ▁patients ▁; ▁h f ▁; ▁lys o - pa f - at ▁; ▁pa f - c pt ▁; ▁pa f ▁; ▁pa f - ah ▁; ▁l p - pla 2
▁follow - up ▁; ▁pa f - c pt ▁; ▁pa f ▁; ▁lys o - pa f - at ▁; ▁down regula ted ▁; ▁pa f - ah ▁; ▁l p - pla 2 ▁; ▁eleva ted
▁diagnose d ▁; ▁patients ▁; ▁h f ▁; ▁drug ▁treatment ▁; ▁pa f ▁; ▁bio syn the tic ▁enzym es ▁; ▁lys o - pa f - at
▁exercise ▁in tolerance ▁; ▁heart ▁failure ▁; ▁exercise ▁; ▁ diagnos is ▁; ▁prognos is ▁; ▁ therapeut ic
▁exercise ▁in tolerance ▁; ▁chronic ▁heart ▁failure ▁; ▁prognos is
▁cardio pul mon ary ▁; ▁exercise ▁; ▁prognos t ically ▁; ▁heart ▁failure
▁pe ak ▁oxygen ▁consum p tion ▁; ▁pe ak ▁vo 2 ▁; ▁exercise ▁; ▁exercise ▁os cilla tory ▁ventilation ▁; ▁e ov ▁; ▁parti al ▁pressure ▁of ▁end - ti dal ▁co 2 ▁; ▁pet co 2 ▁; ▁gain ▁; ▁cardio pul mon ary ▁exercise ▁testing
▁prognos is ▁; ▁pat ho phy si ological
▁exercise ▁; ▁ha emo dynamic ▁; ▁pulmonar y
▁pat ho phy si ological ▁; ▁diagnostic ▁; ▁prognos tic
▁a cute ▁care ▁surgery ▁; ▁heart ▁transplant
▁or tho topic ▁heart ▁transplant ation ▁; ▁oh t ▁; ▁end - s tage ▁heart ▁failure
▁a cute ▁care ▁surgery ▁; ▁ac s ▁; ▁consultation s ▁; ▁oh t ▁; ▁transplant ation ▁; ▁medical ▁ therapy ▁; ▁intra ven ous ▁; ▁in o trop es ▁; ▁vent ri cular ▁assist ▁devices ▁; ▁vad s
▁consultation s ▁; ▁patients ▁; ▁patients
▁transplant ation ▁; ▁consultation ▁; ▁consultation ▁; ▁operation
▁patients ▁; ▁consultation ▁; ▁abdominal
▁ ische mic ▁; ▁infla mma tory ▁; ▁abdominal
▁complica tions ▁; ▁ac s ▁; ▁patients ▁; ▁patients ▁; ▁vad
▁mortal ity ▁; ▁death s ▁; ▁ac s ▁; ▁consultation ▁; ▁operation
▁ac s ▁; ▁patients ▁; ▁oh t ▁; ▁transplant ▁; ▁vad
▁incide nce ▁; ▁vad ▁; ▁ac s ▁; ▁consultation s ▁; ▁operation s ▁; ▁mortal ity ▁; ▁morbi d ity
▁extra corp o real ▁membran e ▁oxygen ation ▁; ▁re frac tory ▁right ▁heart ▁failure
▁clinic al ▁; ▁cardiac ▁arrest ▁; ▁cardio pul mon ary ▁res uscita tion ▁; ▁c pr ▁; ▁ diagnos is ▁; ▁posterior ▁wall ▁in far ction ▁; ▁hospital ized ▁; ▁cardiac
▁cardiac ▁cat heter ization ▁; ▁ thro mbo tic ▁ob struct ion ▁; ▁right ▁corona ry ▁arter y
▁per cuta ne ous ▁; ▁corona ry ▁re vas cular ization ▁; ▁hem o dynamic ally ▁; ▁stable ▁; ▁patient ▁; ▁intensiv e ▁care ▁unit ▁; ▁i cu
▁clinic al ▁; ▁patient ▁; ▁hem o dynamic ally ▁; ▁c pr
▁a cute ▁right ▁heart ▁failure ▁; ▁ therapy ▁; ▁re frac tory ▁cardio ge nic ▁shock ▁; ▁heart ▁; ▁extra ▁corpore al ▁membran e ▁oxygen ation ▁; ▁ec mo ▁; ▁c pr ▁; ▁i cu
▁extra corp o real ▁support
▁cardiac ▁cat heter ization ▁; ▁patient ▁; ▁ex tuba ted ▁; ▁transfer red
▁extra corp o real ▁life ▁support ▁; ▁ therapy ▁; ▁patients ▁; ▁a cute ▁ ische mic ▁right ▁heart ▁failure ▁; ▁re frac tory ▁cardio ge nic ▁shock ▁; ▁reper fusion ▁; ▁ therapy
▁heart ▁failure ▁with ▁pres er ved ▁left ▁vent ri cular ▁e je ction ▁ fraction
▁patients ▁; ▁heart ▁failure ▁; ▁h f ▁; ▁pres er ved ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁h f pe f
▁morbi d ity ▁; ▁mortal ity ▁; ▁h f pe f ▁; ▁patients ▁; ▁h f ▁; ▁reduce d ▁ef
▁dia sto lic ▁dys function ▁; ▁pat ho phy si ology ▁; ▁h f pe f ▁; ▁cardiovascular ▁function
▁ diagnos is ▁; ▁h f pe f ▁; ▁clinic al ▁; ▁e cho - dop pler ▁card i ography ▁; ▁invasi ve ▁ha emo dynamic ▁assessment
▁principal ▁; ▁diagnostic ▁; ▁clinic al
▁incide nce ▁; ▁mortal ity ▁; ▁outcome s ▁; ▁heart ▁failure ▁; ▁a cute ▁my o card ial ▁in far ction ▁; ▁patients ▁; ▁a cute ▁my o card ial ▁in far ction ▁; ▁western ▁austral ia
▁a cute ▁my o card ial ▁in far ction ▁; ▁ami ▁; ▁incide nce ▁; ▁death s ▁; ▁heart ▁failure ▁; ▁h f ▁; ▁ami
▁western ▁; ▁administrative ▁; ▁health ▁; ▁patients ▁; ▁h f ▁; ▁hospital ized ▁; ▁ami
▁incide nce ▁; ▁adjust ed ▁odds ▁ratio ▁; ▁hazard ▁ratio ▁; ▁death ▁; ▁h f ▁; ▁ami ▁; ▁ad mission ▁; ▁dis charge
▁h f ▁; ▁h f
▁prevale nce ▁; ▁h f ▁; ▁ami ▁; ▁adjust ed ▁odds ▁ratio
▁case - fat ality ▁rate ▁; ▁patients ▁; ▁h f ▁; ▁h f ▁; ▁case - fat ality ▁rate
▁h f ▁; ▁multi varia te - ad just ed ▁odds ▁ratio ▁; ▁mortal ity ▁; ▁hazard ▁ratio ▁; ▁mortal ity
▁h f ▁; ▁ami ▁; ▁hazard ▁ratio ▁; ▁mortal ity
▁incide nce ▁; ▁h f ▁; ▁ami ▁; ▁mortal ity
▁patients ▁; ▁prognos is
▁testosteron e ▁ therapy ▁; ▁exercise ▁rehabilita tion ▁; ▁patients ▁; ▁chronic ▁heart ▁failure ▁; ▁testosteron e ▁; ▁double - blind ▁; ▁random ized
▁exercise ▁; ▁intra mus cular ▁testosteron e ▁supplement ation ▁; ▁patients ▁; ▁chronic ▁heart ▁failure ▁; ▁ch f ▁; ▁testosteron e ▁; ▁collect ed ▁; ▁health ▁; ▁outcome s
▁patients ▁; ▁ch f ▁; ▁testosteron e ▁; ▁exercise ▁; ▁testosteron e ▁; ▁place bo
▁compliance ▁; ▁att ri tion
▁outcome s ▁; ▁incrementa l ▁shu ttle ▁walk ▁test ▁; ▁pe ak ▁oxygen ▁up take ▁; ▁muscular ▁; ▁e cho car dio graphic ▁; ▁n - termin al ▁pro - bra in ▁na tri ure tic ▁pe pti de ▁; ▁infla mma tory ▁; ▁ beck ▁depression ▁invent ory ▁; ▁health - related ▁quality ▁of ▁life ▁; ▁minne s ota ▁living ▁with ▁heart ▁failure ▁question naire ▁; ▁medical ▁outcome s ▁study ▁short - form
▁att ri tion ▁; ▁compliance ▁; ▁exercise ▁; ▁inject ions ▁; ▁patients
▁shu ttle ▁walk ▁test ▁; ▁hand ▁; ▁base line
▁exercise ▁; ▁testosteron e ▁; ▁base line ▁; ▁pe ak ▁oxygen ▁up take ▁; ▁ beck ▁depression ▁invent ory ▁; ▁leg ▁; ▁medical ▁outcome s ▁study ▁short - form ▁; ▁quality ▁of ▁life ▁; ▁exercise ▁; ▁place bo
▁e cho car dio graphic ▁; ▁n - termin al ▁pro - bra in ▁na tri ure tic ▁pe pti de ▁; ▁infla mma tory
▁testosteron e ▁supplement ation ▁; ▁exercise ▁rehabilita tion ▁; ▁health ▁; ▁outcome s ▁; ▁patients ▁; ▁ch f ▁; ▁testosteron e
▁functional ▁electric al ▁stimul ation ▁; ▁per i pher al ▁muscle s ▁; ▁en dot heli al ▁function ▁; ▁clinic al ▁; ▁heart ▁failure ▁; ▁patients ▁; ▁pres er ved ▁left ▁vent ri cular ▁e je ction ▁ fraction
▁functional ▁electric al ▁stimul ation ▁; ▁fes ▁; ▁exercise ▁capacity ▁; ▁quality ▁of ▁life ▁; ▁en dot heli al ▁function ▁; ▁chronic ▁heart ▁failure ▁; ▁sy sto lic ▁function
▁fes ▁; ▁patients ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; ▁h f pe f
▁h f pe f ▁; ▁patients ▁; ▁new ▁yor k ▁heart ▁association ▁class ▁i i ▁; ▁e je ction ▁ fraction ▁; ▁fes ▁; ▁place bo
▁base line ▁; ▁training ▁; ▁6- minut e ▁walked ▁distance ▁; ▁quality ▁of ▁life ▁; ▁kansa s ▁city ▁cardio my o pathy ▁question naire ▁; ▁minne s ota ▁living ▁with ▁heart ▁failure ▁question naire ▁; ▁symptoms ▁; ▁ beck ▁depression ▁invent ory ▁; ▁ zung ▁self - rat ed ▁depression ▁score s ▁; ▁b - type ▁na tri ure tic ▁pe pti de ▁; ▁en dot heli al ▁function ▁; ▁flow - media ted ▁di la tation ▁; ▁left ▁vent ri cular ▁dia sto lic ▁function
▁6- minut e ▁walked ▁distance ▁; ▁kansa s ▁city ▁cardio my o pathy ▁question naire ▁; ▁minne s ota ▁living ▁with ▁heart ▁failure ▁question naire ▁; ▁ beck ▁depression ▁invent ory ▁; ▁flow - media ted ▁di la tation ▁; ▁fes ▁; ▁place bo ▁; ▁b - type ▁na tri ure tic ▁pe pti de ▁; ▁mit ral
▁heart ▁failure ▁; ▁reduce d ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁fes ▁; ▁exercise ▁capacity ▁; ▁quality ▁of ▁life ▁; ▁en dot heli al ▁function ▁; ▁h f pe f
▁evidence - based ▁; ▁ therapie s ▁; ▁patients ▁; ▁fes
▁chronic ▁heart ▁failure ▁; ▁yi eld ▁; ▁at rial ▁; ▁cell s
▁cardiac ▁; ▁cell s ▁; ▁cardiac ▁; ▁cell s ▁; ▁cardiac ▁function s ▁; ▁my o card ial ▁in far ction
▁cell ▁ therapy ▁; ▁chronic ▁heart ▁failure ▁; ▁ch f ▁; ▁disease ▁; ▁pro gen itor ▁cell s
▁ch f ▁; ▁ph eno type ▁; ▁cardiac ▁; ▁ex plant ▁; ▁pro geni tors ▁; ▁regula tion
▁my o card ial ▁in far ction ▁; ▁left ▁anterior ▁descend ing ▁corona ry ▁arter y ▁oc clusi on

▁in far cted ▁; ▁left ▁vent ric le ▁end - dia sto lic ▁pressure
▁ch f ▁; ▁at rial ▁ex plant s ▁; ▁cell s ▁; ▁ex plant s
▁cell s ▁; ▁transform ing ▁growth ▁factor - β ▁; ▁t g f - β ▁; ▁epi the li al ▁; ▁mes en chy mal ▁; ▁transition ▁; ▁expression ▁; ▁pluri pote ncy ▁marker s
▁t g f - β ▁signal ing ▁; ▁t g f - β ▁receptor ▁type ▁i ▁; ▁cell ▁; ▁yi eld ▁; ▁epi the li al ▁; ▁mes en chy mal ▁; ▁transition ▁; ▁pluri pote ncy ▁marker ▁; ▁na nog ▁; ▁cell ▁; ▁cell s ▁; ▁in ▁vi tro
▁t g f - β ▁; ▁cell ▁; ▁ph eno type ▁; ▁in ▁vi tro ▁; ▁cardiac ▁pro gen itor ▁function ▁; ▁cell ▁; ▁clinic al
▁periodic ▁breath ing ▁; ▁heart ▁beat
▁breath ing ▁; ▁cardiac ▁arrest ▁; ▁advantage ▁; ▁puls e less ▁vent ri cular ▁fi bril lation ▁; ▁ pv f ▁; ▁implant ed ▁; ▁cardio ver ter - de fi br illa tor ▁device
▁patient ▁; ▁new ▁yor k ▁heart ▁association ▁class ▁i ii ▁; ▁heart ▁failure ▁; ▁h f ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁periodic ▁breath ing ▁; ▁p b ▁; ▁report
▁ pv f ▁; ▁p b ▁; ▁bp
▁ pv f ▁; ▁p b
▁change ▁; ▁pa co 2 ▁; ▁cerebral ▁; ▁blood ▁flow ▁; ▁per fusion ▁; ▁caro tid
▁p b ▁; ▁patients ▁; ▁h f
▁antico a gul ants ▁; ▁anti plate let ▁drugs ▁; ▁heart ▁failure ▁; ▁at rial ▁fi bril lation
▁patients ▁; ▁at rial ▁fi bril lation ▁; ▁heart ▁failure ▁; ▁h f ▁; ▁stroke ▁; ▁antico ag ulation ▁; ▁patients
▁patients ▁; ▁sinus ▁ rhythm ▁; ▁anti plate let ▁agents ▁; ▁antico a gul ants
▁risk ▁strat ification ▁; ▁anti plate let ▁agents ▁; ▁combination ▁; ▁antico a gul ants ▁; ▁vas cular ▁disease s
▁heart ▁failure
▁chronic ▁heart ▁failure ▁; ▁ch f ▁; ▁multi system ▁disease ▁; ▁como rbi di ties ▁; ▁an emia ▁; ▁insulin ▁resist ance ▁; ▁autonomi c ▁dys balance ▁; ▁cardiac ▁cache xia
▁evidence ▁; ▁intestinal ▁; ▁patients ▁; ▁ch f
▁sono graphic ▁; ▁his t ological ▁; ▁gastro inte stin al
▁intestinal ▁dys function ▁; ▁intestinal ▁; ▁lead ▁; ▁chronic ▁; ▁infla mma tory ▁; ▁cata bo lic ▁; ▁anabol ic ▁; ▁cardiac ▁cache xia ▁; ▁terminal ▁; ▁ch f ▁; ▁prognos is
▁ch f ▁; ▁protein s
▁regula tion ▁; ▁anti - in flam ma tory ▁; ▁ch f
▁gut ▁; ▁ inflammation ▁; ▁heart ▁failure ▁; ▁patients ▁; ▁heart ▁failure
▁b - type ▁na tri ure tic ▁pe pti de ▁; ▁n - termin al ▁pro - b - type ▁na tri ure tic ▁pe pti de ▁; ▁diagnostic ▁; ▁stable ▁; ▁corona ry ▁arter y ▁disease ▁; ▁b - type ▁na tri ure tic ▁pe pti de ▁; ▁b np ▁; ▁ nt - prob np ▁; ▁vent ri cular ▁cardio my o cy tes ▁; ▁vent ri cular ▁; ▁wall ▁stress ▁; ▁my o card ial ▁ ische mia
▁b np ▁; ▁ nt - prob np ▁; ▁diagnostic ▁; ▁prognos tic ▁; ▁bio mark ers ▁; ▁patients ▁; ▁heart ▁failure
▁diagnostic ▁; ▁b np ▁; ▁ nt - prob np ▁; ▁patients ▁; ▁corona ry ▁arter y ▁disease ▁; ▁cad
▁patients ▁; ▁a cute ▁corona ry ▁syndrome s ▁; ▁patients ▁; ▁stable ▁; ▁cad ▁; ▁b np ▁; ▁ nt - prob np ▁; ▁cad ▁; ▁prognos tic ▁; ▁clinic al ▁; ▁outcome
▁clinic al ▁; ▁ therapeut ic
▁unilateral ▁renal ▁den er va tion ▁; ▁autonomi c ▁balance ▁; ▁chronic ▁heart ▁failure
▁chronic ▁heart ▁failure ▁; ▁ch f ▁; ▁sympa the tic ▁tone ▁; ▁autonomi c ▁im balance
▁renal ▁den er va tion ▁; ▁d n x ▁; ▁ch f ▁; ▁patients ▁; ▁symptom a tic
▁ch f ▁; ▁unilateral ▁renal ▁d n x ▁; ▁cardiac ▁; ▁autonomi c ▁balance
▁new ▁ze a land ▁; ▁renal ▁d n x ▁; ▁pa cing - indu ced ▁ch f
▁d n x ▁; ▁d n x
▁autonomi c ▁balance
▁baro re flex ▁ sensitiv ity ▁; ▁heart ▁rate ▁variabil ity ▁; ▁hr v ▁; ▁renal ▁d n x
▁power ▁spec tral ▁analysis ▁; ▁h f ▁; ▁d n x
▁sympa the tic ▁tone ▁; ▁para sy mpa the tic ▁tone ▁; ▁heart ▁rate ▁; ▁intra ven ous ▁bol us ▁; ▁met o pro lol ▁; ▁a tropi ne
▁bra dy car dia ▁; ▁intra ven ous ▁; ▁met o pro lol ▁; ▁cardiac ▁; ▁sympa the tic ▁tone
▁ta chy car dia ▁; ▁intra ven ous ▁; ▁a tropi ne ▁; ▁cardiac ▁; ▁va gal ▁tone
▁renal ▁d n x ▁; ▁plasma
▁renal ▁d n x ▁; ▁cardiac ▁; ▁autonomi c ▁balance ▁; ▁ch f ▁; ▁sympa the tic ▁tone
▁vent ri cular ▁assist ▁device ▁; ▁extra corp o real ▁membran e ▁oxygen ation ▁; ▁renal ▁function ▁; ▁heart ▁failure
▁mechanic al ▁cardiac ▁support ▁; ▁renal ▁function ▁; ▁end - s tage ▁heart ▁failure
▁vent ri cular ▁assist ▁device ▁; ▁vad ▁; ▁extra corp o real ▁membran e ▁oxygen ation ▁; ▁ec mo ▁; ▁renal ▁function
▁end - s tage ▁heart ▁failure ▁; ▁mechanic al ▁cardiac ▁support
▁patient ▁; ▁vad ▁; ▁patients ▁; ▁vent ri cular ▁assist ▁device ▁; ▁ec mo ▁; ▁patients ▁; ▁extra corp o real ▁membran e ▁oxygen ation ▁; ▁ec mo ▁; ▁vad ▁; ▁patients ▁; ▁ec mo ▁; ▁vad
▁base line ▁; ▁mechanic al ▁cardiac ▁support ▁; ▁renal ▁function
▁patients ▁; ▁vad ▁; ▁patients ▁; ▁ec mo ▁; ▁vad ▁; ▁patients ▁; ▁ec mo
▁patients ▁; ▁ec mo ▁; ▁patients ▁; ▁vad ▁; ▁ec mo ▁; ▁vad
▁eg fr ▁; ▁vad ▁; ▁ec mo ▁; ▁vad ▁; ▁renal ▁function
▁ec mo ▁; ▁eg fr ▁; ▁eg fr
▁eg fr ▁; ▁vad ▁; ▁ec mo ▁; ▁vad ▁; ▁ec mo
▁renal ▁dys function ▁; ▁mechanic al ▁cardiac ▁support
▁outcome ▁; ▁change ▁; ▁hospital ized ▁; ▁heart ▁failure
▁nur sing ▁; ▁mandat e ▁; ▁account able ▁; ▁outcome s ▁; ▁nur sing
▁nur sing ▁; ▁nur sing
▁outcome ▁; ▁ad mission ▁; ▁dis charge ▁; ▁hospital ized ▁; ▁heart ▁failure ▁; ▁h f ▁; ▁nur sing ▁outcome s ▁classifica tion ▁; ▁noc

▁in patient ▁; ▁patients ▁; ▁dis charge d ▁; ▁h f
▁noc ▁; ▁outcome s ▁; ▁outcome ▁; ▁ad mission ▁; ▁dis charge
▁nur sing ▁; ▁outcome s ▁; ▁hospital ized ▁; ▁h f
▁outcome ▁; ▁prospect ive ▁; ▁hospital ized ▁; ▁h f ▁; ▁nur sing ▁; ▁outcome s
▁beta 1- ad r energi c ▁receptor ▁; ▁sp hing os ine -1 - phos pha te ▁receptor ▁1 ▁; ▁s 1 pr 1 ▁; ▁down regul ation ▁; ▁cardiac ▁; ▁hyper trop hic ▁; ▁heart ▁failure ▁; ▁s 1 pr 1 ▁; ▁cardiac ▁; ▁gene ▁; ▁ therapy
▁sp hing os ine -1 - phos pha te ▁receptor ▁1 ▁; ▁s 1 pr 1 ▁; ▁β 1- ad r energi c ▁receptor ▁; ▁β 1 ar ▁; ▁g - prote in - co up led ▁receptor s ▁; ▁heart
▁receptor s ▁; ▁a den yl yl ▁cy cla se ▁; ▁g - prote in ▁coup ling
▁receptor s ▁; ▁g - prote in - co up led ▁receptor ▁; ▁kina se -2 ▁; ▁down regul ation
▁β 1 ars ▁; ▁s 1 pr 1 s ▁; ▁my o cy te ▁; ▁camp ▁; ▁report ▁; ▁receptor s ▁; ▁g - prote in - co up led ▁receptor ▁; ▁kina se -2
▁hek ▁; ▁human ▁em bry o nic ▁ki dne y ▁; ▁cell s ▁; ▁β 1 ar ▁; ▁s 1 pr 1 ▁; ▁β 1 ar ▁; ▁down regul ation ▁; ▁sp hing os ine -1 - phos pha te ▁; ▁s 1 pr 1 ▁ago nist ▁; ▁s 1 pr 1 ▁; ▁down regul ation ▁; ▁iso prot eren ol ▁; ▁β - ad r energi c ▁receptor ▁ago nist
▁cross ▁talk ▁; ▁g - prote in - co up led ▁receptor s ▁; ▁physio logic al ▁; ▁significa nce ▁; ▁regula tion ▁; ▁heart s ▁; ▁chronic ▁; ▁β - ad r energi c ▁receptor ▁; ▁post ische mic ▁heart ▁failure
▁cardiac ▁plasma ▁membran e ▁; ▁s 1 pr 1 ▁; ▁β 1 ar ▁; ▁heart ▁failure
▁physician ▁; ▁death ▁; ▁read mission ▁; ▁dis charge ▁; ▁patients ▁; ▁heart ▁failure
▁physician ▁; ▁follow - up ▁; ▁dis charge ▁; ▁death ▁; ▁read mission ▁; ▁patients ▁; ▁heart ▁failure
▁physician ▁; ▁outcome s ▁; ▁dis charge
▁administrative ▁; ▁al ber ta ▁; ▁dis charge d ▁; ▁hospital ▁; ▁ diagnos is ▁; ▁heart ▁failure
▁co x ▁proportion al ▁hazard ▁models ▁; ▁co varia tes ▁; ▁follow - up ▁; ▁physician ▁; ▁dis charge ▁; ▁primary ▁outcome ▁; ▁death ▁; ▁all - ca use ▁read mission
▁physician ▁; ▁patient ▁; ▁ad mission ▁; ▁ad mission
▁dis charge ▁; ▁patients ▁; ▁follow - up ▁; ▁physician ▁; ▁physician
▁death ▁; ▁read mission ▁; ▁patients ▁; ▁physician ▁; ▁hazard ▁ratio ▁; ▁confidence ▁interval ▁; ▁physician ▁; ▁follow - up ▁; ▁patients ▁; ▁follow - up
▁follow - up ▁; ▁death ▁; ▁read mission ▁; ▁patients ▁; ▁physician ▁; ▁physician s
▁physician ▁; ▁follow - up ▁; ▁dis charge ▁; ▁physician ▁; ▁outcome s ▁; ▁patients ▁; ▁heart ▁failure
▁physician ▁; ▁conditions ▁; ▁hospital ▁; ▁dis charge
▁heart ▁failure ▁; ▁protein ▁kina se ▁a ▁; ▁expression
▁β - ad r energi c ▁receptor ▁block ade ▁; ▁mortal ity ▁; ▁all - ca use ▁hospital ization s ▁; ▁patients ▁; ▁heart ▁failure ▁; ▁h f
▁β - block ade ▁; ▁halt ▁; ▁disease ▁; ▁protein ▁kina se ▁; ▁ pka ▁; ▁β - ad r energi c ▁receptor
▁my o card ial ▁tissu e ▁; ▁ pka
▁my os in ▁; ▁protein - c ▁; ▁ phos phor y lation ▁; ▁trop onin ▁i ▁; ▁ phos phor y lation ▁; ▁h f
▁ pka ▁; ▁change ▁; ▁ rii α ▁; ▁c α ▁; ▁expression ▁; ▁ rii α ▁; ▁ser 96 ▁; ▁c α ▁; ▁th r 19 7 ▁; ▁ phos phor y lation ▁; ▁h f
▁expression ▁; ▁type ▁i ▁regulator y ▁sub un it ▁; ▁ri ▁; ▁h f
▁iso electric ▁focus ing ▁; ▁ri α ▁; ▁ser 77 ▁; ▁ser 83 ▁; ▁in ▁vivo ▁; ▁ phos phor y lation
▁western ▁blot s ▁; ▁mono clo nal ▁anti bo dies ▁; ▁ser 83 ▁; ▁ phos phor y lation ▁; ▁h f
▁8- flu o - camp ▁; ▁ phos pho mi mic ▁; ▁ser 77 ▁; ▁ser 83 ▁; ▁ri α ▁; ▁protein s ▁; ▁ri α
▁my o car dium ▁; ▁expression ▁; ▁ pka ▁; ▁down stream ▁signal ing
▁repo lar ization ▁; ▁patients ▁; ▁heart ▁failure ▁; ▁vent ri cular ▁ta chy car dia
▁q t ▁variabil ity ▁; ▁q tv ▁; ▁repo lar ization ▁; ▁q tv ▁; ▁cardiac ▁death
▁autonomi c ▁ner vous ▁system ▁; ▁activity ▁; ▁q tv
▁heart ▁failure ▁; ▁h f ▁; ▁patients ▁; ▁spontane ous ▁vent ri cular ▁ta chy car dia ▁; ▁h f ▁; ▁patients ▁; ▁spontane ous ▁v t ▁; ▁heart s
▁q t ▁interval ▁; ▁ec gs ▁; ▁base line ▁; ▁at rial ▁pa cing ▁; ▁es mol ol ▁; ▁iso pren a line ▁; ▁a tropi ne ▁; ▁in fusion
▁q t ▁interval s ▁; ▁s d ▁of ▁all ▁q t ▁interval s ▁; ▁s d q t
▁s d q t ▁; ▁s d ▁of ▁ rr ▁interval s ▁; ▁s dr r ▁; ▁q tv ▁; ▁heart ▁rate ▁variabil ity
▁base line
▁s d q t ▁; ▁at rial ▁pa cing
▁base line ▁; ▁iso pren a line ▁; ▁in fusion ▁; ▁s d q t ▁; ▁h f ▁; ▁patients
▁s d q t ▁; ▁eleva ted ▁; ▁a cute ▁; ▁β - ad re no cept or ▁block ade ▁; ▁es mol ol
▁patients ▁; ▁h f ▁; ▁spontane ous ▁v t ▁; ▁q t ▁interval s
▁heart ▁rate
▁a cute ▁; ▁autonomi c ▁ner vous ▁system ▁; ▁q tv ▁; ▁h f ▁; ▁patients
▁genetic ▁; ▁con ges tive ▁heart ▁failure ▁; ▁ha e mato po ie tic ▁cell ▁transplant ation
▁ha e mato po ie tic ▁cell ▁transplant ation ▁; ▁h ct ▁; ▁con ges tive ▁heart ▁failure ▁; ▁ch f ▁; ▁an thra cycli nes
▁ch f ▁; ▁h ct ▁; ▁poly morph ism s ▁; ▁gene s ▁; ▁an thra cycli ne ▁; ▁metabolism ▁; ▁ir on ▁home osta sis ▁; ▁anti - oxid ant ▁de fen ce ▁; ▁my o card ial ▁remodel ling

▁ch f ▁; ▁patients ▁; ▁h ct ▁; ▁city ▁of ▁hope
▁frame ▁; ▁ch f ▁; ▁an thra cycli ne ▁; ▁stem ▁cell ▁; ▁allo gene ic ▁; ▁auto logo us ▁; ▁follow - up
▁d na ▁; ▁geno type d
▁multi varia te ▁analysis ▁; ▁ch f ▁; ▁odds ▁ratio ▁; ▁che st ▁; ▁hyper tension ▁; ▁gene s ▁; ▁rac 2 ▁; ▁do xor ubi cin ▁ eff lux ▁transporter ▁; ▁ab cc 2
▁clinic al ▁; ▁genetic ▁; ▁ch f ▁; ▁area ▁under ▁the ▁cur ve ▁; ▁au c ▁; ▁genetic ▁; ▁au c ▁; ▁clinic al ▁; ▁au c
▁cache xia ▁; ▁right ▁vent ric le ▁; ▁heart ▁failure
▁international ▁right ▁heart ▁foundation ▁working ▁group ▁; ▁step ▁; ▁syndrome ▁; ▁right ▁heart ▁failure
▁right ▁heart ▁circulation ▁; ▁right ▁heart ▁failure
▁right ▁heart ▁circula tory ▁failure ▁; ▁disease ▁; ▁right ▁heart
▁ang io ten sin ▁receptor ▁nepri ly sin ▁inhibi tor ▁; ▁heart ▁failure
▁nepri ly sin ▁inhibi tors ▁; ▁na tri ure tic ▁pe pti de ▁; ▁at rial ▁na tri ure tic ▁pe pti de ▁; ▁b - type ▁na tri ure tic ▁pe pti de
▁l cz 696 ▁; ▁ang io ten sin ▁receptor ▁nepri ly sin ▁inhibi tor ▁; ▁nepri ly sin ▁inhibi tor ▁; ▁pro drug ▁; ▁ang io ten sin ▁receptor ▁anta gon ist ▁; ▁val sar tan ▁; ▁hyper tension ▁; ▁heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction ▁; ▁outcome s ▁; ▁heart ▁failure ▁with ▁reduce d ▁e je ction ▁ fraction
▁pres er ved ▁e je ction ▁ fraction ▁; ▁outcome s
▁ pharma c ological ▁; ▁a cute ▁heart ▁failure
▁a cute ▁heart ▁failure ▁; ▁ah f ▁; ▁symptoms ▁; ▁heart ▁failure ▁; ▁h f
▁ diagnos is ▁; ▁ therapy
▁patient ▁; ▁clinic al ▁; ▁symptoms
▁clinic al
▁ pharma c ologic ▁; ▁clinic al ▁; ▁ pharma c ologic
▁ therapeut ic ▁; ▁bio mark ers ▁; ▁chronic ▁heart ▁failure
▁chronic ▁heart ▁failure ▁; ▁h f ▁; ▁hem o dynamic ▁; ▁syndrome ▁; ▁dys function ▁; ▁molecular ▁path ways
▁clinic al
▁evidence ▁; ▁bio mark ers ▁; ▁pat ho phy si ology ▁; ▁chronic ▁h f ▁; ▁ therapeut ic
▁bio mark ers ▁; ▁h f
▁clinic al
▁ therapeut ic ▁; ▁bio mark ers ▁; ▁molecular ▁dys function ▁; ▁chronic ▁h f
▁bio mark er ▁; ▁clinic al ▁; ▁ therapeut ic
▁micro rna s ▁; ▁heart ▁failure ▁; ▁disease
▁heart ▁failure ▁; ▁leading ▁; ▁mortal ity ▁; ▁western ▁; ▁society ▁; ▁cardiovascular ▁disease s
▁evidence ▁; ▁micro rna s ▁; ▁mir nas ▁; ▁path ogen es is ▁; ▁heart ▁failure
▁mir nas ▁; ▁ rna s ▁; ▁expression ▁; ▁gene s ▁; ▁messenger ▁ rna ▁; ▁re pression
▁mir nas ▁; ▁cardiac ▁remodel ing ▁; ▁heart ▁failure
▁mir nas ▁; ▁cardiac ▁; ▁path ogen es is
▁mir nas ▁; ▁ therapeut ic ▁; ▁heart ▁failure
▁re nin - angi oten sin - al do ster one ▁system ▁inhibi tors ▁; ▁heart ▁failure
▁heart ▁failure ▁; ▁h f ▁; ▁condition ▁; ▁morbi d ity ▁; ▁mortal ity
▁evidence ▁; ▁h f ▁with ▁reduce d ▁e je ction ▁ fraction ▁; ▁h fre f ▁; ▁h f ▁with ▁pres er ved ▁e je ction ▁ fraction ▁; ▁h f pe f
▁re nin - angi oten sin - al do ster one ▁system ▁; ▁ra as ▁; ▁h fre f ▁; ▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tors ▁; ▁ang io ten sin ▁receptor ▁block ers ▁; ▁al do ster one ▁block ade ▁; ▁evidence ▁; ▁h f pe f
▁evidence ▁; ▁drugs ▁; ▁drugs ▁; ▁ra as ▁; ▁re nin ▁inhibi tors ▁; ▁en dop ep tida se ▁inhibi tors ▁; ▁vaso pe pti das e ▁inhibi tors ▁; ▁ang io ten sin ▁receptor ▁block ers
▁skelet al ▁muscle ▁; ▁exercise ▁capacity ▁; ▁font an ▁circulation
▁per i pher al ▁muscle ▁pump ▁; ▁cardiac ▁fill ing ▁; ▁exercise ▁; ▁sub pul mon ary ▁vent ric le ▁; ▁font an ▁circulation
▁syndrome ▁; ▁heart ▁failure ▁; ▁font an
▁font an ▁circulation ▁; ▁skelet al ▁muscle ▁; ▁metabol ic
▁patients ▁; ▁new ▁yor k ▁heart ▁association ▁class ▁i ▁; ▁font an ▁; ▁cardio pul mon ary ▁exercise ▁testing ▁; ▁lean ▁mass ▁quant ification ▁; ▁dual ▁x - ray ▁ab sor pti ometr y ▁; ▁d xa ▁; ▁cal f ▁; ▁muscle ▁; ▁magnetic ▁res on ance ▁spec tros copy ▁; ▁healthy
▁d xa

▁pe ak ▁vo 2
▁skelet al ▁muscle ▁; ▁lean ▁mass ▁; ▁z - s core
▁skelet al ▁muscle ▁; ▁cor related ▁; ▁vo 2 ▁max
▁skelet al ▁muscle ▁; ▁t - s core ▁; ▁font an ▁; ▁sar co pen ic ▁range ▁muscle ▁was ting ▁; ▁t - s core ▁; ▁clinic ally ▁; ▁t - s core
▁muscle ▁aero bic ▁capacity ▁; ▁poste xer ci se ▁ phos pho creati ne ▁re syn the sis ▁; ▁font an
▁psycho metric ▁; ▁self - care ▁of ▁heart ▁failure ▁index ▁version ▁6.2
▁self - care ▁of ▁heart ▁failure ▁index ▁version ▁6.2 ▁; ▁sch fi ▁v . 6.2 ▁; ▁psycho metric
▁heart ▁failure ▁; ▁patients ▁; ▁ital y ▁; ▁confirma tory ▁factor ▁analysis ▁; ▁c fa ▁; ▁sch fi ▁v . 6.2 ▁; ▁self - care ▁maintenance ▁; ▁self - care ▁management ▁; ▁self - care ▁confidence
▁explora tory ▁factor ▁analysis ▁; ▁c fa
▁c fi ▁; ▁r m se a ▁; ▁self - care ▁maintenance ▁; ▁c fi ▁; ▁r m se a ▁; ▁self - care ▁management ▁; ▁c fi ▁; ▁r m se a ▁; ▁self - care ▁confidence

▁evidence ▁; ▁sch fi ▁v . 6.2 ▁; ▁clinic al
▁n - termin al ▁pro - b - type ▁na tri ure tic ▁pe pti des ▁; ▁plasma ▁; ▁heart ▁failure ▁; ▁patients
▁n - termin al ▁pro - b - type ▁na tri ure tic ▁pe pti de ▁; ▁ nt - prob np ▁; ▁mis diagnos is ▁; ▁heart ▁failure ▁; ▁h f
▁ nt - prob np
▁ nt - prob np ▁; ▁circulation ▁; ▁h f ▁; ▁patients
▁plasma ▁; ▁collect ed ▁; ▁h f ▁; ▁patients
▁ nt - prob np ▁; ▁h f ▁; ▁patient ▁; ▁plasma ▁; ▁immun o preci pit ation ▁; ▁mass ▁spec tro metric ▁analysis
▁al pha lisa ▁; ▁immun o assa ys ▁; ▁ nt - prob np
▁mass ▁spec tro met ry ▁; ▁c - termin ally ▁; ▁ nt - prob np ▁; ▁physio logic al ▁; ▁prote ol ysis
▁al pha lisa ▁; ▁immun o assa ys ▁; ▁anti bo dies ▁; ▁c ▁termini ▁; ▁ nt - prob np
▁ nt - prob np ▁; ▁anti bo dies ▁; ▁non termin al ▁e pito pes
▁plasma ▁; ▁collect ed ▁; ▁h f ▁; ▁patients ▁; ▁immun ore active ▁; ▁ nt - prob np ▁; ▁c - termin ally ▁; ▁ nt - prob np
▁immun o det ection ▁; ▁ nt - prob np ▁; ▁anti bo dies ▁; ▁terminal
▁ nt - prob np ▁; ▁non termin al ▁e pito pes ▁; ▁central ▁gly cos yla ted ▁region
▁prevale nce ▁; ▁clinic al ▁; ▁outcome s ▁; ▁concentr ic ▁left ▁vent ri cular ▁hyper trop hy ▁; ▁heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction
▁concentr ic ▁remodel ing ▁; ▁concentr ic ▁hyper trop hy ▁; ▁left ▁vent ri cular ▁; ▁remodel ing ▁; ▁heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction ▁; ▁h f pe f ▁; ▁ecce n tric ▁hyper trop hy ▁; ▁patients
▁clinic al ▁; ▁outcome s ▁; ▁h f pe f
▁prospect ive ly ▁; ▁patients ▁; ▁h f pe f ▁; ▁ lv ▁hyper trop hy ▁; ▁ lv h ▁; ▁relative ▁wall ▁thi ck ness ▁; ▁r w t ▁; ▁ lv h ▁; ▁r w t ▁; ▁ lv h ▁; ▁r w t ▁; ▁ lv h ▁; ▁r w t
▁clinic al ▁; ▁e cho car dio graphic ▁; ▁invasi ve ▁; ▁hem o dynamic ▁; ▁outcome
▁patients
▁patients ▁; ▁sy sto lic ▁blood ▁pressure ▁; ▁renal ▁im pair ment ▁; ▁hyper tension
▁co varia tes ▁; ▁ lv ▁contract ility ▁; ▁l ve f ▁; ▁β ▁co e ffi cient ▁; ▁confidence ▁interval ▁; ▁sy sto lic ▁blood ▁pressure ▁; ▁end - sy sto lic ▁volume ▁; ▁β ▁co e ffi cient
▁ lv ▁compliance ▁; ▁ lv ▁end - dia sto lic ▁volume ▁; ▁ lv ▁end - dia sto lic ▁pressure ▁; ▁β ▁co e ffi cient
▁eleva ted ▁; ▁cardiac ▁fill ing ▁pressure s ▁; ▁advers e ▁outcome s
▁h f pe f ▁; ▁pat ho phy si ological ly ▁; ▁h f ▁with ▁reduce d ▁ef ▁; ▁h fre f ▁; ▁h fre f ▁; ▁ therapy
▁heart ▁failure ▁; ▁patients ▁; ▁bis phos phon ates
▁heart ▁failure ▁; ▁patients ▁; ▁bis phos phon ates
▁retro spec tive ▁co hor t ▁study ▁; ▁den mark ▁; ▁bis phos phon ates ▁; ▁ra lo xi fen e
▁heart ▁failure ▁; ▁co x ▁proportion al ▁hazard ▁analyse s
▁follow - up ▁; ▁patients
▁heart ▁failure
▁relative ▁risk ▁; ▁ rr ▁; ▁heart ▁failure ▁; ▁bis pho phon ates ▁; ▁ rr ▁; ▁confidence ▁interval ▁; ▁hazard ▁ratio
▁ra lo xi fen e ▁; ▁heart ▁failure
▁bis phos phon ates ▁; ▁ale ndr onate ▁; ▁et id rona te ▁; ▁heart ▁failure ▁; ▁compliance
▁heart ▁failure ▁; ▁compliance ▁; ▁et id rona te ▁; ▁ale ndr onate
▁bis phos phon ate ▁; ▁heart ▁failure
▁ale ndr onate ▁; ▁ale ndr onate ▁; ▁heart ▁failure
▁cardiac ▁dys function ▁; ▁sub cel lular ▁; ▁met o pro lol ▁; ▁heart ▁failure ▁; ▁my o card ial ▁in far ction
▁heart ▁failure ▁; ▁my o card ial ▁in far ction ▁; ▁mi ▁; ▁β - ad re no cept or ▁block ade ▁; ▁in far cted ▁; ▁met o pro lol
▁left ▁vent ri cular ▁; ▁sy sto lic ▁pressure ▁; ▁e je ction ▁ fraction ▁; ▁ fraction al ▁short en ing ▁; ▁cardiac ▁output ▁; ▁ lv ▁end - dia sto lic ▁pressure ▁; ▁mi ▁; ▁met o pro lol
▁sept um ▁; ▁sy sto lic ▁; ▁ lv ▁posterior ▁wall ▁; ▁ lv ▁internal ▁diameter ▁; ▁met o pro lol
▁mi ▁; ▁met o pro lol ▁; ▁eleva ted ▁; ▁plasma ▁no re pine ph rine ▁; ▁dop amine ▁; ▁eleva ted ▁; ▁e pine ph rine
▁sar co plas mic ▁reti cular ▁; ▁protein ▁; ▁ phos pho lam ban ▁; ▁in far cted ▁; ▁heart s ▁; ▁met o pro lol
▁my o fi bril lar ▁; ▁at pas e ▁; ▁activity ▁; ▁m rna ▁; ▁ phos pho lam ban ▁; ▁α - my os in ▁heavy ▁chain ▁; ▁m rna ▁; ▁β - my os in ▁heavy ▁chain ▁; ▁met o pro lol
▁cardiac ▁; ▁β - ad re no cept or ▁block ade ▁; ▁heart ▁failure ▁; ▁rever se ▁; ▁cardiac ▁remodel ing ▁; ▁eleva ted ▁; ▁plasma ▁cate chol amine s
▁psoriasis ▁; ▁at hero sc ler osis ▁; ▁cardiovascular ▁events ▁; ▁ro tter dam ▁study
▁psoriasis ▁; ▁cardiovascular ▁disease ▁; ▁cv d
▁ro tter dam ▁study ▁; ▁psoriasis ▁; ▁cardiovascular ▁; ▁outcome s
▁sub clin ical ▁; ▁at hero sc ler osis ▁; ▁linear ▁models
▁co x ▁re gression ▁; ▁cardiovascular ▁events ▁; ▁psoriasis
▁psoriasis ▁; ▁system ic ▁; ▁followed ▁up
▁psoriasis ▁; ▁patients ▁; ▁dia sto lic ▁blood ▁pressure ▁; ▁body ▁mass ▁index
▁caro tid ▁intim a - media ▁thi ck ness ▁; ▁psoriasis
▁an kle - bra chi al ▁index ▁; ▁puls e - wa ve ▁; ▁corona ry ▁arter y ▁calci um ▁score s
▁cv d ▁; ▁psoriasis ▁; ▁hazard ▁ratio ▁; ▁confidence ▁interval
▁corona ry ▁heart ▁disease ▁; ▁stroke ▁; ▁heart ▁failure
▁psoriasis ▁; ▁patients ▁; ▁disease ▁; ▁at hero sc ler osis ▁; ▁cardiovascular ▁events ▁; ▁psoriasis
▁dia sto lic ▁dys function ▁; ▁patients ▁; ▁per i pher al ▁arter y ▁disease
▁per i pher al ▁arter y ▁disease ▁; ▁pad ▁; ▁heart ▁failure ▁; ▁h f ▁; ▁prevale nce ▁; ▁h f ▁; ▁patients ▁; ▁pad
▁patients ▁; ▁pad ▁; ▁an kle - bra chi al ▁index
▁patients ▁; ▁brain ▁na tri ure tic ▁pe pti de ▁; ▁b np ▁; ▁b np ▁; ▁patients ▁; ▁b np ▁; ▁b np
▁uni varia te ▁analysis ▁; ▁b np ▁; ▁estima ted ▁glo mer ular ▁filtr ation ▁rate ▁; ▁hyper tension ▁; ▁transmit ral ▁; ▁e - wa ve ▁; ▁dia sto lic ▁mit ral ▁ann ular ▁veloci ty
▁multi varia te ▁logistic ▁re gression ▁analysis ▁; ▁b np ▁; ▁patients ▁; ▁dia sto lic ▁dys function
▁prevale nce ▁; ▁b np ▁; ▁patients ▁; ▁pad ▁; ▁b np ▁; ▁h f
▁hospital - to - home ▁; ▁hospital ▁; ▁read mission ▁; ▁con ges tive ▁heart ▁failure
▁read mission ▁; ▁hospital ▁; ▁con ges tive ▁heart ▁failure ▁; ▁unit ed ▁states
▁patients ▁; ▁condition ▁; ▁economic
▁prospect ive
▁hospital ▁; ▁cardiac ▁; ▁hospital ▁; ▁south ▁da kota
▁patients ▁; ▁ diagnos is ▁; ▁con ges tive ▁heart ▁failure
▁transition s ▁; ▁training ▁; ▁patients ▁; ▁out - patient ▁; ▁follow - up ▁; ▁patient ▁; ▁health ▁care
▁outcome ▁; ▁all - ca use ▁read missions
▁read mission ▁; ▁patients
▁economic ▁; ▁account ing ▁; ▁cost
▁transition s ▁; ▁read mission ▁; ▁patients ▁; ▁con ges tive ▁heart ▁failure ▁; ▁south ▁da kota
▁heart ▁rate ▁variabil ity ▁; ▁risk ▁strat ification ▁; ▁cardiac ▁; ▁patients
▁heart ▁rate ▁; ▁cardiac ▁; ▁patients ▁; ▁patients ▁; ▁a cute ▁my o card ial ▁in far ction ▁; ▁ami ▁; ▁patients ▁; ▁con ges tive ▁heart ▁failure ▁; ▁ch f ▁; ▁left ▁vent ri cular ▁; ▁dys function
▁patients ▁; ▁hr ▁variabil ity ▁; ▁mortal ity ▁; ▁ami ▁; ▁ diagnos is ▁; ▁ch f ▁; ▁ lv ▁dys function
▁hr ▁variabil ity ▁; ▁risk ▁strat ification
▁prognos tic ▁; ▁r - r ▁interval ▁; ▁hr ▁variabil ity ▁; ▁short - term ▁fra c tal ▁scal ing ▁ex ponent ▁; ▁prognos tic
▁hr ▁variabil ity ▁; ▁cardiac ▁death
▁remodel ing ▁; ▁ar rhythm ia ▁; ▁ami ▁; ▁hr ▁variabil ity ▁; ▁ar rhythm ia
▁random ized ▁; ▁hr ▁variabil ity ▁; ▁hr ▁variabil ity ▁; ▁clinic al ▁; ▁risk ▁strat ification ▁; ▁cardiac ▁; ▁patients
▁renal ▁arter y ▁sten osis
▁renal ▁arter y ▁sten osis ▁; ▁ras ▁; ▁per i pher al ▁arterial ▁disease
▁ras ▁; ▁at hero sc ler osis

▁pat ho phy si ologic ▁; ▁renal ▁under per fusion ▁; ▁re nin - ▁ang io ten sin - al do ster one ▁path way
▁patients ▁; ▁ras ▁; ▁as ym pto matic ▁; ▁clinic ally ▁; ▁hyper tension ▁; ▁nep hro pathy ▁; ▁con ges tive ▁heart ▁failure
▁disease ▁; ▁lead ▁; ▁hyper tension ▁; ▁ki dne y ▁failure
▁patients ▁; ▁ras ▁; ▁dop pler ▁ultra son ography ▁; ▁to mo graphic ▁ang i ography ▁; ▁magnetic ▁res on ance ▁ang i ography
▁blood ▁pressure ▁; ▁ therapy ▁; ▁patients ▁; ▁ras
▁per cuta ne ous ▁; ▁re vas cular ization ▁; ▁ang io plast y ▁; ▁sten ting ▁; ▁clinic al ▁; ▁patients ▁; ▁random ized ▁; ▁clinic al
▁cardiovascular ▁outcome s ▁in ▁renal ▁a ther os cle ro tic ▁les ions ▁; ▁coral ▁; ▁sten ting ▁; ▁ras
▁sur g ical ▁; ▁re vas cular ization ▁; ▁re vas cular ization
▁american ▁college ▁of ▁card i ology ▁; ▁american ▁heart ▁association ▁; ▁patients ▁; ▁ras ▁; ▁patients ▁; ▁ras
▁micro arra y ▁; ▁gene s ▁; ▁heart ▁failure
▁heart ▁failure ▁; ▁public ▁; ▁health

▁differenti ally ▁express ed ▁gene s ▁; ▁deg s ▁; ▁ ische mic ▁heart ▁failure ▁; ▁healthy ▁; ▁ diagnos is ▁; ▁heart ▁failure
▁gene ▁expression ▁profile ▁; ▁g se 91 28 ▁; ▁gene ▁expression ▁omnibus ▁; ▁non - ische mic ▁heart ▁failure ▁; ▁ ische mic
▁differenti al ▁analysis ▁; ▁cluster ▁analysis
▁deg s ▁; ▁o spre y
▁cy to scape ▁; ▁functional ▁en rich ment ▁analysis ▁; ▁da vid
▁deg s ▁; ▁ ische mic ▁heart ▁failure
▁functional ▁en rich ment ▁analysis ▁; ▁regula tion ▁; ▁cell ▁death ▁; ▁deg s
▁gene s ▁; ▁ ische mic ▁heart ▁failure ▁; ▁bio mark ers ▁; ▁heart ▁failure
▁gene s
▁tele health ▁; ▁longitud in al ▁; ▁medica re
▁mortal ity ▁; ▁health care ▁; ▁tele health ▁; ▁con ges tive ▁heart ▁failure ▁; ▁chronic ▁ob struct ive ▁pulmonar y ▁disease ▁; ▁diabetes ▁mell itus
▁retro spec tive ▁match ed ▁co hor t ▁study
▁unit ed ▁states
▁medica re ▁; ▁center s ▁for ▁medica re ▁and ▁medica id ▁services ▁; ▁clinic s ▁; ▁pro pens ity - s core
▁health ▁bu ddy ▁program ▁; ▁tele health
▁mortal ity ▁; ▁in patient ▁; ▁ad missions ▁; ▁hospital ▁; ▁emergency ▁department
▁co x - propor tional ▁hazard ▁models ▁; ▁negative ▁bi nom ial ▁re gression ▁models ▁; ▁health
▁health ▁bu ddy ▁program ▁; ▁all - ca use ▁mortal ity ▁; ▁hazard ▁ratio ▁; ▁confidence ▁interval ▁; ▁in patient ▁; ▁ad missions ▁; ▁base line
▁health ▁bu ddy ▁program ▁; ▁hospital ▁; ▁hospital ized
▁health ▁bu ddy ▁program ▁; ▁ad missions ▁; ▁chronic ▁ob struct ive ▁pulmonar y ▁disease ▁; ▁mortal ity ▁; ▁con ges tive ▁heart ▁failure
▁tele health ▁; ▁health ▁; ▁outcome s ▁; ▁medica re
▁exercise ▁; ▁training ▁; ▁outcome s ▁; ▁chronic ▁heart ▁failure ▁; ▁heart ▁failure ▁- ▁a ▁control led ▁trial ▁investiga ting ▁outcome s ▁in ▁exercise ▁training ▁; ▁h f - action
▁outcome s ▁; ▁chronic ▁heart ▁failure ▁; ▁h f ▁; ▁exercise ▁; ▁training
▁outcome s ▁; ▁exercise ▁; ▁training ▁; ▁patients ▁; ▁ambula tory ▁; ▁h f
▁h f - action ▁; ▁random ized ▁; ▁patients ▁; ▁h f ▁; ▁e je ction ▁ fraction ▁; ▁exercise ▁; ▁training
▁outcome s ▁; ▁mortal ity ▁; ▁hospital ization ▁; ▁mortal ity ▁; ▁cardiovascular ▁mortal ity ▁; ▁h f ▁; ▁hospital ization ▁; ▁co x ▁models ▁; ▁exercise ▁; ▁training
▁patients
▁hyper tension ▁; ▁diabetes ▁; ▁ ische mic ▁; ▁et i ology
▁6- minut e ▁walk ▁distance ▁; ▁pe ak ▁vo 2 ▁; ▁base line
▁follow - up ▁; ▁outcome s ▁; ▁mortal ity
▁multi vari able ▁adjust ment ▁; ▁mortal ity ▁; ▁hospital ization ▁; ▁hazard ▁ratio ▁; ▁cardiovascular ▁mortal ity ▁; ▁h f ▁; ▁hospital ization
▁h f ▁; ▁hospital ization ▁; ▁cardiovascular ▁mortal ity
▁exercise ▁; ▁training ▁; ▁outcome s
▁patients ▁; ▁chronic ▁h f ▁; ▁prevale nce ▁; ▁exercise ▁; ▁h f ▁; ▁hospital ization ▁; ▁mortal ity ▁; ▁exercise ▁; ▁training
▁outcome s ▁; ▁patients ▁; ▁at rial ▁fi bril lation ▁; ▁early ▁treatment ▁of ▁at rial ▁fi bril lation ▁for ▁stroke ▁pre vention ▁trial
▁ therapy ▁; ▁antico ag ulation ▁; ▁rate ▁control ▁; ▁cardiovascular ▁; ▁complica tions ▁; ▁stroke ▁; ▁cardiovascular ▁death ▁; ▁a cute ▁heart ▁failure ▁; ▁patients ▁; ▁at rial ▁fi bril lation
▁sinus ▁ rhythm ▁; ▁advers e ▁outcome s
▁ rhythm ▁control ▁ therapy
▁ rhythm ▁control ▁ therapy ▁; ▁ diagnos is ▁; ▁at rial ▁; ▁sinus ▁ rhythm ▁; ▁ rhythm ▁control ▁; ▁symptoms ▁; ▁rate ▁control
▁cat heter ▁ab lation ▁; ▁anti ar rhythm ic ▁drugs ▁; ▁ rhythm ▁control ▁ therapy
▁e ast ▁; ▁ rhythm ▁control ▁ therapy ▁; ▁cardiovascular ▁; ▁complica tions
▁e ast ▁; ▁early ▁treatment ▁of ▁at rial ▁fi bril lation ▁for ▁stroke ▁pre vention ▁trial ▁; ▁random ize ▁; ▁patients ▁; ▁stroke ▁; ▁ rhythm ▁control ▁ therapy ▁; ▁prospect ive ▁; ▁random ized ▁; ▁outcome
▁patients ▁; ▁followed ▁up ▁; ▁com posit e ▁primary ▁outcome ▁; ▁cardiovascular ▁death ▁; ▁stroke ▁; ▁heart ▁failure ▁; ▁my o card ial ▁in far ction
▁hospital ▁; ▁co prima ry ▁outcome
▁antico ag ulation ▁; ▁ therapy ▁; ▁heart ▁disease ▁; ▁rate ▁control
▁ rhythm ▁control ▁ therapy ▁; ▁ rhythm ▁control ▁ therapy ▁; ▁anti ar rhythm ic ▁drugs ▁; ▁cat heter ▁ab lation ▁; ▁electro car dio graphic ▁; ▁ rhythm
▁seconda ry ▁outcome s ▁; ▁quality ▁of ▁life
▁e ast ▁; ▁ rhythm ▁control ▁ therapy ▁; ▁ diagnos is ▁; ▁cardiovascular ▁; ▁complica tions
▁gastro inte stin al ▁ble ed ing ▁; ▁patients ▁; ▁vent ri cular ▁assist ▁devices ▁; ▁cardiac ▁; ▁nurse
▁patients ▁; ▁end - s tage ▁heart ▁failure ▁; ▁implant ation ▁; ▁vent ri cular ▁assist ▁device
▁health ▁care ▁; ▁clinic ally ▁; ▁gastro inte stin al ▁ble ed ing
▁gastro inte stin al ▁ble ed ing ▁; ▁reported ▁; ▁patients ▁; ▁vent ri cular ▁assist ▁devices
▁patients ▁; ▁vent ri cular ▁assist ▁devices ▁; ▁cardiac ▁; ▁nurse s ▁; ▁gastro inte stin al ▁ble ed ing
▁diagnostic ▁; ▁complica tion
▁cardiac ▁; ▁nurse s
▁end ▁stage ▁heart ▁failure ▁; ▁heart ▁failure ▁; ▁public ▁; ▁health ▁; ▁patient ▁; ▁ europe ▁; ▁north ▁ america
▁incide nce ▁; ▁prevale nce ▁; ▁heart ▁failure ▁; ▁leading ▁; ▁death ▁; ▁hospital isation
▁life ▁expect an cy ▁; ▁heart ▁failure ▁; ▁patients ▁; ▁disease ▁; ▁terminal ▁heart ▁failure
▁patients ▁; ▁end ▁stage ▁heart ▁failure ▁; ▁ab cd ▁classifica tion ▁; ▁american ▁college ▁of ▁card i ology ▁; ▁acc ▁; ▁american ▁heart ▁association ▁; ▁a ha ▁; ▁new ▁yor k ▁heart ▁association ▁; ▁ny ha ▁; ▁heart ▁disease ▁; ▁symptoms ▁; ▁heart ▁failure ▁; ▁physical ▁; ▁medical ▁treatment
▁patient ▁; ▁mortal ity ▁; ▁ therapeut ic
▁heart ▁failure ▁; ▁patient ▁; ▁compliance ▁; ▁my o card ial ▁is cha emia ▁; ▁bra dy ar rhythm ias ▁; ▁val vu lar ▁re gur gi tation ▁; ▁pulmonar y ▁e mbol ism ▁; ▁infection ▁; ▁renal ▁dys function
▁end ▁stage ▁heart ▁failure
▁rad ▁variant ▁; ▁con ges tive ▁heart ▁failure
▁vent ri cular ▁action ▁potential s ▁; ▁excita tion - con traction ▁; ▁my o car dium
▁rad ▁; ▁ rg k ▁; ▁rem ▁; ▁rem 2 ▁; ▁rad ▁; ▁mono me ric ▁g ▁protein s ▁; ▁vent ri cular ▁action ▁potential ▁; ▁gain ▁; ▁cardiac ▁; ▁l - type ▁channel ▁; ▁activity
▁dys function ▁; ▁rad ▁variant ▁; ▁q 66 p ▁; ▁con ges tive ▁heart ▁failure
▁rad ▁; ▁q 66 p ▁; ▁rad ▁; ▁ca v 1.2 ▁; ▁ca v 1.3 ▁; ▁l - type ▁channel ▁; ▁iso form s ▁; ▁heart
▁rad ▁; ▁q 65 p ▁; ▁mur ine ▁; ▁rad ▁; ▁q 66 p ▁; ▁l - type ▁current s ▁; ▁ca v 1.2 ▁; ▁ca v 1.3 ▁; ▁wild - type ▁rad
▁rad ▁; ▁q 65 p ▁; ▁movement ▁; ▁wild - type ▁rad ▁; ▁q 65 p ▁; ▁l - type ▁channel ▁; ▁ rg k ▁protein s
▁rad ▁; ▁q 66 p ▁; ▁cardio my o pathy
▁rule ▁; ▁expression ▁; ▁regula tion ▁; ▁rad ▁; ▁q 66 p ▁; ▁ rg k ▁protein ▁; ▁in ▁vivo
▁witness ▁; ▁an emia
▁et h ically ▁; ▁legal ▁; ▁decisions
▁et hic s ▁round s
▁witness ▁; ▁sick le ▁cell ▁disease ▁; ▁an emia
▁heart ▁failure
▁doctor s ▁; ▁blood ▁trans fusion s

▁doctor s

▁in patient ▁; ▁medical ▁; ▁conditions
▁public ▁report ing ▁; ▁patients ▁; ▁hospital s
▁hospital s ▁; ▁outcome
▁outcome ▁; ▁heart ▁failure ▁; ▁h f ▁; ▁a cute ▁my o card ial ▁in far ction ▁; ▁ami ▁; ▁pneu monia ▁; ▁p na
▁hospital ▁; ▁mortal ity
▁medica re ▁; ▁patients ▁; ▁a cute ▁; ▁hospital ▁; ▁h f ▁; ▁ami ▁; ▁p na
▁hospital s
▁mortal ity ▁; ▁hospital s
▁mortal ity
▁hospital ▁compare ▁; ▁ami ▁; ▁mortal ity
▁ami ▁; ▁patient ▁; ▁hospital ▁; ▁hospital ▁compare ▁; ▁p - valu e
▁h f ▁; ▁p na
▁h f ▁; ▁ami ▁; ▁p na ▁; ▁mortal ity
▁spi rono lac tone ▁; ▁severe ▁heart ▁failure
▁incide nce ▁; ▁hyper kal emia ▁; ▁mineral o cor tico id ▁receptor ▁anta gon ists ▁; ▁mineral o cor tico id ▁receptor ▁anta gon ists ▁; ▁heart ▁failure ▁; ▁h f
▁hyper kal emia ▁; ▁outcome s ▁; ▁ african ▁american s ▁; ▁a as ▁; ▁new ▁yor k ▁heart ▁association ▁; ▁ny ha ▁; ▁h f ▁; ▁left ▁vent ri cular ▁dys function ▁; ▁random ized ▁; ▁spi rono lac tone ▁; ▁ti tra ted ▁; ▁place bo ▁; ▁random ized ▁alda cto ne ▁evaluation ▁study ▁; ▁ra les
▁a a ▁; ▁ ische mic ▁h f ▁; ▁path ogen es is ▁; ▁ny ha ▁functional ▁class ▁i v ▁; ▁estima ted ▁glo mer ular ▁filtr ation ▁rate ▁; ▁heart ▁rate ▁; ▁hyper tension ▁; ▁diabetes ▁mell itus ▁; ▁my o card ial ▁in far ction
▁po tas s ium ▁; ▁spi rono lac tone ▁; ▁a as
▁a as ▁; ▁spi rono lac tone ▁; ▁hyper kal emia ▁; ▁po tas s ium ▁; ▁hypo kal emia ▁; ▁po tas s ium
▁base line ▁; ▁drug ▁; ▁spi rono lac tone ▁; ▁combine d ▁end ▁point ▁; ▁death ▁; ▁hospital ization ▁; ▁h f ▁; ▁hazard ▁ratio ▁; ▁confidence ▁interval ▁; ▁a as ▁; ▁hazard ▁ratio ▁; ▁confidence ▁interval ▁; ▁p ▁value
▁a as ▁; ▁h f ▁; ▁hyper kal emia ▁; ▁hypo kal emia ▁; ▁spi rono lac tone ▁; ▁clinic al
▁mineral o cor tico id ▁receptor ▁anta gon ists
▁re hospital ization ▁; ▁medica re ▁; ▁dis charge d ▁; ▁nur sing
▁re hospital ization
▁retro spec tive ▁co hor t ▁study
▁hospital s
▁medica re ▁; ▁hospital ization s
▁re hospital ization ▁; ▁medica re ▁; ▁hospital ▁; ▁medica re ▁; ▁policy
▁medica re ▁; ▁policy
▁re hospital ization ▁; ▁confidence ▁interval ▁; ▁a cute ▁my o card ial ▁in far ction ▁; ▁ami ▁; ▁complica tions ▁; ▁ki dne y ▁infection ▁; ▁urin ary ▁tract ▁infection ▁; ▁ut i ▁; ▁complica tions
▁hospital ized ▁; ▁ami ▁; ▁complica tions ▁; ▁heart ▁failure ▁; ▁ki dne y ▁infection ▁; ▁ut i ▁; ▁complica tions ▁; ▁re hospital ization
▁hospital ▁; ▁re hospital ization
▁physician ▁; ▁outcome s ▁; ▁patients ▁; ▁heart ▁failure
▁outcome s ▁; ▁costs ▁; ▁patients ▁; ▁heart ▁failure ▁; ▁h f
▁physician ▁; ▁outcome s ▁; ▁patients ▁; ▁outcome s ▁; ▁med ically ▁; ▁disease s ▁; ▁h f
▁medica re ▁; ▁in patient ▁; ▁h f ▁; ▁ad missions ▁; ▁a cute ▁; ▁hospital s ▁; ▁unit ed ▁states
▁physician s ▁; ▁patients ▁; ▁h f
▁mortal ity ▁; ▁read missions ▁; ▁costs ▁; ▁patient ▁; ▁physician ▁; ▁hospital
▁physician ▁; ▁hospital ▁; ▁physician
▁patients ▁; ▁physician s ▁; ▁mortal ity ▁; ▁physician s ▁; ▁hospital s
▁patients ▁; ▁physician s ▁; ▁read mission ▁; ▁hospital
▁costs ▁; ▁physician s ▁; ▁hospital
▁physician ▁; ▁mortal ity ▁; ▁intern ists ▁; ▁cardio logist s
▁physician ▁; ▁mortal ity ▁; ▁h f ▁; ▁physician s
▁clinic ian ▁; ▁h f
▁al do ster one ▁anta gon ism ▁; ▁heart ▁failure ▁; ▁al do ster one ▁; ▁neuro hormon e ▁; ▁electro ly tes ▁; ▁heart ▁failure ▁; ▁patients ▁; ▁sy sto lic ▁dys function
▁clinic al ▁; ▁clinic al ▁; ▁outcome s ▁; ▁al do ster one ▁anta gon ist ▁; ▁heart ▁failure
▁random ized ▁alda cto ne ▁evaluation ▁study ▁; ▁symptom a tic ▁chronic ▁advanced ▁heart ▁failure ▁; ▁patients ▁; ▁al do ster one ▁anta gon ist ▁; ▁spi rono lac tone ▁; ▁mortal ity ▁; ▁place bo
▁patients ▁; ▁ therapy ▁; ▁beta ▁block ade
▁e pler en one ▁post ▁my o card ial ▁in far ction ▁heart ▁failure ▁ef fica cy ▁and ▁survival ▁study ▁; ▁e phe sus ▁; ▁post - my o card ial ▁in far ction ▁; ▁patients ▁; ▁heart ▁failure ▁; ▁mortal ity ▁; ▁hospital ization s ▁; ▁patients ▁; ▁random ized ▁; ▁al do ster one ▁anta gon ist ▁; ▁e pler en one
▁al do ster one ▁anta gon ist ▁; ▁ therapy ▁; ▁chronic ▁advanced ▁heart ▁failure ▁; ▁patients ▁; ▁post - my o card ial ▁in far ction ▁; ▁heart ▁failure ▁; ▁patients
▁patients ▁; ▁ idio pathi c ▁dil ated ▁cardio my o pathy ▁; ▁tu sca ny ▁; ▁evidence - based
▁ therapeut ic ▁; ▁patients ▁; ▁heart ▁failure
▁evidence ▁; ▁ idio pathi c ▁dil ated ▁cardio my o pathy
▁prognos is ▁; ▁ idio pathi c ▁dil ated ▁cardio my o pathy
▁patients ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁world ▁health ▁organization ▁; ▁ idio pathi c ▁dil ated ▁cardio my o pathy ▁; ▁corona ry ▁ang i ography ▁; ▁followed ▁up
▁patients ▁; ▁heart ▁failure
▁patients ▁; ▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tors ▁; ▁ang io ten sin ▁receptor s ▁block ers ▁; ▁β - block ers
▁patients ▁; ▁left ▁vent ri cular ▁di la tation ▁; ▁dys function
▁follow - up ▁; ▁patients ▁; ▁combine d ▁end ▁point ▁; ▁death ▁; ▁heart ▁failure ▁; ▁death ▁; ▁cardiac ▁transplant
▁outcome ▁; ▁hazard ▁ratio
▁confidence ▁interval ▁; ▁heart ▁; ▁mortal ity ▁; ▁death
▁evidence - based ▁; ▁prognos is ▁; ▁ idio pathi c ▁dil ated ▁cardio my o pathy
▁random ized ▁; ▁follow - up
▁prognos tic ▁; ▁ana ero bic ▁thre s hold ▁; ▁heart ▁failure
▁patients ▁; ▁heart ▁failure ▁; ▁h f ▁; ▁cardio pul mon ary ▁exercise ▁test ▁; ▁ana ero bic ▁thre s hold
▁prognos tic
▁prospect ive ly ▁; ▁followed ▁up ▁; ▁h f ▁; ▁patients ▁; ▁sy sto lic ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁h f ▁; ▁stable ▁; ▁clinic al ▁; ▁conditions ▁; ▁new ▁yor k ▁heart ▁association ▁class ▁i ▁; ▁clinic al ▁; ▁e cho car dio graphic ▁; ▁cardio pul mon ary ▁exercise ▁test
▁patients ▁; ▁exercise ▁; ▁ana ero bic ▁metabolism ▁; ▁pe ak ▁respirator y ▁ quot ient
▁end ▁point ▁; ▁cardiovascular ▁death ▁; ▁cardiac ▁transplant ▁; ▁seconda ry ▁end ▁point ▁; ▁death
▁follow - up
▁patients
▁multi vari able ▁logistic ▁analysis ▁; ▁pe ak ▁oxygen ▁up take ▁; ▁metabol ic ▁exercise ▁; ▁cardiac ▁; ▁ki dne y ▁; ▁prognos tic ▁; ▁h f ▁index
▁multi vari able ▁analysis ▁; ▁end ▁point ▁; ▁pe ak ▁oxygen ▁up take ▁; ▁hazard ▁ratio ▁; ▁confidence ▁interval ▁; ▁ventilator y ▁efficiency ▁s lope ▁; ▁hem o glob in ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁renal ▁function ▁; ▁renal ▁disease ▁; ▁so dium
▁prognos is ▁; ▁metabol ic ▁exercise ▁; ▁cardiac ▁; ▁ki dne y
▁end ▁point
▁patients ▁; ▁severe ▁h f ▁; ▁prognos tic ▁; ▁h f
▁cardio re spira tory ▁fitness ▁; ▁body ▁mass ▁index ▁; ▁heart ▁failure ▁; ▁mortal ity ▁; ▁co oper ▁center ▁longitud in al ▁study
▁joint ▁; ▁cardio re spira tory ▁fitness ▁; ▁cr f ▁; ▁body ▁mass ▁index ▁; ▁heart ▁failure ▁; ▁h f ▁; ▁mortal ity ▁; ▁cardiovascular ▁; ▁h f ▁; ▁mortal ity
▁cardiovascular ▁disease ▁; ▁base line
▁body ▁mass ▁index ▁; ▁cr f ▁; ▁exercise
▁cr f
▁hazard ▁ratio s ▁; ▁co x ▁re gression ▁analysis
▁follow - up ▁; ▁h f ▁; ▁death s
▁hazard ▁ratio s ▁; ▁cr f ▁; ▁obes e ▁; ▁body ▁mass ▁index
▁cr f ▁; ▁hazard ▁ratio s ▁; ▁body ▁mass ▁index ▁; ▁obes e
▁h f ▁; ▁h f ▁; ▁mortal ity
▁base line ▁; ▁cr f ▁; ▁h f ▁; ▁mortal ity ▁; ▁h f
▁physical ▁; ▁activity ▁; ▁cr f ▁; ▁h f ▁; ▁mortal ity
▁cardiac ▁; ▁insulin - re si stance ▁; ▁mito cho ndri al ▁energy ▁production ▁; ▁sy sto lic ▁heart ▁failure ▁; ▁pressure - over load ▁hyper trop hy
▁cardiac ▁hyper trop hy ▁; ▁energy ▁metabolism
▁energy ▁metabolism ▁; ▁heart ▁failure ▁; ▁hyper trop hi ed ▁; ▁heart
▁cardiac ▁hyper trop hy ▁; ▁pressure - over load ▁; ▁abdominal ▁a or tic ▁con stri ction ▁; ▁a ac
▁energy ▁substrat e ▁metabolism ▁; ▁heart s ▁; ▁a ac
▁a ac ▁; ▁cardiac ▁hyper trop hy
▁in ▁vivo ▁; ▁cardiac ▁function ▁; ▁e cho card i ography ▁; ▁dia sto lic ▁dys function ▁; ▁sy sto lic ▁dys function ▁; ▁e je ction ▁ fraction
▁cardiac ▁; ▁insulin - re si stance ▁; ▁gly col ysis ▁; ▁gluco se ▁oxid ation ▁; ▁plasma ▁membran e ▁trans location ▁; ▁gluco se
▁at p ▁; ▁mito cho ndri al ▁oxid ation ▁; ▁gluco se ▁; ▁lac tate ▁; ▁fa tty ▁acid s ▁; ▁my o card ial ▁; ▁gly col ysis
▁mito cho ndri al ▁complex ▁v ▁activity ▁; ▁ phos pho creati ne ▁; ▁at p
▁cardiac ▁; ▁insulin - re si stance ▁; ▁mito cho ndri al ▁oxid ative ▁metabolism ▁; ▁metabol ic ▁; ▁cardiac ▁hyper trop hy ▁; ▁hyper trop hy ▁; ▁heart ▁failure
▁heart ▁failure ▁; ▁latin ▁ america
▁heart ▁failure ▁; ▁h f ▁; ▁latin ▁ america ▁; ▁health ▁; ▁h f
▁h f ▁; ▁epidemi ology ▁; ▁health ▁; ▁h f
▁world ▁health ▁organization ▁; ▁h f
▁income ▁; ▁ex pendi ture ▁; ▁health
▁h f ▁; ▁blood ▁gluco se ▁; ▁obes ity ▁; ▁system ic ▁hyper tension ▁; ▁rhe u matic ▁fe ver ▁; ▁disease
▁et i ologie s ▁; ▁h f ▁; ▁ idio pathi c ▁dil ated ▁cardio my o pathy ▁; ▁ ische mic ▁; ▁val vu lar
▁prognos is ▁; ▁h f ▁; ▁et i ologie s
▁chronic ▁h f ▁; ▁death
▁de com pensa ted ▁h f ▁; ▁cardiovascular ▁; ▁hospital ization
▁prevale nce ▁; ▁sy sto lic ▁h f
▁h f ▁; ▁h f ▁; ▁epidemi ology ▁; ▁rhe u matic ▁fe ver
▁ex pendi ture ▁; ▁health ▁; ▁income ▁; ▁h f
▁cl c nka ▁; ▁poly morph ism ▁; ▁rs 109 27 887 ▁; ▁p . arg 83 gly ▁; ▁heart ▁failure ▁; ▁estima ted ▁glo mer ular ▁filtr ation ▁rate ▁; ▁rena stur
▁geno type d ▁; ▁s np ▁; ▁rs 109 27 887 ▁; ▁ka ▁renal ▁chlor ide ▁channel ▁gene ▁; ▁cl c nka
▁estima ted ▁glo mer ular ▁filtr ation ▁rate ▁; ▁eg fr ▁; ▁type ▁2 ▁diabetes ▁; ▁cholesterol ▁; ▁l dl - ch olesterol ▁; ▁cl c nka ▁; ▁geno type
▁reported ▁; ▁heart ▁failure ▁; ▁cl c nka ▁; ▁s np
▁air ▁; ▁heart ▁failure
▁air ▁; ▁cardiovascular ▁; ▁health ▁; ▁a cute ▁my o card ial ▁in far ction
▁the ▁lance t ▁; ▁ano op ▁shah ▁; ▁air ▁; ▁heart ▁failure ▁; ▁morbi d ity ▁; ▁mortal ity
▁physician s ▁; ▁public ▁; ▁health ▁; ▁air ▁; ▁cardiovascular ▁; ▁health ▁; ▁lead ▁; ▁hospital isation ▁; ▁death
▁cardiac ▁over expression ▁; ▁mamma lian ▁enabled ▁; ▁mena ▁; ▁heart ▁failure
▁mamma lian ▁enabled ▁; ▁mena ▁; ▁cy tos kelet al ▁act in ▁dynamic s ▁; ▁heart ▁failure ▁; ▁h f
▁cardiac ▁; ▁mena ▁dele tion ▁; ▁cardiac ▁dys function ▁; ▁hyper trop hy
▁eleva ted ▁; ▁mena ▁expression ▁; ▁corre late s ▁; ▁h f ▁; ▁mena ▁; ▁cardiac ▁; ▁pat ho phy si ology
▁cardiac ▁; ▁my o cy te - specific ▁mena ▁over expression ▁; ▁cardiac ▁; ▁path ology
▁heart s ▁; ▁heart ▁mass ▁; ▁trans ge nic
▁cardiac ▁injury ▁; ▁e je ction ▁ fraction ▁; ▁ fraction al ▁short en ing ▁; ▁heart ▁di la tation ▁; ▁hyper trop hy ▁; ▁trans verse ▁a or tic ▁con stri ction ▁; ▁tac
▁mena ▁over expression ▁; ▁tac ▁; ▁surgery ▁; ▁mena ▁; ▁cardiac ▁hyper trop hy ▁; ▁cardiac
▁heart s ▁; ▁mena ▁; ▁cardiac ▁injury ▁; ▁mena ▁; ▁h f ▁; ▁pat ho phy si ology
▁heart ▁failure ▁; ▁card i ology - car dio vas cular ▁surgery ▁consensu s ▁report ▁; ▁heart ▁failure ▁; ▁disease
▁patients ▁; ▁terminal ▁; ▁diagnostic ▁; ▁follow - up
▁palli ative ▁care ▁; ▁patients ▁; ▁terminal ▁; ▁disease ▁; ▁ therapeut ic
▁patients ▁; ▁heart ▁failure
▁patients ▁; ▁heart ▁failure ▁; ▁heart ▁; ▁cardio logist s ▁; ▁cardiovascular ▁; ▁surge ons ▁; ▁medical ▁; ▁patient
▁physician s ▁; ▁patients ▁; ▁heart ▁failure ▁; ▁equi table ▁; ▁ therapeut ic
▁patient ▁; ▁circulation
▁report ▁; ▁connection ▁; ▁patients ▁; ▁disease ▁; ▁health care ▁; ▁conditions ▁; ▁tur key
▁hospital ized ▁; ▁heart ▁failure ▁; ▁sax ag lip tin ▁; ▁si tag lip tin ▁; ▁anti hy per gly ce mic ▁drugs ▁; ▁retro spec tive ▁co hor t ▁study
▁hospital ized ▁; ▁heart ▁failure ▁; ▁di pe pti dy l ▁pep tida se -4 ▁; ▁d pp -4 ▁; ▁anti hy per gly ce mic ▁agents
▁sax ag lip tin ▁; ▁si tag lip tin
▁co hor t ▁study
▁health ▁; ▁health ▁; ▁u . s . ▁; ▁drug ▁; ▁administration
▁patients ▁; ▁patients ▁; ▁type ▁2 ▁diabetes ▁; ▁ therapy ▁; ▁sax ag lip tin ▁; ▁si tag lip tin ▁; ▁pi og lita zone ▁; ▁second - genera tion ▁sul fon yl ure as ▁; ▁insulin
▁hospital ized ▁; ▁h f ▁; ▁international ▁classifica tion ▁of ▁disease s ▁; ▁clinic al ▁; ▁principal ▁; ▁dis charge ▁; ▁ diagnos is
▁sax ag lip tin ▁; ▁si tag lip tin ▁; ▁follow - up
▁d pp -4 ▁inhibi tors ▁; ▁drugs
▁hazard ▁ratio s ▁; ▁disease ▁risk ▁score ▁; ▁dr s ▁; ▁sax ag lip tin ▁; ▁si tag lip tin ▁; ▁sax ag lip tin ▁; ▁pi og lita zone ▁; ▁sax ag lip tin ▁; ▁sul fon yl ure as ▁; ▁sax ag lip tin ▁; ▁insulin
▁hazard ▁ratio s ▁; ▁si tag lip tin ▁; ▁pi og lita zone ▁; ▁si tag lip tin ▁; ▁sul fon yl ure as ▁; ▁si tag lip tin ▁; ▁insulin

▁patients ▁; ▁cardiovascular ▁disease ▁; ▁dr s
▁follow - up
▁co hor t ▁study ▁; ▁sax ag lip tin ▁; ▁si tag lip tin ▁; ▁anti hy per gly ce mic ▁agents
▁physician ▁; ▁heart ▁failure ▁; ▁clinic al ▁practice ▁guide line ▁; ▁c p g ▁; ▁outcome s ▁; ▁heart ▁failure ▁; ▁h f
▁physician ▁; ▁evidence
▁american ▁; ▁h f
▁med line ▁; ▁em base ▁; ▁health star ▁; ▁ cina hl ▁; ▁co ch rane ▁libra ry ▁; ▁camp bell ▁collaboration ▁; ▁joan na ▁brig gs ▁institut e ▁evidence ▁based ▁practice ▁; ▁centre ▁for ▁reviews ▁and ▁disse mination ▁; ▁evidence ▁based ▁practice ▁centres
▁prospect ive ▁studies ▁; ▁c p g ▁; ▁h f

▁financial ▁; ▁co ch rane ▁effective ▁practice ▁and ▁organisation ▁of ▁care ▁tax ono my
▁c p gs
▁outcome s ▁; ▁patients ▁; ▁pre scribe d ▁; ▁ pharma c ological ▁; ▁dis charge ▁; ▁left ▁vent ri cular ▁function
▁clinic al ▁; ▁outcome s ▁; ▁hospital isation s ▁; ▁read missions ▁; ▁mortal ity

▁meta - analys is
▁physician ▁; ▁h f ▁; ▁c p gs


▁patient ▁; ▁implant able ▁cardio ver ter - de fi br illa tor
▁implant able ▁cardio ver ter - de fi br illa tor ▁; ▁physician s ▁; ▁heart ▁failure ▁; ▁patients
▁reported ▁; ▁patient ▁; ▁implant able ▁cardio ver ter - de fi br illa tor
▁patient ▁; ▁implant able ▁cardio ver ter - de fi br illa tor
▁collect ▁; ▁heart ▁failure ▁; ▁patients ▁; ▁implant able ▁cardio ver ter - de fi br illa tor
▁patients ▁; ▁implant able ▁cardio ver ter - de fi br illa tor ▁; ▁heart ▁function ▁clinic ▁; ▁university ▁health ▁network ▁; ▁tor onto ▁; ▁can ada

▁patients ▁; ▁implant able ▁cardio ver ter - de fi br illa tor ▁; ▁implant ation ▁; ▁engage ▁; ▁patients ▁; ▁decisions ▁; ▁implant able ▁cardio ver ter - de fi br illa tor
▁patients
▁patient ▁; ▁implant able ▁cardio ver ter - de fi br illa tor ▁; ▁implant ▁; ▁change ▁; ▁clinic al
▁patients ▁; ▁implant able ▁cardio ver ter - de fi br illa tor ▁; ▁patients ▁; ▁implant able ▁cardio ver ter - de fi br illa tor
▁baro re flex ▁activa tion ▁ therapy ▁for ▁the ▁treatment ▁of ▁heart ▁failure ▁with ▁a ▁reduce d ▁e je ction ▁ fraction ▁; ▁clinic al ▁; ▁caro tid ▁; ▁baro re flex ▁activa tion ▁ therapy ▁; ▁bat ▁; ▁heart ▁failure ▁; ▁h f
▁sympa the tic ▁; ▁para sy mpa the tic ▁activity ▁; ▁h f ▁; ▁symptoms ▁; ▁disease
▁bat ▁; ▁sympa the tic ▁out flow ▁; ▁para sy mpa the tic ▁activity
▁patients ▁; ▁new ▁yor k ▁heart ▁association ▁; ▁ny ha ▁; ▁functional ▁class ▁; ▁h f ▁; ▁e je ction ▁ fraction s ▁; ▁chronic ▁; ▁stable ▁; ▁guide line - direct ed ▁medical ▁ therapy ▁; ▁g d m t ▁; ▁unit ed ▁states ▁; ▁can ada ▁; ▁ europe
▁g d m t ▁; ▁g d m t ▁; ▁bat
▁end ▁point ▁; ▁neurologi cal ▁; ▁cardiovascular ▁events
▁end ▁points ▁; ▁ny ha ▁functional ▁class ▁; ▁quality - of - life ▁; ▁6- minut e ▁hall ▁walk
▁patients ▁; ▁random ized
▁neurologi cal ▁; ▁cardiovascular ▁; ▁ bound
▁patients ▁; ▁bat ▁; ▁patients ▁; ▁quality - of - life ▁; ▁ny ha ▁functional ▁class ▁; ▁change
▁bat ▁; ▁n - termin al ▁pro - bra in ▁na tri ure tic ▁pe pti de ▁; ▁hospital ized ▁; ▁h f
▁bat ▁; ▁functional ▁status ▁; ▁quality ▁of ▁life ▁; ▁exercise ▁capacity ▁; ▁n - termin al ▁pro - bra in ▁na tri ure tic ▁pe pti de ▁; ▁heart ▁failure ▁; ▁hospital ization s ▁; ▁patients ▁; ▁ny ha ▁functional ▁class ▁i ii ▁; ▁h f
▁report ▁; ▁cardio pul mon ary ▁exercise ▁testing ▁; ▁exercise ▁rehabilita tion ▁; ▁patients ▁; ▁chronic ▁heart ▁failure ▁; ▁exercise ▁rehabilita tion ▁; ▁patient ▁; ▁chronic ▁heart ▁failure ▁; ▁ch f ▁; ▁clinic al ▁; ▁cardio pul mon ary ▁exercise ▁testing ▁; ▁c pet ▁; ▁exercise ▁rehabilita tion ▁; ▁ china
▁symptom ▁; ▁c pet ▁; ▁patients ▁; ▁ch f ▁; ▁patients ▁; ▁exercise ▁; ▁exercise ▁; ▁patients ▁; ▁exercise ▁; ▁rehabilita tion
▁patients
▁exercise ▁; ▁rehabilita tion ▁; ▁walking ▁; ▁minne s ota ▁quality ▁of ▁life ▁; ▁exercise
▁no signif i cant ▁; ▁exercise
▁c pet ▁; ▁exercise ▁rehabilita tion ▁; ▁patients ▁; ▁ch f
▁heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction
▁heart ▁failure
▁patients ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction ▁; ▁h f pe f
▁sy sto lic ▁function ▁; ▁h f pe f ▁; ▁patients ▁; ▁long ▁a xis ▁function ▁; ▁exercise
▁patients ▁; ▁hyper tension
▁cardiovascular ▁; ▁diabetes ▁mell itus ▁; ▁at rial ▁fi bril lation ▁; ▁corona ry ▁arter y ▁disease ▁; ▁h f pe f
▁clinic al ▁; ▁symptoms ▁; ▁h f pe f ▁; ▁symptoms ▁; ▁breath less ness ▁; ▁fluid ▁re tention
▁diagnostic ▁; ▁h f pe f ▁; ▁medical ▁history ▁; ▁physical ▁examina tion
▁symptoms ▁; ▁patients ▁; ▁ny ha
▁physical ▁examina tion ▁; ▁patient ▁; ▁b mi ▁; ▁heart ▁rate ▁; ▁ rhythm ▁; ▁blood ▁pressure ▁; ▁aus cul tation ▁; ▁rule ▁; ▁val vu lar ▁disease ▁; ▁pulmonar y ▁con gestion
▁jugu lar ▁ve nous ▁pressure ▁; ▁per i pher al ▁oed ema ▁; ▁patient
▁patients ▁; ▁heart ▁failure ▁; ▁heart ▁failure ▁; ▁nurse s ▁; ▁follow - up ▁; ▁card i ology ▁; ▁mortal ity
▁exercise ▁; ▁cardiovascular ▁; ▁health
▁physical ▁; ▁activity ▁; ▁cardiovascular ▁; ▁obes ity ▁; ▁diabetes ▁mell itus ▁; ▁hyper tension ▁; ▁hyper li pida emia
▁exercise ▁; ▁advers e ▁events ▁; ▁corona ry ▁arter y ▁disease ▁; ▁cad
▁exercise ▁; ▁cardiovascular
▁evidence ▁; ▁exercise ▁; ▁cell ▁se nesc ence ▁; ▁active ▁; ▁osteo por osis
▁exercise ▁; ▁life ▁expect an cy
▁healthy ▁; ▁engage ▁; ▁exercise
▁exercise ▁; ▁health ▁; ▁cardiac ▁disease ▁; ▁heart ▁failure
▁cardiac ▁death
▁heredita ry ▁; ▁con geni tal ▁; ▁heart ▁; ▁death
▁cardiac ▁death s ▁; ▁a ther os cle ro tic ▁cad
▁a ha ▁; ▁ esc
▁ec g ▁; ▁con geni tal ▁; ▁accesso ry ▁; ▁ion ▁channel o pathi es ▁; ▁cardio my o pathy
▁ec g ▁; ▁a ther os cle ro tic ▁cad ▁; ▁cardiac ▁death
▁training ▁; ▁heart ▁failure ▁; ▁patients
▁ga it ▁; ▁ therapy ▁; ▁loko mat ▁; ▁heart ▁failure ▁; ▁patients
▁patients ▁; ▁stable ▁heart ▁failure ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁training ▁; ▁training
▁patients ▁; ▁cardiac ▁; ▁infla mma tory ▁; ▁bio mark ers
▁cardio pul mon ary ▁exercise ▁test ▁; ▁quality ▁of ▁life ▁; ▁muscular ▁; ▁pe ak ▁quadri cep s ▁force
▁advers e ▁events
▁combine d ▁training ▁; ▁pe ak ▁work ▁rate ▁; ▁pe ak ▁quadri cep s ▁force
▁pe ak ▁oxygen ▁consum p tion ▁; ▁puls e ▁; ▁patients
▁quality ▁of ▁life
▁ nt - prob np ▁; ▁infla mma tory ▁; ▁bio mark ers ▁; ▁h sc rp ▁; ▁il 6 ▁; ▁patients ▁; ▁h sc rp
▁ga it ▁; ▁ therapy ▁; ▁loko mat ▁; ▁heart ▁failure ▁; ▁patients
▁training ▁; ▁exercise ▁capacity ▁; ▁muscle ▁; ▁quality ▁of ▁life ▁; ▁cardiac ▁; ▁ nt - prob np ▁; ▁infla mma tory ▁; ▁il 6 ▁; ▁h sc rp ▁; ▁bio mark ers

▁psycho social ▁; ▁exercise ▁; ▁outcome s ▁; ▁heart ▁failure ▁; ▁patients ▁; ▁heart ▁failure ▁; ▁outcome s ▁; ▁exercise ▁; ▁training ▁; ▁h f - action
▁psycho social ▁; ▁exercise ▁; ▁training ▁; ▁heart ▁failure ▁; ▁h f ▁; ▁patients
▁exercise ▁; ▁clinic al ▁; ▁outcome s
▁patients ▁; ▁heart ▁failure ▁; ▁outcome s ▁; ▁exercise ▁; ▁training ▁; ▁h f - action ▁; ▁exercise ▁; ▁perc ei ved ▁social ▁support ▁score ▁; ▁ps s s ▁; ▁barrier s ▁to ▁exercise ▁score ▁; ▁b tes
▁ps s s ▁; ▁b tes ▁; ▁exercise
▁exercise ▁; ▁cor related ▁; ▁ps s s ▁; ▁b tes ▁; ▁exercise ▁; ▁ps s s ▁; ▁b tes
▁cardiovascular ▁death ▁; ▁h f ▁; ▁hospital ization ▁; ▁random ization ▁; ▁b tes ▁; ▁b tes ▁; ▁cardiovascular ▁death ▁; ▁h f ▁; ▁hospital ization ▁; ▁exercise ▁; ▁hazard ▁ratio ▁; ▁confidence ▁interval ▁; ▁hazard ▁ratio ▁; ▁confidence ▁interval
▁exercise ▁; ▁exercise
▁ps s s ▁; ▁exercise ▁; ▁training ▁; ▁outcome s
▁cardiovascular ▁death ▁; ▁h f ▁; ▁hospital ization ▁; ▁exercise ▁; ▁training ▁; ▁patients ▁; ▁b tes
▁exercise ▁; ▁training ▁; ▁outcome s ▁; ▁h f ▁; ▁patients ▁; ▁exercise ▁; ▁training ▁; ▁ therapy ▁; ▁clinic al
▁heart ▁rate ▁re duction ▁; ▁exercise ▁; ▁heart ▁failure ▁with ▁reduce d ▁e je ction ▁ fraction ▁; ▁beta - block er
▁beta ▁block ers ▁; ▁all - ca use ▁mortal ity ▁; ▁read missions ▁; ▁heart ▁failure ▁with ▁reduce d ▁e je ction ▁ fraction ▁; ▁h fre f ▁; ▁heart ▁rate
▁hr ▁re duction ▁; ▁beta ▁block ers ▁; ▁exercise ▁capacity ▁; ▁h fre f
▁patients ▁; ▁h fre f ▁; ▁exercise ▁; ▁respirator y ▁gas ▁analysis ▁; ▁base line
▁patients ▁; ▁beta - block er ▁; ▁ therapy
▁base line ▁; ▁patients ▁; ▁rest ing ▁hr ▁; ▁bp m
▁beta - block er ▁; ▁patients ▁; ▁rest ing ▁hr ▁; ▁bp m ▁; ▁p ▁value
▁up tit ration ▁; ▁hr ▁re duction ▁; ▁bp m ▁; ▁p ▁value
▁pe ak ▁oxygen ▁consum p tion ▁; ▁vo 2 max ▁; ▁rest ing ▁hr ▁; ▁bp m ▁; ▁p ▁value

▁patients ▁; ▁rest ing ▁hr ▁; ▁follow - up ▁; ▁base line ▁; ▁vo 2 max ▁; ▁patients ▁; ▁rest ing ▁hr ▁; ▁p ▁value
▁h fre f ▁; ▁exercise ▁; ▁rest ing ▁hr ▁; ▁bp m ▁; ▁beta - block er ▁; ▁ therapy
▁up tit ration ▁; ▁patients ▁; ▁hr ▁re duction ▁; ▁beta - block er ▁; ▁ therapy
▁inter at rial ▁sh unting ▁; ▁patients ▁; ▁heart ▁failure ▁with ▁reduce d ▁e je ction ▁ fraction ▁; ▁ proof - of - princip le ▁co hor t ▁study
▁patients ▁; ▁heart ▁failure ▁; ▁eleva ted ▁; ▁left ▁at rial ▁pressure ▁; ▁symptoms ▁; ▁hospital ▁; ▁ad mission
▁ therapeut ic ▁; ▁inter at rial ▁sh unting ▁; ▁patients ▁; ▁heart ▁failure ▁with ▁reduce d ▁e je ction ▁ fraction
▁ proof - of - princip le ▁co hor t ▁study ▁; ▁can ada
▁patients ▁; ▁new ▁yor k ▁heart ▁association ▁; ▁ny ha ▁; ▁chronic ▁heart ▁failure ▁; ▁reduce d ▁e je ction ▁ fraction
▁shu nt ▁; ▁implant s ▁; ▁trans sept al ▁cat heter isation ▁; ▁trans o es op hage al ▁e cho car dio graphic ▁; ▁general ▁ana es the sia
▁patients ▁; ▁clinic al ▁; ▁e cho card i ography ▁; ▁base line ▁; ▁shu nt ▁; ▁implant ation
▁patients
▁implant ed ▁; ▁patients ▁; ▁advers e ▁events ▁; ▁follow - up
▁trans o es op hage al ▁e cho card i ography ▁; ▁shu nts ▁; ▁ thro mbo sis
▁base line ▁; ▁follow - up ▁; ▁ny ha ▁classifica tion ▁; ▁patients ▁; ▁patient ▁; ▁change ▁; ▁patient ▁; ▁quality ▁of ▁life ▁; ▁duke ▁activity ▁status ▁index ▁; ▁kansa s ▁city ▁cardio my o pathy ▁question naire ▁; ▁6 ▁min ▁walk ▁test
▁pulmonar y ▁cap illa ry ▁we dge ▁pressure ▁; ▁base line ▁; ▁right ▁at rial ▁pressure ▁; ▁pulmonar y ▁arterial ▁pressure ▁; ▁pulmonar y ▁resist ance
▁patient ▁; ▁hospital ▁; ▁heart ▁failure
▁patient ▁; ▁hospital ▁; ▁gastro inte stin al ▁ble ed ing ▁; ▁patient ▁; ▁vent ri cular ▁ta chy car dia ▁; ▁terminal ▁heart ▁failure
▁implant ed ▁; ▁inter at rial ▁shu nt ▁; ▁clinic al ▁; ▁ha emo dynamic ▁; ▁outcome s ▁; ▁patients ▁; ▁heart ▁failure ▁with ▁reduce d ▁e je ction ▁ fraction
▁random ised
▁paradigm - h f ▁; ▁shift ▁; ▁chronic ▁heart ▁failure ▁; ▁chronic ▁heart ▁failure ▁; ▁card i ology
▁ therapy
▁ar ni ▁inhibi tors ▁; ▁ang io ten sin - recept or ▁nepri ly sin ▁inhibi tors
▁at 1 ▁receptor s ▁; ▁nepri ly sin ▁; ▁re nin - angi oten sin - al do ster on ▁; ▁ras ▁; ▁vaso dila tory ▁; ▁di ure tic ▁; ▁na tri ure tic ▁pe pti des
▁prospect ive ▁; ▁random ized ▁; ▁paradigm - h f ▁; ▁chronic ▁heart ▁failure ▁; ▁sy sto lic ▁dys function ▁; ▁ lv ▁ef ▁; ▁functional ▁class ▁; ▁ny ha ▁; ▁eleva ted ▁; ▁b np ▁; ▁ nt - pro ▁b np ▁; ▁primary ▁end point ▁; ▁cardiovascular ▁death ▁; ▁hospital ization ▁; ▁heart ▁failure ▁; ▁ar ni ▁; ▁l cz 696 ▁; ▁sa cubi lt ril ▁; ▁val sar tan
▁ar ni ▁; ▁cardiovascular ▁mortal ity ▁; ▁hospital ization ▁; ▁heart ▁failure ▁; ▁quality ▁of ▁life
▁advers e ▁event ▁; ▁hypo tension
▁ras ▁; ▁nepri ly sin ▁inhibi tion ▁; ▁change ▁; ▁stable ▁; ▁chronic ▁heart ▁failure ▁; ▁sy sto lic ▁dys function
▁ cze ch ▁re public
▁exercise ▁; ▁training ▁; ▁pe ak ▁oxygen ▁consum p tion ▁; ▁quality ▁of ▁life ▁; ▁obes e ▁; ▁patients ▁; ▁heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction ▁; ▁random ized ▁; ▁clinic al
▁patients ▁; ▁heart ▁failure ▁with ▁pres er ved ▁e je ction ▁ fraction ▁; ▁h f pe f ▁; ▁heart ▁failure ▁; ▁obes e
▁exercise ▁in tolerance ▁; ▁symptom ▁; ▁chronic ▁h f pe f ▁; ▁quality ▁of ▁life ▁; ▁qol
▁exercise ▁; ▁training ▁; ▁exercise ▁; ▁exercise ▁capacity ▁; ▁qol ▁; ▁obes e ▁; ▁patients ▁; ▁h f pe f
▁random ized ▁; ▁medical
▁obes e ▁; ▁body ▁mass ▁index ▁; ▁chronic ▁; ▁stable ▁; ▁h f pe f
▁exercise
▁outcome s ▁; ▁exercise ▁capacity ▁; ▁pe ak ▁oxygen ▁consum p tion ▁; ▁vo 2 ▁; ▁co - prima ry ▁outcome ▁; ▁qol ▁; ▁minne s ota ▁; ▁heart ▁failure ▁; ▁heart ▁; ▁qol ▁; ▁co - prima ry ▁outcome
▁random ized ▁; ▁exercise ▁; ▁exercise

▁exercise
▁pe ak ▁vo 2 ▁; ▁exercise
▁combination ▁; ▁exercise ▁; ▁pe ak ▁vo 2 ▁; ▁joint
▁change ▁; ▁exercise ▁; ▁exercise
▁change ▁; ▁pe ak ▁vo 2 ▁; ▁cor related ▁; ▁change ▁; ▁lean ▁body ▁mass ▁; ▁change ▁; ▁th igh ▁; ▁muscle
▁advers e ▁events
▁exercise ▁; ▁exercise
▁obes e ▁; ▁patients ▁; ▁clinic ally ▁; ▁stable ▁; ▁h f pe f ▁; ▁exercise ▁; ▁training ▁; ▁pe ak ▁vo 2
▁quality ▁of ▁life ▁; ▁ml h f ▁question naire
▁fully ▁magnet ically ▁le vita ted ▁left ▁vent ri cular ▁assist ▁system ▁; ▁h f
▁heart mate ▁; ▁left ▁vent ri cular ▁assist ▁system ▁; ▁l vas ▁; ▁patients ▁; ▁heart ▁failure
▁centri fu gal ▁flow ▁pump ▁; ▁hem o com pati bility ▁; ▁blood - flow ▁; ▁puls e
▁prospect ive ▁; ▁l vas
▁primary ▁end point ▁; ▁inter mac s ▁; ▁inter age ncy ▁registr y ▁for ▁mechanic ally ▁assist ed ▁circula tory ▁support
▁patients ▁; ▁e je ction ▁ fraction ▁; ▁cardiac ▁index ▁; ▁in o trop es ▁; ▁medical ▁; ▁transplant
▁patients
▁l vas ▁; ▁ bridge ▁to ▁transplant ation ▁; ▁destination ▁ therapy
▁patients ▁; ▁transplant s
▁mortal ity
▁fully ▁magnet ically ▁le vita ted ▁l vas ▁; ▁mortal ity ▁; ▁sea ttle ▁; ▁heart ▁failure
▁advers e ▁events ▁; ▁re opera tion ▁; ▁ble ed ing ▁; ▁drive line ▁; ▁infection ▁; ▁gastro inte stin al ▁ble ed ing ▁; ▁stroke ▁; ▁rank in ▁score
▁pump ▁; ▁pump ▁; ▁pump ▁ thro mbo sis ▁; ▁hem ol ysis
▁new ▁yor k ▁heart ▁association ▁classifica tion ▁; ▁6- min ▁walk ▁test ▁; ▁quality - of - life
▁fully ▁magnet ically ▁le vita ted ▁centri fu gal - flow ▁chronic ▁l vas ▁; ▁advers e ▁event ▁; ▁quality ▁of ▁life ▁; ▁functional ▁status
▁tools ▁for ▁economic ▁analysis ▁of ▁patient ▁management ▁intervention s ▁in ▁heart ▁failure ▁cost - effect ive ness ▁model ▁; ▁disease ▁; ▁heart ▁failure
▁heart ▁failure ▁; ▁disease ▁; ▁medical
▁costs ▁; ▁outcome s
▁tools ▁for ▁economic ▁analysis ▁of ▁patient ▁management ▁intervention s ▁in ▁heart ▁failure ▁cost - effect ive ness ▁model ▁; ▁clinic al ▁; ▁evidence - based ▁; ▁medication s ▁; ▁costs ▁; ▁outcome s
▁sea ttle ▁heart ▁failure ▁model
▁quality ▁of ▁life ▁; ▁sea ttle ▁heart ▁failure ▁model

▁costs
▁costs ▁; ▁clinic al
▁heart ▁failure ▁; ▁disease ▁; ▁evidence - based ▁; ▁health ▁care
▁tools ▁for ▁economic ▁analysis ▁of ▁patient ▁management ▁intervention s ▁in ▁heart ▁failure ▁cost - effect ive ness ▁model ▁; ▁disease ▁; ▁heart ▁failure
▁heart ▁failure ▁; ▁pat ho phy si ology ▁; ▁ diagnos is ▁; ▁medical ▁treatment ▁; ▁nur sing
▁heart ▁failure ▁; ▁h f ▁; ▁chronic ▁; ▁disease
▁nurse s ▁; ▁patients ▁; ▁disease
▁pat ho phy si ology ▁; ▁h f ▁; ▁ diagnos is ▁; ▁medical ▁; ▁nur sing
▁nurse s ▁; ▁pat ho phy si ology ▁; ▁h f ▁; ▁nur sing ▁; ▁medical ▁; ▁symptoms ▁; ▁pat ho phy si ologic
▁morbi d ity ▁; ▁mortal ity ▁; ▁quality ▁of ▁life ▁; ▁patients ▁; ▁h f
